{
  "Record": {
    "RecordType": "CID",
    "RecordNumber": 42611257,
    "RecordTitle": "Vemurafenib-3",
    "Section": [
      {
        "TOCHeading": "Structures",
        "Description": "Structure depictions and information for 2D, 3D, and crystal related",
        "Section": [
          {
            "TOCHeading": "2D Structure",
            "Description": "A two-dimensional representation of the compound",
            "DisplayControls": {
              "MoveToTop": true
            },
            "Information": [
              {
                "ReferenceNumber": 52,
                "Value": {
                  "Boolean": [
                    true
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "3D Conformer",
            "Description": "A three-dimensional representation of the compound. The 3D structure is not experimentally determined, but computed by PubChem. More detailed information on this conformer model is described in the PubChem3D thematic series published in the Journal of Cheminformatics.",
            "DisplayControls": {
              "MoveToTop": true
            },
            "Information": [
              {
                "ReferenceNumber": 52,
                "Description": "Vemurafenib",
                "Value": {
                  "Number": [
                    42611257
                  ]
                }
              }
            ]
          }
        ]
      },
      {
        "TOCHeading": "Chemical Safety",
        "Description": "Launch the Laboratory Chemical Safety Summary datasheet, and link to the safety and hazard section",
        "DisplayControls": {
          "HideThisSection": true,
          "MoveToTop": true
        },
        "Information": [
          {
            "ReferenceNumber": 52,
            "Name": "Chemical Safety",
            "Value": {
              "StringWithMarkup": [
                {
                  "String": "          ",
                  "Markup": [
                    {
                      "Start": 0,
                      "Length": 1,
                      "URL": "https://pubchem.ncbi.nlm.nih.gov/images/ghs/GHS07.svg",
                      "Type": "Icon",
                      "Extra": "Irritant"
                    },
                    {
                      "Start": 1,
                      "Length": 1,
                      "URL": "https://pubchem.ncbi.nlm.nih.gov/images/ghs/GHS08.svg",
                      "Type": "Icon",
                      "Extra": "Health Hazard"
                    }
                  ]
                }
              ]
            }
          }
        ]
      },
      {
        "TOCHeading": "Names and Identifiers",
        "Description": "Record identifiers, synonyms, chemical names, descriptors, etc.",
        "Section": [
          {
            "TOCHeading": "Record Description",
            "Description": "Summary Information",
            "DisplayControls": {
              "HideThisSection": true,
              "MoveToTop": true
            },
            "Information": [
              {
                "ReferenceNumber": 2,
                "Name": "Record Description",
                "Description": "Ontology Summary",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Vemurafenib is a pyrrolopyridine that is 1H-pyrrolo[2,3-b]pyridine which is substituted at position 5 by a p-chlorophenyl group and at positions 3 by a 3-amino-2,6-difluorobenzoyl group, the amino group of which has undergone formal condensation with propane-1-sulfonic acid to give the corresponding sulfonamide. An inhibitor of BRAF and other kinases. It has a role as an antineoplastic agent and a B-Raf inhibitor. It is a pyrrolopyridine, a sulfonamide, a member of monochlorobenzenes, a difluorobenzene and an aromatic ketone.",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 17,
                          "Length": 15,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/pyrrolopyridine",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-9226"
                        },
                        {
                          "Start": 41,
                          "Length": 25,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/1H-pyrrolo%5B2%2C3-b%5Dpyridine",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-21959101"
                        },
                        {
                          "Start": 191,
                          "Length": 5,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/amino",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-136037442"
                        },
                        {
                          "Start": 251,
                          "Length": 23,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/propane-1-sulfonic%20acid",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-136202161"
                        },
                        {
                          "Start": 426,
                          "Length": 15,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/pyrrolopyridine",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-9226"
                        },
                        {
                          "Start": 492,
                          "Length": 15,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/difluorobenzene",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-9706"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 8,
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 148,
                          "Length": 3,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/ATP",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-5957"
                        },
                        {
                          "Start": 187,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 30,
                "Description": "FDA Pharmacology Summary",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Vemurafenib is a Kinase Inhibitor. The mechanism of action of vemurafenib is as a Protein Kinase Inhibitor, and Cytochrome P450 1A2 Inhibitor, and P-Glycoprotein Inhibitor.",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 62,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 31,
                "Description": "FDA Pharmacology Summary",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Vemurafenib is a Kinase Inhibitor. The mechanism of action of vemurafenib is as a Protein Kinase Inhibitor.",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 62,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 34,
                "Description": "LiverTox Summary",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Vemurafenib is a selective inhibitor of BRAF kinase that is used in the therapy of patients with metastatic and advanced malignant melanoma. Vemurafenib therapy is commonly associated with transient elevations in serum aminotransferase during therapy and has been linked to rare, but occasionally severe cases of clinically apparent acute liver injury.",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 141,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 39,
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Vemurafenib is an orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 39,
                          "Length": 3,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/ATP",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-5957"
                        },
                        {
                          "Start": 143,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 180,
                          "Length": 3,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/ATP",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-5957"
                        },
                        {
                          "Start": 476,
                          "Length": 6,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/valine",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-6287"
                        },
                        {
                          "Start": 486,
                          "Length": 13,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/glutamic%20acid",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-33032"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 51,
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "An indole sulfonamide compound and inhibitor of BRAF KINASES that is used for the treatment of unresectable or metastatic MELANOMA."
                    }
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "Computed Descriptors",
            "Description": "Descriptors generated from chemical structure input",
            "Section": [
              {
                "TOCHeading": "IUPAC Name",
                "Description": "Chemical name computed from chemical structure that uses International Union of Pure and Applied Chemistry (IUPAC) nomenclature standards.",
                "URL": "http://old.iupac.org/publications/books/seriestitles/nomenclature.html",
                "Information": [
                  {
                    "ReferenceNumber": 52,
                    "Reference": [
                      "Computed by Lexichem TK 2.7.0 (PubChem release 2021.05.07)"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide",
                          "Markup": [
                            {
                              "Start": 0,
                              "Length": 1,
                              "Type": "Italics"
                            },
                            {
                              "Start": 26,
                              "Length": 1,
                              "Type": "Italics"
                            }
                          ]
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "InChI",
                "Description": "International Chemical Identifier (InChI) computed from chemical structure using the International Union of Pure and Applied Chemistry (IUPAC) standard.",
                "URL": "http://www.iupac.org/home/publications/e-resources/inchi.html",
                "Information": [
                  {
                    "ReferenceNumber": 52,
                    "Reference": [
                      "Computed by InChI 1.0.6 (PubChem release 2021.05.07)"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)"
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "InChI Key",
                "Description": "International Chemical Identifier hash (InChIKey) computed from chemical structure using the International Union of Pure and Applied Chemistry (IUPAC) standard.",
                "URL": "http://www.iupac.org/home/publications/e-resources/inchi.html",
                "Information": [
                  {
                    "ReferenceNumber": 52,
                    "Reference": [
                      "Computed by InChI 1.0.6 (PubChem release 2021.05.07)"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "GPXBXXGIAQBQNI-UHFFFAOYSA-N"
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Canonical SMILES",
                "Description": "Simplified Molecular-Input Line-Entry System (SMILES) computed from chemical structure devoid of isotopic and stereochemical information.",
                "URL": "http://www.daylight.com/dayhtml/doc/theory/theory.smiles.html",
                "Information": [
                  {
                    "ReferenceNumber": 52,
                    "Reference": [
                      "Computed by OEChem 2.3.0 (PubChem release 2021.05.07)"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F"
                        }
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "TOCHeading": "Molecular Formula",
            "Description": "A chemical formula is a way of expressing information about the proportions of atoms that constitute a particular chemical compound, using a single line of chemical element symbols and numbers. PubChem uses the Hill system whereby the number of carbon atoms in a molecule is indicated first, the number of hydrogen atoms second, and then the number of all other chemical elements in alphabetical order. When the formula contains no carbon, all the elements, including hydrogen, are listed alphabetically. Sources other than PubChem may include a variant of the formula that is more structural or natural to chemists, for example \"H2SO4\" for sulfuric acid, rather than the Hill version \"H2O4S.\"",
            "DisplayControls": {
              "MoveToTop": true
            },
            "Information": [
              {
                "ReferenceNumber": 52,
                "Reference": [
                  "Computed by PubChem 2.1 (PubChem release 2021.05.07)"
                ],
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "C23H18ClF2N3O3S"
                    }
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "Other Identifiers",
            "Description": "Important identifiers assigned to this chemical substance by authoritative organizations",
            "Section": [
              {
                "TOCHeading": "CAS",
                "Description": "A proprietary registry number assigned by the Chemical Abstracts Service (CAS) division of the American Chemical Society (ACS) often used to help describe chemical ingredients.",
                "URL": "http://en.wikipedia.org/wiki/CAS_Registry_Number",
                "Information": [
                  {
                    "ReferenceNumber": 1,
                    "URL": "https://commonchemistry.cas.org/detail?cas_rn=918504-65-1",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "918504-65-1"
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 3,
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "918504-65-1"
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 8,
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "918504-65-1"
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 12,
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "918504-65-1"
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 16,
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "918504-65-1"
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 17,
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "1029872-54-5"
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 33,
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "918504-65-1"
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Deprecated CAS",
                "Description": "The CAS registry number(s) in this section refer(s) to old, deprecated, previously assigned, deleted, etc. CAS number(s) which are no longer used, but users can still see in references, sometimes.",
                "Information": [
                  {
                    "ReferenceNumber": 3,
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "1029872-54-5"
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "European Community (EC) Number",
                "Description": "A seven-digit regulatory identifier currently assigned by the European Chemicals Agency (ECHA) known as a European Community (EC) number.  It is sometimes referred to as an EINECS, ELINCS, or NLP number, which are subsets of an EC number.",
                "URL": "http://en.wikipedia.org/wiki/European_Community_number",
                "Information": [
                  {
                    "ReferenceNumber": 16,
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "850-250-7"
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 17,
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "800-227-2"
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "NSC Number",
                "Description": "The NSC number is a numeric identifier for substances submitted to the National Cancer Institute (NCI) for testing and evaluation. It is a registration number for the Developmental Therapeutics Program (DTP) repository. NSC stands for National Service Center.",
                "Information": [
                  {
                    "ReferenceNumber": 10,
                    "Name": "NSC Number",
                    "URL": "https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=761431",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "761431"
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "UNII",
                "Description": "A non-proprietary registry number assigned by the U.S. Food and Drug Administration (FDA) known as an UNique Ingredient Identifier (UNII) code.",
                "URL": "http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSystem-UniqueIngredientIdentifierUNII/",
                "Information": [
                  {
                    "ReferenceNumber": 32,
                    "Name": "UNII",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "207SMY3FQT"
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "DSSTox Substance ID",
                "Description": "Substance identifier at the Distributed Structure-Searchable Toxicity (DSSTox) Database.",
                "URL": "https://www.epa.gov/chemical-research/distributed-structure-searchable-toxicity-dsstox-database/",
                "Information": [
                  {
                    "ReferenceNumber": 12,
                    "URL": "https://comptox.epa.gov/dashboard/chemical/details/DTXSID50238710",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "DTXSID50238710"
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Wikipedia",
                "Description": "Links to Wikipedia for this record.",
                "Information": [
                  {
                    "ReferenceNumber": 50,
                    "URL": "https://en.wikipedia.org/wiki/Vemurafenib",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Vemurafenib"
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Wikidata",
                "Description": "Wikidata entity identifier for the given compound.",
                "URL": "https://www.wikidata.org/w/index.php?title=Special:WhatLinksHere/Property:P662",
                "Information": [
                  {
                    "ReferenceNumber": 49,
                    "URL": "https://www.wikidata.org/wiki/Q423111",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Q423111"
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "NCI Thesaurus Code",
                "Description": "Stable, unique code for biomedical concept",
                "URL": "https://ncithesaurus.nci.nih.gov",
                "Information": [
                  {
                    "ReferenceNumber": 39,
                    "URL": "https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C64768",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "C64768"
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "RXCUI",
                "Description": "RxNorm concept unique identifier (RXCUI)",
                "URL": "https://www.nlm.nih.gov/research/umls/rxnorm/index.html",
                "Information": [
                  {
                    "ReferenceNumber": 41,
                    "URL": "https://rxnav.nlm.nih.gov/id/rxnorm/1147220",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "1147220"
                        }
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "TOCHeading": "Synonyms",
            "Description": "Alternative names for this PubChem Compound record.  A compound can have many different names.  For example, acetone (CH3C(=O)CH3) is also known as propanone, propan-2-one, or dimethyl ketone.  The brand name of a product is commonly used to indicate the primary chemical ingredient(s) in the product (e.g., Tylenol, a common pain killer, is often used for acetaminophen, its active ingredient).  Another example of common synonyms is record identifiers used in different data collections, such as Chemical Abstract Service (CAS) registry numbers, FDA UNII (Unique Ingredient Identifiers), and many others.  All these various names and identifiers that designate this compound are organized under the Synonyms section.",
            "Section": [
              {
                "TOCHeading": "MeSH Entry Terms",
                "Description": "Medical Subject Heading (MeSH) names or identifiers matching this PubChem Compound record.  The matching between the MeSH and compound records is performed by name matching (i.e., identical common names).",
                "DisplayControls": {
                  "ListType": "Columns"
                },
                "Information": [
                  {
                    "ReferenceNumber": 51,
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "PLX 4032"
                        },
                        {
                          "String": "PLX4032"
                        },
                        {
                          "String": "R05185426"
                        },
                        {
                          "String": "RG 7204"
                        },
                        {
                          "String": "RG-7204"
                        },
                        {
                          "String": "RG7204"
                        },
                        {
                          "String": "vemurafenib"
                        },
                        {
                          "String": "Zelboraf"
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Depositor-Supplied Synonyms",
                "Description": "Chemical names provided by individual data contributors. Synonyms of Substances corresponding to a PubChem Compound record are combined. Some contributed names may be considered erroneous and filtered out. The link on each synonym shows which depositors provided that particular synonym for this structure.",
                "DisplayControls": {
                  "ListType": "Columns",
                  "MoveToTop": true
                },
                "Information": [
                  {
                    "ReferenceNumber": 52,
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Vemurafenib"
                        },
                        {
                          "String": "918504-65-1"
                        },
                        {
                          "String": "PLX4032"
                        },
                        {
                          "String": "Zelboraf"
                        },
                        {
                          "String": "1029872-54-5"
                        },
                        {
                          "String": "PLX-4032"
                        },
                        {
                          "String": "N-(3-(5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide"
                        },
                        {
                          "String": "RG7204"
                        },
                        {
                          "String": "PLX 4032"
                        },
                        {
                          "String": "RG 7204"
                        },
                        {
                          "String": "Vemurafenib (PLX4032, RG7204)"
                        },
                        {
                          "String": "Vemurafenib (PLX4032)"
                        },
                        {
                          "String": "N-(3-{[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl}-2,4-difluorophenyl)propane-1-sulfonamide"
                        },
                        {
                          "String": "RO5185426"
                        },
                        {
                          "String": "RO 5185426"
                        },
                        {
                          "String": "UNII-207SMY3FQT"
                        },
                        {
                          "String": "RG-7204"
                        },
                        {
                          "String": "207SMY3FQT"
                        },
                        {
                          "String": "CHEBI:63637"
                        },
                        {
                          "String": "MFCD18074504"
                        },
                        {
                          "String": "NSC761431"
                        },
                        {
                          "String": "Vemurafenib;PLX-4032"
                        },
                        {
                          "String": "RO-5185426"
                        },
                        {
                          "String": "C23H18ClF2N3O3S"
                        },
                        {
                          "String": "1-PROPANESULFONAMIDE, N-[3-[[5-(4-CHLOROPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-3-YL]CARBONYL]-2,4-DIFLUOROPHENYL]-"
                        },
                        {
                          "String": "N-(3-((5-(4-Chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4- difluorophenyl)propane-1-sulfonamide"
                        },
                        {
                          "String": "N-[3-[[5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-1-PropanesulfonaMide"
                        },
                        {
                          "String": "N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide"
                        },
                        {
                          "String": "N-{3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide"
                        },
                        {
                          "String": "Zelboraf (TN)"
                        },
                        {
                          "String": "1-Propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-"
                        },
                        {
                          "String": "n-(3-((5-(4-chlorophenyl)-1h-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-1-propanesulfonamide"
                        },
                        {
                          "String": "Vemurafenib [USAN:INN]"
                        },
                        {
                          "String": "vemurafenibum"
                        },
                        {
                          "String": "Ro 51-85426"
                        },
                        {
                          "String": "HSDB 8143"
                        },
                        {
                          "String": "N-(3-{(5-(4-chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)carbonyl}-2,4- difluorophenyl)propane-1-sulfonamide"
                        },
                        {
                          "String": "3og7"
                        },
                        {
                          "String": "Vemurafenib; PLX4032"
                        },
                        {
                          "String": "PLX4032 - Vemurafenib"
                        },
                        {
                          "String": "SCHEMBL298931"
                        },
                        {
                          "String": "Vemurafenib (JAN/USAN/INN)"
                        },
                        {
                          "String": "GTPL5893"
                        },
                        {
                          "String": "QCR-44"
                        },
                        {
                          "String": "CHEMBL1229517"
                        },
                        {
                          "String": "DTXSID50238710"
                        },
                        {
                          "String": "EX-A053"
                        },
                        {
                          "String": "SYN1161"
                        },
                        {
                          "String": "HMS3265M03"
                        },
                        {
                          "String": "HMS3265M04"
                        },
                        {
                          "String": "HMS3265N03"
                        },
                        {
                          "String": "HMS3265N04"
                        },
                        {
                          "String": "HMS3654P09"
                        },
                        {
                          "String": "HMS3748G15"
                        },
                        {
                          "String": "AOB87705"
                        },
                        {
                          "String": "BCP25783"
                        },
                        {
                          "String": "EX-A1335"
                        },
                        {
                          "String": "BDBM50396483"
                        },
                        {
                          "String": "NSC800964"
                        },
                        {
                          "String": "s1267"
                        },
                        {
                          "String": "ZINC52509366"
                        },
                        {
                          "String": "AKOS007930804"
                        },
                        {
                          "String": "AM81259"
                        },
                        {
                          "String": "CCG-264883"
                        },
                        {
                          "String": "CS-0216"
                        },
                        {
                          "String": "DB08881"
                        },
                        {
                          "String": "MCULE-7244406627"
                        },
                        {
                          "String": "ME-0096"
                        },
                        {
                          "String": "NSC-761431"
                        },
                        {
                          "String": "NSC-800964"
                        },
                        {
                          "String": "PB11741"
                        },
                        {
                          "String": "NCGC00250399-01"
                        },
                        {
                          "String": "NCGC00250399-05"
                        },
                        {
                          "String": "NCGC00250399-08"
                        },
                        {
                          "String": "Vemurafenib, RG7204, RO5185426"
                        },
                        {
                          "String": "1-Propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3- yl)carbonyl)-2,4-difluorophenyl)-"
                        },
                        {
                          "String": "AC-25010"
                        },
                        {
                          "String": "HY-12057"
                        },
                        {
                          "String": "N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl]propane-1-sulfonamide"
                        },
                        {
                          "String": "SY067868"
                        },
                        {
                          "String": "FT-0660388"
                        },
                        {
                          "String": "FT-0675792"
                        },
                        {
                          "String": "FT-0689782"
                        },
                        {
                          "String": "SW218095-2"
                        },
                        {
                          "String": "Y0473"
                        },
                        {
                          "String": "RO-51-85426"
                        },
                        {
                          "String": "A25476"
                        },
                        {
                          "String": "A25742"
                        },
                        {
                          "String": "D09996"
                        },
                        {
                          "String": "R-7204"
                        },
                        {
                          "String": "AB01273970-01"
                        },
                        {
                          "String": "AB01273970_03"
                        },
                        {
                          "String": "Q423111"
                        },
                        {
                          "String": "SR-01000941568"
                        },
                        {
                          "String": "carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide"
                        },
                        {
                          "String": "J-522975"
                        },
                        {
                          "String": "J-690009"
                        },
                        {
                          "String": "SR-01000941568-1"
                        },
                        {
                          "String": "BRD-K56343971-001-02-3"
                        },
                        {
                          "String": "BRD-K56343971-001-05-6"
                        },
                        {
                          "String": "PLX4032,Vemurafenib, RG7204, RO5185426, Zelboraf"
                        },
                        {
                          "String": "N-{3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-"
                        },
                        {
                          "String": "[(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[(5-fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6 -dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl]methanone"
                        },
                        {
                          "String": "1415041-85-8"
                        },
                        {
                          "String": "N-(3-(5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)-propane-1-sulfonamide"
                        },
                        {
                          "String": "propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide"
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Removed Synonyms",
                "Description": "Potentially erroneous chemical names and identifiers provided by PubChem Substance records for the same chemical structure that were removed by name/structure consistency filtering.",
                "DisplayControls": {
                  "HideThisSection": true
                },
                "Information": [
                  {
                    "ReferenceNumber": 52,
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Vemurafenib [USAN]"
                        },
                        {
                          "String": "cc-7"
                        },
                        {
                          "String": "D0Y9EW"
                        },
                        {
                          "String": "PLX4032 (Vemurafenib)"
                        },
                        {
                          "String": "PLX4032 ,Vemurafenib ,"
                        },
                        {
                          "String": "Vemurafenib (BRAF inhibitor)"
                        },
                        {
                          "String": "CTK8C3113"
                        },
                        {
                          "String": "L01XE15"
                        },
                        {
                          "String": "GPXBXXGIAQBQNI-UHFFFAOYSA-N"
                        },
                        {
                          "String": "ABP000429"
                        },
                        {
                          "String": "ANW-69692"
                        },
                        {
                          "String": "RW4117"
                        },
                        {
                          "String": "ACN-030372"
                        },
                        {
                          "String": "AN-1313"
                        },
                        {
                          "String": "CS-O-10915"
                        },
                        {
                          "String": "RL05788"
                        },
                        {
                          "String": "TRA0082406"
                        },
                        {
                          "String": "C23-H18-Cl-F2-N3-O3-S"
                        },
                        {
                          "String": "KS-0000002Q"
                        },
                        {
                          "String": "Vemurafenib, 99% - 100MG 100mg"
                        },
                        {
                          "String": "R7204"
                        },
                        {
                          "String": "4CA-1032"
                        },
                        {
                          "String": "AK-56796"
                        },
                        {
                          "String": "BC626573"
                        },
                        {
                          "String": "SC-54548"
                        },
                        {
                          "String": "AB0031775"
                        },
                        {
                          "String": "AB1009703"
                        },
                        {
                          "String": "TC-158437"
                        },
                        {
                          "String": "A3004"
                        },
                        {
                          "String": "NS00008103"
                        },
                        {
                          "String": "ST24048327"
                        },
                        {
                          "String": "PLX-4032(RG7204)/PLX4032"
                        },
                        {
                          "String": "A10739"
                        },
                        {
                          "String": "Q-3409"
                        },
                        {
                          "String": "C551177"
                        },
                        {
                          "String": "R05185426"
                        },
                        {
                          "String": "D000077484"
                        },
                        {
                          "String": "N-(3-(5-(4-Chlorophenyl)-1H-pyrrolo[2,3-B]pyridine"
                        },
                        {
                          "String": "2-(4-tert-Butyl-2,6-dimethylbenzyl)-2-imidazoline hydrochloride"
                        },
                        {
                          "String": "PLX4032, RG7204, RO5185426, 1029872-54-5"
                        },
                        {
                          "String": "918505-61-0"
                        },
                        {
                          "String": "N-(2,4-Difluoro-3-(5-(pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)phenyl)propane-2-sulfinamide"
                        }
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "TOCHeading": "Create Date",
            "Description": "Date the compound record was initially added to PubChem",
            "DisplayControls": {
              "HideThisSection": true,
              "MoveToTop": true
            },
            "Information": [
              {
                "ReferenceNumber": 52,
                "Value": {
                  "DateISO8601": [
                    "2009-06-22"
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "Modify Date",
            "Description": "Date this record was last updated in PubChem",
            "DisplayControls": {
              "HideThisSection": true,
              "MoveToTop": true
            },
            "Information": [
              {
                "ReferenceNumber": 52,
                "Value": {
                  "DateISO8601": [
                    "2022-07-02"
                  ]
                }
              }
            ]
          }
        ]
      },
      {
        "TOCHeading": "Chemical and Physical Properties",
        "Description": "Chemical and physical properties such as melting point, molecular weight, etc.",
        "Section": [
          {
            "TOCHeading": "Computed Properties",
            "Description": "Properties computed automatically from the given chemical structure",
            "DisplayControls": {
              "CreateTable": {
                "FromInformationIn": "Subsections",
                "NumberOfColumns": 3,
                "ColumnHeadings": [
                  "Property Name",
                  "Property Value",
                  "Reference"
                ],
                "ColumnContents": [
                  "Name",
                  "Value",
                  "Reference"
                ]
              }
            },
            "Section": [
              {
                "TOCHeading": "Molecular Weight",
                "Description": "Molecular weight or molecular mass refers to the mass of a molecule. It is calculated as the sum of the mass of each constituent atom multiplied by the number of atoms of that element in the molecular formula.",
                "DisplayControls": {
                  "MoveToTop": true
                },
                "Information": [
                  {
                    "ReferenceNumber": 52,
                    "Reference": [
                      "Computed by PubChem 2.1 (PubChem release 2021.05.07)"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "489.9"
                        }
                      ],
                      "Unit": "g/mol"
                    }
                  }
                ]
              },
              {
                "TOCHeading": "XLogP3",
                "Description": "Computed Octanol/Water Partition Coefficient",
                "Information": [
                  {
                    "ReferenceNumber": 52,
                    "Name": "XLogP3-AA",
                    "Reference": [
                      "Computed by XLogP3 3.0 (PubChem release 2021.05.07)"
                    ],
                    "Value": {
                      "Number": [
                        5
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Hydrogen Bond Donor Count",
                "Description": "The number of hydrogen bond donors in the structure.",
                "Information": [
                  {
                    "ReferenceNumber": 52,
                    "Reference": [
                      "Computed by Cactvs 3.4.8.18 (PubChem release 2021.05.07)"
                    ],
                    "Value": {
                      "Number": [
                        2
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Hydrogen Bond Acceptor Count",
                "Description": "The number of hydrogen bond acceptors in the structure.",
                "Information": [
                  {
                    "ReferenceNumber": 52,
                    "Reference": [
                      "Computed by Cactvs 3.4.8.18 (PubChem release 2021.05.07)"
                    ],
                    "Value": {
                      "Number": [
                        7
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Rotatable Bond Count",
                "Description": "A rotatable bond is defined as any single-order non-ring bond, where atoms on either side of the bond are in turn bound to nonterminal heavy (i.e., non-hydrogen) atoms. That is, where rotation around the bond axis changes the overall shape of the molecule, and generates conformers which can be distinguished by standard fast spectroscopic methods.",
                "Information": [
                  {
                    "ReferenceNumber": 52,
                    "Reference": [
                      "Computed by Cactvs 3.4.8.18 (PubChem release 2021.05.07)"
                    ],
                    "Value": {
                      "Number": [
                        7
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Exact Mass",
                "Description": "The exact mass of an isotopic species is obtained by summing the masses of the individual isotopes of the molecule.",
                "Information": [
                  {
                    "ReferenceNumber": 52,
                    "Reference": [
                      "Computed by PubChem 2.1 (PubChem release 2021.05.07)"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "489.0725466"
                        }
                      ],
                      "Unit": "g/mol"
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Monoisotopic Mass",
                "Description": "The monoisotopic mass is the sum of the masses of the atoms in a molecule using the unbound, ground-state, rest mass of the principal (most abundant) isotope for each element instead of the isotopic average mass.",
                "Information": [
                  {
                    "ReferenceNumber": 52,
                    "Reference": [
                      "Computed by PubChem 2.1 (PubChem release 2021.05.07)"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "489.0725466"
                        }
                      ],
                      "Unit": "g/mol"
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Topological Polar Surface Area",
                "Description": "The topological polar surface area (TPSA) of a molecule is defined as the surface sum over all polar atoms in a molecule.",
                "Information": [
                  {
                    "ReferenceNumber": 52,
                    "Reference": [
                      "Computed by Cactvs 3.4.8.18 (PubChem release 2021.05.07)"
                    ],
                    "Value": {
                      "Number": [
                        100
                      ],
                      "Unit": ""
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Heavy Atom Count",
                "Description": "A heavy atom is defined as any atom except hydrogen in a chemical structure.",
                "Information": [
                  {
                    "ReferenceNumber": 52,
                    "Reference": [
                      "Computed by PubChem"
                    ],
                    "Value": {
                      "Number": [
                        33
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Formal Charge",
                "Description": "Formal charge is the difference between the number of valence electrons of each atom and the number of electrons the atom is associated with. Formal charge assumes any shared electrons are equally shared between the two bonded atoms.",
                "Information": [
                  {
                    "ReferenceNumber": 52,
                    "Reference": [
                      "Computed by PubChem"
                    ],
                    "Value": {
                      "Number": [
                        0
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Complexity",
                "Description": "The complexity rating of a compound is a rough estimate of how complicated a structure is, seen from both the point of view of the elements contained and the displayed structural features including symmetry. This complexity rating is computed using the Bertz/Hendrickson/Ihlenfeldt formula.",
                "Information": [
                  {
                    "ReferenceNumber": 52,
                    "Reference": [
                      "Computed by Cactvs 3.4.8.18 (PubChem release 2021.05.07)"
                    ],
                    "Value": {
                      "Number": [
                        790
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Isotope Atom Count",
                "Description": "Isotope Atom Count is the number of isotopes that are not most abundant for the corresponding chemical elements.  Isotopes are variants of a chemical element which differ in neutron number.  For example, among three isotopes of carbon (i.e., C-12, C-13, and C-14), the isotope atom count considers the C-13 and C-14 atoms, because C-12 is the most abundant isotope of carbon.",
                "Information": [
                  {
                    "ReferenceNumber": 52,
                    "Reference": [
                      "Computed by PubChem"
                    ],
                    "Value": {
                      "Number": [
                        0
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Defined Atom Stereocenter Count",
                "Description": "An atom stereocenter, also known as a chiral center, is an atom that is attached to four different types of atoms (or groups of atoms) in the tetrahedral arrangement. It can have either (R)- or (S)- configurations.  Some compounds, such as racemic mixtures, have an undefined atom stereocenter, whose (R/S)-configuration is not specifically defined.",
                "Information": [
                  {
                    "ReferenceNumber": 52,
                    "Reference": [
                      "Computed by PubChem"
                    ],
                    "Value": {
                      "Number": [
                        0
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Undefined Atom Stereocenter Count",
                "Description": "An atom stereocenter, also known as a chiral center, is an atom that is attached to four different types of atoms (or groups of atoms) in the tetrahedral arrangement. It can have either (R)- or (S)- configurations.  Some compounds, such as racemic mixtures, have an undefined atom stereocenter, whose (R/S)-configuration is not specifically defined.",
                "Information": [
                  {
                    "ReferenceNumber": 52,
                    "Reference": [
                      "Computed by PubChem"
                    ],
                    "Value": {
                      "Number": [
                        0
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Defined Bond Stereocenter Count",
                "Description": "A bond stereocenter is a non-rotatable bond around which two atoms can have different arrangement (as in cis- and trans-forms of butene around its double bond).  Some compounds have an undefined bond stereocenter, whose stereochemistry is not specifically defined.",
                "Information": [
                  {
                    "ReferenceNumber": 52,
                    "Reference": [
                      "Computed by PubChem"
                    ],
                    "Value": {
                      "Number": [
                        0
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Undefined Bond Stereocenter Count",
                "Description": "A bond stereocenter is a non-rotatable bond around which two atoms can have different arrangement (as in cis- and trans-forms of butene around its double bond).  Some compounds have an undefined bond stereocenter, whose stereochemistry is not specifically defined.",
                "Information": [
                  {
                    "ReferenceNumber": 52,
                    "Reference": [
                      "Computed by PubChem"
                    ],
                    "Value": {
                      "Number": [
                        0
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Covalently-Bonded Unit Count",
                "Description": "The number of separate chemical structures not connected by covalent bonds.",
                "Information": [
                  {
                    "ReferenceNumber": 52,
                    "Reference": [
                      "Computed by PubChem"
                    ],
                    "Value": {
                      "Number": [
                        1
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Compound Is Canonicalized",
                "Description": "Whether the compound has successfully passed PubChem's valence bond canonicalization procedure. Some large, complex, or highly symmetric structures may fail this process.",
                "Information": [
                  {
                    "ReferenceNumber": 52,
                    "Reference": [
                      "Computed by PubChem (release 2021.05.07)"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Yes"
                        }
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "TOCHeading": "Experimental Properties",
            "Description": "Properties determined experimentally (See also Safety and Hazard Properties section for more information if available)",
            "Section": [
              {
                "TOCHeading": "Color/Form",
                "Description": "Physical description - color",
                "Information": [
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "US Natl Inst Health; DailyMed. Current Medical Information. Available from, as of Jun 27, 2013: https://dailymed.nlm.nih.gov/dailymed/about.cfm"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "White to off-white crystalline solid"
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Melting Point",
                "Description": "This section provides the melting point and/or freezing point. The melting point is the temperature at which a substance changes state from solid to liquid at atmospheric pressure. When considered as the temperature of the reverse change, from liquid to solid, it is referred to as the freezing point.",
                "Information": [
                  {
                    "ReferenceNumber": 8,
                    "Reference": [
                      "MSDS"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "272C"
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Solubility",
                "Description": "The solubility of a substance is the amount of that substance that will dissolve in a given amount of solvent. The default solvent is water, if not indicated.",
                "Information": [
                  {
                    "ReferenceNumber": 8,
                    "Reference": [
                      "MSDS"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "<1 mg/mL"
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.1. Nov, 2012. Available from, as of Jun 26, 2013: https://www.epa.gov/oppt/exposure/pubs/episuitedl.htm"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "In water, 3.2X10-2 mg/L at 25 C (est)",
                          "Markup": [
                            {
                              "Start": 3,
                              "Length": 5,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/water",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-962"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "US Natl Inst Health; DailyMed. Current Medical Information. Available from, as of Jun 27, 2013: https://dailymed.nlm.nih.gov/dailymed/about.cfm"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Practically insoluble in aqueous media"
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Vapor Pressure",
                "Description": "Vapor pressure is the pressure of a vapor in thermodynamic equilibrium with its condensed phases in a closed system.",
                "Information": [
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.1. Nov, 2012. Available from, as of Jun 26, 2013: https://www.epa.gov/oppt/exposure/pubs/episuitedl.htm"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "8.21X10-15 mm Hg at 25 C (est)"
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "LogP",
                "Description": "Log P is the partition coefficient expressed in logarithmic form.  The partition coefficient is the ratio of concentrations of a compound in a mixture of two immiscible solvents at equilibrium.  This ratio is therefore used to compare the solubilities of the solute in these two solvents.  Because octanol and water are the most commonly used pair of solvents for measuring partition coefficients, the Log P values listed in this section refer to \"octanol/water partition coefficients\", unless indicated otherwise.",
                "Information": [
                  {
                    "ReferenceNumber": 8,
                    "Reference": [
                      "MSDS"
                    ],
                    "Value": {
                      "Number": [
                        5.1
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.1. Nov, 2012. Available from, as of Jun 26, 2013: https://www.epa.gov/oppt/exposure/pubs/episuitedl.htm"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "log Kow = 5.17 (est)"
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Henrys Law Constant",
                "Description": "At a constant temperature, the amount of a given gas that dissolves in a given type and volume of liquid is directly proportional to the partial pressure of that gas in equilibrium with that liquid",
                "Information": [
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.1. Nov, 2012. Available from, as of Jun 26, 2013: https://www.epa.gov/oppt/exposure/pubs/episuitedl.htm"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Henry's Law constant = 1.23X10-17 atm-cu m/mol at 25 C (est)"
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Stability/Shelf Life",
                "Description": "Tendency of a material to resist change or decomposition due to internal reaction, or due to the action of air, heat, light, pressure, etc. (See also Stability and Reactivity section under Safety and Hazards)",
                "Information": [
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "Selleck Chemicals; Material Safety Data Sheet: Vemurafenib, Cat. Number S1267, RN 918504-65-1 (Revision Date: 10/1/2012). Available from, as of July 19, 2013: https://www.selleckchem.com/msds/PLX-4032-MSDS.html"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Stable if stored as directed; avoid strong oxidizing agents"
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Decomposition",
                "Description": "The decomposition temperature of a substance is the temperature at which the substance chemically decomposes",
                "Information": [
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "Selleck Chemicals; Material Safety Data Sheet: Vemurafenib, Cat. Number S1267, RN 918504-65-1 (Revision Date: 10/1/2012). Available from, as of July 19, 2013: https://www.selleckchem.com/msds/PLX-4032-MSDS.html"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Dangerous products of decomposition: thermal ecomposition may produce toxic gases such as carbon monoxide, carbon dioxide, and nitrogen oxides.",
                          "Markup": [
                            {
                              "Start": 90,
                              "Length": 15,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/carbon%20monoxide",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-281"
                            },
                            {
                              "Start": 107,
                              "Length": 14,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/carbon%20dioxide",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-280"
                            }
                          ]
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Caco2 Permeability",
                "Description": "Caco2 Permeability is a measure of human intestinal absorption of drugs or compound based on the Caco-2 cells assay. Caco-2 cells are a human colon epithelial cancer cell line.",
                "Information": [
                  {
                    "ReferenceNumber": 8,
                    "Reference": [
                      "FDA review"
                    ],
                    "Value": {
                      "Number": [
                        2.9e-06
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Dissociation Constants",
                "Description": "A specific type of equilibrium constant that measures the propensity of a larger object to separate (dissociate) reversibly into smaller components, as when a complex falls apart into its component molecules, or when a salt splits up into its component ions. This includes pKa (the negative logarithm of the acid dissociation constant) and pKb (the negative logarithm of the base dissociation constant).",
                "Information": [
                  {
                    "ReferenceNumber": 8,
                    "Name": "pKa",
                    "Reference": [
                      "Royal Soc Chem"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "7.1"
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "Royal Soc Chem; ChemSpider. Vemurafenib. (918504-65-1). Available from, as of Jan 29, 2014: https://www.chemspider.com/Search.aspx"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "pKa = 7.2 (amine) (est)"
                        }
                      ]
                    }
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "TOCHeading": "Spectral Information",
        "Description": "Spectral data for chemical compounds",
        "Section": [
          {
            "TOCHeading": "Mass Spectrometry",
            "Description": "Mass spectrometry (MS or mass spec) is a technique to determine molecular structure through ionization and fragmentation of the parent compound into smaller components.",
            "DisplayControls": {
              "CreateTable": {
                "FromInformationIn": "ThisSection",
                "NumberOfColumns": 2,
                "ColumnContents": [
                  "Name",
                  "Value"
                ]
              },
              "ShowAtMost": 2
            },
            "Section": [
              {
                "TOCHeading": "LC-MS",
                "Description": "Linking to LC-MS spectrum.",
                "DisplayControls": {
                  "CreateTable": {
                    "FromInformationIn": "ThisSection",
                    "NumberOfColumns": 2,
                    "ColumnContents": [
                      "Name",
                      "Value"
                    ]
                  },
                  "ShowAtMost": 2
                },
                "Information": [
                  {
                    "ReferenceNumber": 35,
                    "Name": "MoNA ID",
                    "URL": "https://mona.fiehnlab.ucdavis.edu/spectra/display/CCMSLIB00000078077",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "CCMSLIB00000078077"
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 35,
                    "Name": "MS Category",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Experimental"
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 35,
                    "Name": "MS Type",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "LC-MS"
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 35,
                    "Name": "MS Level",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "MS2"
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 35,
                    "Name": "Precursor Type",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "[M+H]+"
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 35,
                    "Name": "Precursor m/z",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "490.08"
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 35,
                    "Name": "Instrument",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "qTof"
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 35,
                    "Name": "Ionization Mode",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "positive"
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 35,
                    "Name": "Top 5 Peaks",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "490.081696 100"
                        },
                        {
                          "String": "492.077911 40.29"
                        },
                        {
                          "String": "383.063477 39.65"
                        },
                        {
                          "String": "491.083527 32.53"
                        },
                        {
                          "String": "255.032471 25.79"
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 35,
                    "Name": "SPLASH",
                    "URL": "https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=splash.splash%3D%3D%22splash10-0006-0024900000-4911e6c7ad52fd2c2896%22",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "splash10-0006-0024900000-4911e6c7ad52fd2c2896"
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 35,
                    "Name": "Thumbnail",
                    "URL": "https://pubchem.ncbi.nlm.nih.gov/image/ms.cgi?peaks=490.081696:100,492.077911:40.29,383.063477:39.65,491.083527:32.53,255.032471:25.79",
                    "Value": {
                      "ExternalDataURL": [
                        "https://pubchem.ncbi.nlm.nih.gov/image/ms.cgi?peaks=490.081696:100,492.077911:40.29,383.063477:39.65,491.083527:32.53,255.032471:25.79"
                      ],
                      "MimeType": "image/svg"
                    }
                  },
                  {
                    "ReferenceNumber": 35,
                    "Name": "Submitter",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "GNPS Team, University of California, San Diego"
                        }
                      ]
                    }
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "TOCHeading": "Related Records",
        "Description": "Related compounds/substances information based on the similar structure, annotations, etc.",
        "Section": [
          {
            "TOCHeading": "Related Compounds with Annotation",
            "Description": "The subset of compounds that are related to the one currently displayed AND that have biomedical annotations.",
            "Information": [
              {
                "ReferenceNumber": 52,
                "Value": {
                  "Boolean": [
                    true
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "Related Compounds",
            "Description": "Compound records closely associated to this record.",
            "DisplayControls": {
              "CreateTable": {
                "FromInformationIn": "ThisSection",
                "NumberOfColumns": 2,
                "ColumnContents": [
                  "Name",
                  "Value"
                ]
              },
              "ShowAtMost": 1
            },
            "Information": [
              {
                "ReferenceNumber": 52,
                "Name": "Same Connectivity Count",
                "URL": "https://www.ncbi.nlm.nih.gov/pccompound?cmd=Link&LinkName=pccompound_pccompound_sameconnectivity_pulldown&from_uid=42611257",
                "Value": {
                  "Number": [
                    17
                  ]
                }
              },
              {
                "ReferenceNumber": 52,
                "Name": "Same Parent, Connectivity Count",
                "URL": "https://www.ncbi.nlm.nih.gov/pccompound?cmd=Link&LinkName=pccompound_pccompound_parent_connectivity_pulldown&from_uid=42611257",
                "Value": {
                  "Number": [
                    37
                  ]
                }
              },
              {
                "ReferenceNumber": 52,
                "Name": "Same Parent, Exact Count",
                "URL": "https://www.ncbi.nlm.nih.gov/pccompound?cmd=Link&LinkName=pccompound_pccompound_parent_pulldown&from_uid=42611257",
                "Value": {
                  "Number": [
                    21
                  ]
                }
              },
              {
                "ReferenceNumber": 52,
                "Name": "Mixtures, Components, and Neutralized Forms Count",
                "URL": "https://www.ncbi.nlm.nih.gov/pccompound?cmd=Link&LinkName=pccompound_pccompound_mixture&from_uid=42611257",
                "Value": {
                  "Number": [
                    61
                  ]
                }
              },
              {
                "ReferenceNumber": 52,
                "Name": "Similar Compounds Count",
                "URL": "https://www.ncbi.nlm.nih.gov/pccompound?cmd=Link&LinkName=pccompound_pccompound&from_uid=42611257",
                "Value": {
                  "Number": [
                    1231
                  ]
                }
              },
              {
                "ReferenceNumber": 52,
                "Name": "Similar Conformers Count",
                "URL": "https://www.ncbi.nlm.nih.gov/pccompound?cmd=Link&LinkName=pccompound_pccompound_3d&from_uid=42611257",
                "Value": {
                  "Number": [
                    188
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "Substances",
            "Description": "Substance records linked to this compound.",
            "Section": [
              {
                "TOCHeading": "Related Substances",
                "Description": "Substances identical or nearly identical to this record.",
                "URL": "https://pubchemdocs.ncbi.nlm.nih.gov/substances",
                "DisplayControls": {
                  "CreateTable": {
                    "FromInformationIn": "ThisSection",
                    "NumberOfColumns": 2,
                    "ColumnContents": [
                      "Name",
                      "Value"
                    ]
                  },
                  "ShowAtMost": 1
                },
                "Information": [
                  {
                    "ReferenceNumber": 52,
                    "Name": "All Count",
                    "URL": "https://www.ncbi.nlm.nih.gov/pcsubstance/?term=42611257[CompoundID]",
                    "Value": {
                      "Number": [
                        271
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 52,
                    "Name": "Same Count",
                    "URL": "https://www.ncbi.nlm.nih.gov/pcsubstance/?term=42611257[StandardizedCID]",
                    "Value": {
                      "Number": [
                        199
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 52,
                    "Name": "Mixture Count",
                    "URL": "https://www.ncbi.nlm.nih.gov/pcsubstance/?term=42611257[ComponentCID]",
                    "Value": {
                      "Number": [
                        72
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Substances by Category",
                "Description": "Substance category according to the depositors. Substance Categorization Classification - The subheaders in this section of a PubChem Compound record reflect the various categories of depositors that have submitted corresponding PubChem Substance records. This allows you to quickly find the corresponding PubChem Substance records that are likely to contain a given type of information, such as Chemical Reactions.",
                "URL": "https://pubchemdocs.ncbi.nlm.nih.gov/substances",
                "Information": [
                  {
                    "ReferenceNumber": 52,
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Chemical Vendors"
                        },
                        {
                          "String": "Curation Efforts"
                        },
                        {
                          "String": "Governmental Organizations"
                        },
                        {
                          "String": "Journal Publishers"
                        },
                        {
                          "String": "Legacy Depositors"
                        },
                        {
                          "String": "NIH Initiatives"
                        },
                        {
                          "String": "Research and Development"
                        },
                        {
                          "String": "Subscription Services"
                        }
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "TOCHeading": "Entrez Crosslinks",
            "Description": "Cross-references to associated records in other Entrez databases such as PubMed, Gene, Protein, etc.",
            "DisplayControls": {
              "CreateTable": {
                "FromInformationIn": "ThisSection",
                "NumberOfColumns": 2,
                "ColumnContents": [
                  "Name",
                  "Value"
                ]
              },
              "ShowAtMost": 1
            },
            "Information": [
              {
                "ReferenceNumber": 52,
                "Name": "PubMed Count",
                "URL": "https://www.ncbi.nlm.nih.gov/sites/entrez?LinkName=pccompound_pubmed&db=pccompound&cmd=Link&from_uid=42611257",
                "Value": {
                  "Number": [
                    41
                  ]
                }
              },
              {
                "ReferenceNumber": 52,
                "Name": "Protein Structures Count",
                "URL": "https://www.ncbi.nlm.nih.gov/sites/entrez?LinkName=pccompound_structure&db=pccompound&cmd=Link&from_uid=42611257",
                "Value": {
                  "Number": [
                    3
                  ]
                }
              },
              {
                "ReferenceNumber": 52,
                "Name": "Taxonomy Count",
                "URL": "https://www.ncbi.nlm.nih.gov/sites/entrez?LinkName=pccompound_taxonomy&db=pccompound&cmd=Link&from_uid=42611257",
                "Value": {
                  "Number": [
                    3
                  ]
                }
              },
              {
                "ReferenceNumber": 52,
                "Name": "OMIM Count",
                "URL": "https://www.ncbi.nlm.nih.gov/sites/entrez?LinkName=pccompound_omim&db=pccompound&cmd=Link&from_uid=42611257",
                "Value": {
                  "Number": [
                    1
                  ]
                }
              },
              {
                "ReferenceNumber": 52,
                "Name": "Gene Count",
                "URL": "https://www.ncbi.nlm.nih.gov/sites/entrez?LinkName=pccompound_gene&db=pccompound&cmd=Link&from_uid=42611257",
                "Value": {
                  "Number": [
                    80
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "NCBI LinkOut",
            "Description": "LinkOut is a service that allows one to link directly from NCBI databases to a wide range of information and services beyond NCBI systems.",
            "URL": "https://www.ncbi.nlm.nih.gov/projects/linkout",
            "Information": [
              {
                "ReferenceNumber": 77,
                "Value": {
                  "Boolean": [
                    true
                  ]
                }
              }
            ]
          }
        ]
      },
      {
        "TOCHeading": "Chemical Vendors",
        "Description": "A list of chemical vendors that sell this compound.  Each vendor may have multiple products containing the same chemical, but different in various aspects, such as amount and purity.  For each product, the external identifier used to locate the product on the vendor's website is provided under the Purcharsable Chemical column, and clicking this identifier directs you to the vendor's website.  The information on the product provided by the vendor to PubChem can be accessed at the Summary page of the corresponding PubChem Substance ID (SID).  Note that the order of chemical vendors on the list is randomized, and that PubChem do not endorse any of the vendors.",
        "Information": [
          {
            "ReferenceNumber": 52,
            "Value": {
              "Boolean": [
                true
              ]
            }
          }
        ]
      },
      {
        "TOCHeading": "Drug and Medication Information",
        "Description": "Drug and medication information from multiple sources.",
        "Section": [
          {
            "TOCHeading": "Drug Indication",
            "Description": "Drug Indication information from various sources.",
            "DisplayControls": {
              "ShowAtMost": 3
            },
            "Information": [
              {
                "ReferenceNumber": 8,
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E. The V600E mutation, a substitution of glutamic acid for valine, accounts for 54% of the cases of cutaneous melanoma.  Vemurafenib approval was extended in 2017, for its use as a treatment of adult patients with Erdheim-Chester Disease whose cancer cells present BRAF V600 mutation. Erdheim-Chester disease is an extremely rare histiocyte cell disorder that affects large bones, large vessels, central nervous system, as well as, skin and lungs. It is reported an association of Erdheim-Chester disease and V600E mutation.",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 107,
                          "Length": 6,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/valine",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-6287"
                        },
                        {
                          "Start": 228,
                          "Length": 13,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/glutamic%20acid",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-33032"
                        },
                        {
                          "Start": 246,
                          "Length": 6,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/valine",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-6287"
                        },
                        {
                          "Start": 308,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 8,
                "URL": "http://s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB08881.pdf?1369117050",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "FDA Label"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 18,
                "Name": "Drug Indication",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma.",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 21,
                "Name": "Drug Indication",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Treatment of melanoma"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 38,
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Drug: Vemurafenib",
                      "Markup": [
                        {
                          "Start": 6,
                          "Length": 11,
                          "URL": "https://www.cancer.gov/about-cancer/treatment/drugs/vemurafenib"
                        }
                      ]
                    },
                    {
                      "String": "US Brand Name(s): Zelboraf",
                      "Markup": [
                        {
                          "Start": 18,
                          "Length": 8,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Zelboraf",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    },
                    {
                      "String": "FDA Approval: Yes"
                    },
                    {
                      "String": "Vemurafenib is approved to treat patients whose disease has a certain mutation in the BRAF gene , including:",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    },
                    {
                      "String": " Erdheim-Chester disease."
                    },
                    {
                      "String": " Melanoma that cannot be removed by surgery or has metastasized (spread to other parts of the body)."
                    },
                    {
                      "String": "Vemurafenib is also being studied in the treatment of other types of cancer.",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "LiverTox Summary",
            "Description": "This section provides an overview of drug induced liver injury, diagnostic criteria, assessment of causality and severity, descriptions of different clinical patterns (phenotypes), information on management and treatment, and standardized nomenclature.  The role of liver biopsy and major histological patterns of drug induced liver disease are also given.",
            "URL": "https://livertox.nlm.nih.gov/aboutus.html",
            "Information": [
              {
                "ReferenceNumber": 34,
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Vemurafenib is a selective inhibitor of BRAF kinase that is used in the therapy of patients with metastatic and advanced malignant melanoma. Vemurafenib therapy is commonly associated with transient elevations in serum aminotransferase during therapy and has been linked to rare, but occasionally severe cases of clinically apparent acute liver injury.",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 141,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "Drug Classes",
            "Description": "Drug classes information from various sources.",
            "Information": [
              {
                "ReferenceNumber": 34,
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Antineoplastic Agents"
                    }
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "Drug Effects during Lactation",
            "Description": "summry for Drug Effects during Lactation from LactMed",
            "DisplayControls": {
              "CreateTable": {
                "FromInformationIn": "ThisSection",
                "NumberOfColumns": 2,
                "ColumnContents": [
                  "Name",
                  "Value"
                ]
              }
            },
            "Information": [
              {
                "ReferenceNumber": 9,
                "Name": "Summary",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "No information is available on the clinical use of vemurafenib during breastfeeding. Because vemurafenib is more than 99% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is 57 hours and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during vemurafenib therapy and for 2 weeks after the final dose.",
                      "Markup": [
                        {
                          "Start": 51,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 93,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 332,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 9,
                "Name": "PubMed",
                "URL": "https://www.ncbi.nlm.nih.gov/pubmed/29999925",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "29999925"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 9,
                "Name": "NCBI Books",
                "URL": "https://www.ncbi.nlm.nih.gov/books/NBK500866/",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "NBK500866"
                    }
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "FDA Medication Guides",
            "Description": "FDA Medication Guides are paper handouts that come with many prescription medicines. The guides address issues that are specific to particular drugs and drug classes, and they contain FDA-approved information that can help patients avoid serious adverse events.",
            "URL": "https://www.fda.gov/Drugs/DrugSafety/ucm085729.htm",
            "DisplayControls": {
              "CreateTable": {
                "FromInformationIn": "ThisSection",
                "NumberOfColumns": 5,
                "ColumnsFromNamedLists": {
                  "Name": [
                    "Drug",
                    "Active Ingredient",
                    "Form;Route",
                    "Company",
                    "Date"
                  ],
                  "UseNamesAsColumnHeadings": true
                }
              },
              "ShowAtMost": 3
            },
            "Information": [
              {
                "ReferenceNumber": 22,
                "Name": "Drug",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Zelboraf",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 8,
                          "URL": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202429s016lbl.pdf#page=21"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 22,
                "Name": "Active Ingredient",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Vemurafenib"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 22,
                "Name": "Form;Route",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "TABLET;ORAL"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 22,
                "Name": "Company",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "HOFFMANN LA ROCHE"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 22,
                "Name": "Date",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "05/18/2020"
                    }
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "FDA Orange Book",
            "Description": "The Orange Book identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act.",
            "URL": "https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book",
            "Information": [
              {
                "ReferenceNumber": 29,
                "Value": {
                  "ExternalTableName": "fdaorangebook",
                  "ExternalTableNumRows": 1
                }
              }
            ]
          },
          {
            "TOCHeading": "FDA National Drug Code Directory",
            "Description": "The National Drug Code (NDC) is a unique product identifier in three-segment number used in the United States for human drugs (the Drug Listing Act of 1972).",
            "URL": "https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory",
            "Information": [
              {
                "ReferenceNumber": 36,
                "Value": {
                  "ExternalTableName": "fdandc"
                }
              },
              {
                "ReferenceNumber": 37,
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "VEMURAFENIB is an active ingredient in the product ZELBORAF.",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/VEMURAFENIB",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 51,
                          "Length": 8,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/ZELBORAF",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "Drug Labels for Ingredients",
            "Description": "This section contains the drug label information for given drug ingredients (compounds) from DailyMed.  DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).",
            "URL": "https://dailymed.nlm.nih.gov/dailymed/",
            "DisplayControls": {
              "CreateTable": {
                "FromInformationIn": "Subsections",
                "NumberOfColumns": 2,
                "ColumnContents": [
                  "Name",
                  "Value"
                ]
              },
              "ShowAtMost": 2
            },
            "Section": [
              {
                "TOCHeading": "Label Title",
                "Description": "The drug title on the given label.",
                "Information": [
                  {
                    "ReferenceNumber": 6,
                    "Name": "Label Title",
                    "URL": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38eea320-7e0c-485a-bc30-98c3c45e2763",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "ZELBORAF- vemurafenib tablet, film coated",
                          "Markup": [
                            {
                              "Start": 0,
                              "Length": 8,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/ZELBORAF",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 10,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Label Ingredient",
                "Description": "The drug ingredient in the given label.",
                "Information": [
                  {
                    "ReferenceNumber": 6,
                    "Name": "Drug Ingredient",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "VEMURAFENIB"
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Label Image",
                "Description": "A photo image for the drug label when available.",
                "Information": [
                  {
                    "ReferenceNumber": 6,
                    "Name": "Label Image",
                    "Value": {
                      "ExternalDataURL": [
                        "https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/2127912_1"
                      ],
                      "MimeType": "image/jpg"
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Label Download",
                "Description": "A PDF drug label can be downloaded from DailyMed.",
                "Information": [
                  {
                    "ReferenceNumber": 6,
                    "Name": "Label Download",
                    "URL": "https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=38eea320-7e0c-485a-bc30-98c3c45e2763&type=pdf&name=38eea320-7e0c-485a-bc30-98c3c45e2763",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "PDF Label"
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "NDC Code(s)",
                "Description": "The related NDC code(s) for the drug.",
                "Information": [
                  {
                    "ReferenceNumber": 6,
                    "Name": "NDC Code(s)",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "50242-090-02, 50242-090-86"
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Packager",
                "Description": "The manufacture company.",
                "Information": [
                  {
                    "ReferenceNumber": 6,
                    "Name": "Packager",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Genentech, Inc."
                        }
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "TOCHeading": "Clinical Trials",
            "Description": "Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention. They are the primary way that researchers find out if a new treatment, like a new drug or diet or medical device (for example, a pacemaker) is safe and effective in people.",
            "Section": [
              {
                "TOCHeading": "ClinicalTrials.gov",
                "Description": "The brief clinical trials summary from the ClinicalTrials.gov at the U.S. National Library of Medicine.",
                "URL": "https://clinicaltrials.gov/",
                "Information": [
                  {
                    "ReferenceNumber": 4,
                    "Name": "ClinicalTrials.gov",
                    "Value": {
                      "ExternalTableName": "clinicaltrials",
                      "ExternalTableNumRows": 125
                    }
                  }
                ]
              },
              {
                "TOCHeading": "EU Clinical Trials Register",
                "Description": "The clinical trials summary from the EU Clinical Trials Register.",
                "URL": "https://www.clinicaltrialsregister.eu/",
                "Information": [
                  {
                    "ReferenceNumber": 13,
                    "Name": "EU Clinical Trials Register",
                    "Value": {
                      "ExternalTableName": "clinicaltrials_eu",
                      "ExternalTableNumRows": 44
                    }
                  }
                ]
              },
              {
                "TOCHeading": "NIPH Clinical Trials Search of Japan",
                "Description": "The brief clinical trials summary from the NIPH Clinical Trials Search of Japan.",
                "URL": "https://rctportal.niph.go.jp/en/",
                "Information": [
                  {
                    "ReferenceNumber": 40,
                    "Name": "NIPH Clinical Trials Search of Japan",
                    "Value": {
                      "ExternalTableName": "clinicaltrials_jp",
                      "ExternalTableNumRows": 2
                    }
                  }
                ]
              }
            ]
          },
          {
            "TOCHeading": "EMA Drug Information",
            "Description": "Drug and medicines information from the European Medicines Agency (EMA)",
            "URL": "https://www.ema.europa.eu/en/medicines",
            "DisplayControls": {
              "CreateTable": {
                "FromInformationIn": "ThisSection",
                "NumberOfColumns": 2,
                "ColumnContents": [
                  "Name",
                  "Value"
                ]
              },
              "ShowAtMost": 2
            },
            "Information": [
              {
                "ReferenceNumber": 18,
                "Name": "Medicine",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Zelboraf"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 18,
                "Name": "Therapeutic area",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Melanoma"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 18,
                "Name": "Active Substance",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "vemurafenib"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 18,
                "Name": "INN/Common name",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "vemurafenib"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 18,
                "Name": "Pharmacotherapeutic Classes",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Antineoplastic agents"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 18,
                "Name": "Status",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "This medicine is authorized for use in the European Union"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 18,
                "Name": "Company",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Roche Registration GmbH"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 18,
                "Name": "Market Date",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "2012-02-17"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 19,
                "Name": "Disease/Condition",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Treatment of Langerhans' cell histiocytosis"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 19,
                "Name": "Active Substance",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "vemurafenib"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 19,
                "Name": "Status of Orphan Designation",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Positive"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 19,
                "Name": "Decision Date",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "2016-05-30"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 20,
                "Name": "Disease/Condition",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Treatment of Erdheim-Chester disease"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 20,
                "Name": "Active Substance",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "vemurafenib"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 20,
                "Name": "Status of Orphan Designation",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Positive"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 20,
                "Name": "Decision Date",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "2017-02-27"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 21,
                "Name": "Active Substance",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "vemurafenib"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 21,
                "Name": "Therapeutic Area",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Oncology"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 21,
                "Name": "Drug Form",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Film-coated tablet"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 21,
                "Name": "Administration Route",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Oral use"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 21,
                "Name": "Decision Type",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "PM: decision on the application for modification of an agreed PIP"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 21,
                "Name": "Decision Date",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "2016-08-12"
                    }
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "Therapeutic Uses",
            "Description": "Therapeutic Uses information from HSDB",
            "Information": [
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Reference": [
                  "American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1233"
                ],
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Vemurafenib is used for the treatment of unresectable or metastatic melanoma with BRAF V600E mutation. Vemurafenib is designated an orphan drug by the US Food and Drug Administration (FDA) for the treatment of this cancer. An FDA-approved diagnostic test (e.g., cobas 4800 BRAF V600 Mutation Test) is required to confirm the presence of the BRAF V600E mutation prior to initiation of therapy. /Included in US product label/",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 103,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Reference": [
                  "US Natl Inst Health; DailyMed. Current Medication Information for ZELBORAF (vemurafenib) tablet, film coated (April 2012). Available from, as of July 17, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=38eea320-7e0c-485a-bc30-98c3c45e2763"
                ],
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Zelboraf is not recommended for use in patients with wild-type BRAF melanoma.",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 8,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Zelboraf",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "Drug Warnings",
            "Description": "Drug Warning information from HSDB",
            "Information": [
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Reference": [
                  "American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1234"
                ],
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Serious hypersensitivity reactions (e.g., anaphylaxis, generalized rash and erythema, hypotension) have been reported in patients receiving vemurafenib. Vemurafenib should be permanently discontinued in patients who experience a severe hypersensitivity reaction.",
                      "Markup": [
                        {
                          "Start": 140,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 153,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Reference": [
                  "American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1234"
                ],
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Photosensitivity reactions (mild to severe) have been reported in 33-49% of patients receiving vemurafenib in clinical trials. If intolerable grade 2 (i.e., tender erythema covering 10-30% of body surface area) or greater reaction occurs, the dosage of vemurafenib should be reduced.",
                      "Markup": [
                        {
                          "Start": 95,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 253,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Reference": [
                  "American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1234"
                ],
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Vemurafenib prolongs the QT interval in a concentration-dependent manner. In a multicenter, open-label, phase 2 study, QT interval prolongation was evaluated in patients with BRAF V600E mutation-positive, metastatic melanoma who were receiving vemurafenib (960 mg twice daily). A maximum mean corrected QT (QTc) interval change from baseline of 12.8 msec during the first month of treatment and 15.1 msec during the first 6 months of treatment was observed in these patients. The manufacturer does not recommend initiation of vemurafenib in patients with electrolyte abnormalities unresponsive to corrective measures or congenital long QT syndrome. In addition, concomitant use of vemurafenib with drugs known to prolong the QT interval (e.g., class Ia and III antiarrhythmic agents) is not recommended. ECGs and serum electrolyte concentrations, including concentrations of potassium, magnesium, and calcium, should be obtained prior to initiation of therapy or following dosage modification, and monitored 15 days following initiation of therapy, then monthly for the first 3 months of treatment, and then every 3 months thereafter or more often as clinically indicated. Interruption or discontinuance of vemurafenib may be necessary if increases in the QTc interval occur during therapy with the drug.",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 244,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 526,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 681,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 875,
                          "Length": 9,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/element/Potassium",
                          "Type": "PubChem Internal Link",
                          "Extra": "Element-Potassium"
                        },
                        {
                          "Start": 886,
                          "Length": 9,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/element/Magnesium",
                          "Type": "PubChem Internal Link",
                          "Extra": "Element-Magnesium"
                        },
                        {
                          "Start": 901,
                          "Length": 7,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/element/Calcium",
                          "Type": "PubChem Internal Link",
                          "Extra": "Element-Calcium"
                        },
                        {
                          "Start": 1207,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Reference": [
                  "American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1234"
                ],
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported with vemurafenib. If severe skin reactions occur, vemurafenib therapy should be permanently discontinued.",
                      "Markup": [
                        {
                          "Start": 107,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 152,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "For more Drug Warnings (Complete) data for Vemurafenib (18 total), please visit the HSDB record page.",
                      "Markup": [
                        {
                          "Start": 84,
                          "Length": 16,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/source/hsdb/8143#section=Drug-Warnings-(Complete)"
                        },
                        {
                          "Start": 43,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "Drug Tolerance",
            "Description": "Drug Tolerance information from HSDB",
            "Information": [
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Reference": [
                  "PMID:23647573",
                  "Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753831",
                  "Sale MJ, Cook SJ; Br J Pharmacol. 2013 May 3. doi: 10.1111/bph.12220. (Epub ahead of print)"
                ],
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Oncogenic mutations in RAS or BRAF can drive the inappropriate activation of the extracellular signal-regulated kinases, ERK1/2. In many cases tumor cells adapt to become addicted to this deregulated ERK1/2 signalling for their proliferation, providing a therapeutic window for tumor-selective growth inhibition. As a result, inhibition of ERK1/2 signalling by BRAF or MEK1/2 inhibitors is an attractive therapeutic strategy. Indeed, the first BRAF inhibitor, vemurafenib, has now been approved for clinical use, whilst clinical evaluation of MEK1/2 inhibitors is at an advanced stage. Despite this progress it is apparent that tumor cells adapt quickly to these new, targeted agents so that tumors with acquired resistance can emerge within 6-9 months of primary treatment. One of the major reasons for this is that tumor cells typically respond to BRAF or MEK1/2 inhibitors by undergoing a G1 cell cycle arrest rather than dying. Indeed, although inhibition of ERK1/2 invariably increases the expression of pro-apoptotic BCL2 family proteins, tumor cells undergo minimal apoptosis. This cytostatic response may simply provide the cell with the opportunity to adapt and acquire resistance. Here /the investigators/ discuss recent studies that demonstrate that combination of BRAF or MEK1/2 inhibitors with inhibitors of pro-survival BCL2 proteins is synthetic lethal for ERK1/2-addicted tumour cells. This combination effectively transforms the cytostatic response of BRAF and MEK1/2 inhibitors into a striking apoptotic cell death response. This not only augments the primary efficacy of BRAF and MEK1/2 inhibitors but delays the onset of acquired resistance to these agents, validating their combination in the clinic.",
                      "Markup": [
                        {
                          "Start": 460,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Reference": [
                  "PMID:23714462",
                  "Chapman PB; Am Soc Clin Oncol Educ Book 2013;2013:80-2. doi: E10.1200/EdBook_AM.2013.33.e80."
                ],
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "BRAF-mutated melanomas with RAF inhibitors (either vemurafenib or dabrafenib) results in rapid and dramatic responses in most patients-results that are associated with improved progression-free survival (PFS) and in the case of vemurafenib, overall survival (OS). However, resistance develops at a median time of approximately 6 months. Understanding the mechanisms of resistance is critical to develop strategies to prolong PFS and OS. Negative feedback mechanisms inherent in the MAPK pathway serve to modulate responses to these drugs. However, genetic changes develop within the tumor, which lead to reactivation of the MAPK and resistance to these drugs. The mechanisms that have been demonstrated in many patients by multiple investigators are (1) development of an activating mutation in NRAS, and (2) appearance of a BRAFV600E splice variant that encourages RAF dimerization. Several other mechanisms of resistance have also been described in individual patients or in preclinical models of resistance. In addition, there is evidence that activation of parallel pathways, such as the PI3K/AKT pathway, may represent another mechanism of resistance. Understanding the various mechanisms of resistance will inform our attempts to prevent resistance to RAF inhibitors.",
                      "Markup": [
                        {
                          "Start": 51,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 66,
                          "Length": 10,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/dabrafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-44462760"
                        },
                        {
                          "Start": 228,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Reference": [
                  "PMID:23764003",
                  "Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3810180",
                  "Roesch A et al; Cancer Cell. 2013 Jun 10;23(6):811-25 (2013)"
                ],
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Despite success with BRAFV600E inhibitors, therapeutic responses in patients with metastatic melanoma are short-lived because of the acquisition of drug resistance. /The investigators/ identified a mechanism of intrinsic multidrug resistance based on the survival of a tumor cell subpopulation. Treatment with various drugs, including cisplatin and vemurafenib, uniformly leads to enrichment of slow-cycling, long-term tumor-maintaining melanoma cells expressing the H3K4-demethylase JARID1B/KDM5B/PLU-1. Proteome-profiling revealed an upregulation in enzymes of mitochondrial oxidative-ATP-synthesis (oxidative phosphorylation) in this subpopulation. Inhibition of mitochondrial respiration blocked the emergence of the JARID1B(high) subpopulation and sensitized melanoma cells to therapy, independent of their genotype. ... Findings support a two-tiered approach combining anticancer agents that eliminate rapidly proliferating melanoma cells with inhibitors of the drug-resistant slow-cycling subpopulation.",
                      "Markup": [
                        {
                          "Start": 335,
                          "Length": 9,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/cisplatin",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-5702198"
                        },
                        {
                          "Start": 349,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 587,
                          "Length": 3,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/ATP",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-5957"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Reference": [
                  "PMID:23302800",
                  "Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930354",
                  "Das Thakur M et al; Nature 494 (7436): 251-5 (2013)"
                ],
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Mutational activation of BRAF is the most prevalent genetic alteration in human melanoma, with?=50% of tumours expressing the BRAF(V600E) oncoprotein. Moreover, the marked tumor regression and improved survival of late-stage BRAF-mutated melanoma patients in response to treatment with vemurafenib demonstrates the essential role of oncogenic BRAF in melanoma maintenance. However, as most patients relapse with lethal drug-resistant disease, understanding and preventing mechanism(s) of resistance is critical to providing improved therapy. Here /the researchers/ investigate the cause and consequences of vemurafenib resistance using two independently derived primary human melanoma xenograft models in which drug resistance is selected by continuous vemurafenib administration. In one of these models, resistant tumors show continued dependency on BRAF(V600E)?MEK?ERK signalling owing to elevated BRAF(V600E) expression. Most importantly, /the researchers/ demonstrate that vemurafenib-resistant melanomas become drug dependent for their continued proliferation, such that cessation of drug administration leads to regression of established drug-resistant tumours. /The researchers/ further demonstrate that a discontinuous dosing strategy, which exploits the fitness disadvantage displayed by drug-resistant cells in the absence of the drug, forestalls the onset of lethal drug-resistant disease. These data highlight the concept that drug-resistant cells may also display drug dependency, such that altered dosing may prevent the emergence of lethal drug resistance. Such observations may contribute to sustaining the durability of the vemurafenib response with the ultimate goal of curative therapy for the subset of melanoma patients with BRAF mutations.",
                      "Markup": [
                        {
                          "Start": 286,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 607,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 753,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 863,
                          "Length": 3,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/MEK",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-6569"
                        },
                        {
                          "Start": 977,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 1641,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              }
            ]
          }
        ]
      },
      {
        "TOCHeading": "Pharmacology and Biochemistry",
        "Description": "Pharmacology and biochemistry information related to this record",
        "Section": [
          {
            "TOCHeading": "Pharmacology",
            "Description": "Pharmacology information related to this record",
            "Information": [
              {
                "ReferenceNumber": 8,
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "BRAF activation results in cell growth, proliferation, and metastasis. BRAF is an intermediary molecule in MAPK whose activation depends on ERK activation, elevation of cyclin D1 and cellular proliferation. The mutation V600E produces a constitutively form of BRAF. Vemurafenib has been shown to reduce all activation markers related to BRAF; in clinical trials, vemurafenib treatment showed a reduction of cytoplasmic phosphorylated ERK and a cell proliferation driven by Ki-67. Studies also reported decrease in MAPK-related metabolic activity. All the different reports indicate thet Vemurafenib generates an almost complete inhibition of the MAPK pathway.",
                      "Markup": [
                        {
                          "Start": 266,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 363,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 587,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "MeSH Pharmacological Classification",
            "Description": "Pharmacological action classes that provided by MeSH",
            "Information": [
              {
                "ReferenceNumber": 74,
                "Name": "Antineoplastic Agents",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)",
                      "Markup": [
                        {
                          "Start": 72,
                          "Length": 49,
                          "URL": "https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pccompound&DbFrom=mesh&Cmd=Link&LinkName=mesh_pccompound&IdsFromResult=68000970"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 75,
                "Name": "Protein Kinase Inhibitors",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)",
                      "Markup": [
                        {
                          "Start": 42,
                          "Length": 53,
                          "URL": "https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pccompound&DbFrom=mesh&Cmd=Link&LinkName=mesh_pccompound&IdsFromResult=68047428"
                        }
                      ]
                    }
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "FDA Pharmacological Classification",
            "Description": "Pharmacological classes codes are from the National Drug File Reference Terminology (NDF-RT) maintained by the Department of Veterans Affairs. Click the class link to see all drugs information under the class from DailyMed",
            "URL": "https://www.fda.gov/industry/structured-product-labeling-resources/pharmacologic-class",
            "DisplayControls": {
              "CreateTable": {
                "FromInformationIn": "ThisSection",
                "NumberOfColumns": 2,
                "ColumnContents": [
                  "Name",
                  "Value"
                ]
              }
            },
            "Information": [
              {
                "ReferenceNumber": 30,
                "Name": "FDA UNII",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "207SMY3FQT"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 30,
                "Name": "Active Moiety",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "VEMURAFENIB"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 30,
                "Name": "Pharmacological Classes",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Established Pharmacologic Class [EPC] - Kinase Inhibitor"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 30,
                "Name": "Pharmacological Classes",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Mechanisms of Action [MoA] - Protein Kinase Inhibitors"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 30,
                "Name": "Pharmacological Classes",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Mechanisms of Action [MoA] - Cytochrome P450 1A2 Inhibitors"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 30,
                "Name": "Pharmacological Classes",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Mechanisms of Action [MoA] - P-Glycoprotein Inhibitors"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 30,
                "Name": "FDA Pharmacology Summary",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Vemurafenib is a Kinase Inhibitor. The mechanism of action of vemurafenib is as a Protein Kinase Inhibitor, and Cytochrome P450 1A2 Inhibitor, and P-Glycoprotein Inhibitor.",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 62,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 31,
                "Name": "FDA UNII",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "207SMY3FQT"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 31,
                "Name": "Active Moiety",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "VEMURAFENIB"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 31,
                "Name": "Pharmacological Classes",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Established Pharmacologic Class [EPC] - Kinase Inhibitor"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 31,
                "Name": "Pharmacological Classes",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Mechanisms of Action [MoA] - Protein Kinase Inhibitors"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 31,
                "Name": "FDA Pharmacology Summary",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Vemurafenib is a Kinase Inhibitor. The mechanism of action of vemurafenib is as a Protein Kinase Inhibitor.",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 62,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 36,
                "Name": "Non-Proprietary Name",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "VEMURAFENIB"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 36,
                "Name": "Pharmacological Classes",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Kinase Inhibitor [EPC]; P-Glycoprotein Inhibitors [MoA]; Protein Kinase Inhibitors [MoA]; Cytochrome P450 1A2 Inhibitors [MoA]"
                    }
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "ATC Code",
            "Description": "The Anatomical Therapeutic Chemical (ATC) Classification System is used for the classification of drugs. This pharmaceutical coding system divides drugs into different groups according to the organ or system on which they act and/or their therapeutic and chemical characteristics. Each bottom-level ATC code stands for a pharmaceutically used substance, or a combination of substances, in a single indication (or use). This means that one drug can have more than one code: acetylsalicylic acid (aspirin), for example, has A01AD05 as a drug for local oral treatment, B01AC06 as a platelet inhibitor, and N02BA01 as an analgesic and antipyretic. On the other hand, several different brands share the same code if they have the same active substance and indications.",
            "URL": "http://www.whocc.no/atc/",
            "Information": [
              {
                "ReferenceNumber": 18,
                "Name": "ATC Code",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "L01EC01"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 42,
                "Reference": [
                  "S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355"
                ],
                "URL": "https://www.whocc.no/atc_ddd_index/?code=L01XE15",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "L01XE15"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 48,
                "Name": "ATC Code",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "L - Antineoplastic and immunomodulating agents",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 1,
                          "URL": "https://www.whocc.no/atc_ddd_index/?code=L"
                        }
                      ]
                    },
                    {
                      "String": "L01 - Antineoplastic agents",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 3,
                          "URL": "https://www.whocc.no/atc_ddd_index/?code=L01"
                        }
                      ]
                    },
                    {
                      "String": "L01E - Protein kinase inhibitors",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 4,
                          "URL": "https://www.whocc.no/atc_ddd_index/?code=L01E"
                        }
                      ]
                    },
                    {
                      "String": "L01EC - B-raf serine-threonine kinase (braf) inhibitors",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 5,
                          "URL": "https://www.whocc.no/atc_ddd_index/?code=L01EC"
                        },
                        {
                          "Start": 14,
                          "Length": 6,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/serine",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-5951"
                        },
                        {
                          "Start": 21,
                          "Length": 9,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/threonine",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-6288"
                        }
                      ]
                    },
                    {
                      "String": "L01EC01 - Vemurafenib",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 7,
                          "URL": "https://www.whocc.no/atc_ddd_index/?code=L01EC01"
                        }
                      ]
                    }
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "Absorption, Distribution and Excretion",
            "Information": [
              {
                "ReferenceNumber": 8,
                "Name": "Absorption",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Vemurafenib is well absorbed after oral administration. Peak concentrations are reached in 3 hours when an oral dose of 960 mg twice daily for 15 days has been given to patients. In the same conditions, Vemurafenib presents a Cmax of 62 mcg/ml and AUC of 601 mcg h/ml. It is unknown how food affects the absorption of vemurafenib. It presents an accumulation ratio of 7.36 after repeating doses of 960 mg",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 203,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 318,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 8,
                "Name": "Route of Elimination",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Analysis showed that 94% of administered Vemurafenib is excreted via feces and 1% is excreted by urine.",
                      "Markup": [
                        {
                          "Start": 41,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 8,
                "Name": "Volume of Distribution",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "The estimation of the volume of distribution for Vemurafenib is 106 L.",
                      "Markup": [
                        {
                          "Start": 49,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 8,
                "Name": "Clearance",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "The total body clearance is 31 L/day."
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Reference": [
                  "US Natl Inst Health; DailyMed. Current Medication Information for ZELBORAF (vemurafenib) tablet, film coated (April 2012). Available from, as of July 17, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=38eea320-7e0c-485a-bc30-98c3c45e2763"
                ],
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Following oral administration of (14)C-vemurafenib 960 mg in the tablet formulation, plasma samples were analyzed over 48 hours for vemurafenib and its metabolites. Mean data showed that vemurafenib and its metabolites represented 95% and 5% of the components in plasma, respectively.",
                      "Markup": [
                        {
                          "Start": 39,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 132,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 187,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Reference": [
                  "US Natl Inst Health; DailyMed. Current Medication Information for ZELBORAF (vemurafenib) tablet, film coated (April 2012). Available from, as of July 17, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=38eea320-7e0c-485a-bc30-98c3c45e2763"
                ],
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Vemurafenib is highly bound (> 99%) to human albumin and alpha-1 acid glycoprotein plasma proteins. The population apparent volume of distribution for vemurafenib in metastatic melanoma patients is estimated to be 106 L (with 66% inter-patient variability).",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 151,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Reference": [
                  "US Natl Inst Health; DailyMed. Current Medication Information for ZELBORAF (vemurafenib) tablet, film coated (April 2012). Available from, as of July 17, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=38eea320-7e0c-485a-bc30-98c3c45e2763"
                ],
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "The bioavailability of vemurafenib has not been determined. Following oral administration of vemurafenib at 960 mg twice daily for 15 days to patients with metastatic melanoma, the median Tmax was approximately 3 hours.  Following 15 days of dosing at 960 mg twice daily, the mean (+ or - SD) Cmax and AUC0-12 were 62 ug/mL + or - 17 and 601 + or - 170 ug*h/mL, respectively. The median accumulation ratio estimate from the population pharmacokinetic analysis for the twice daily regimen is 7.36, with steady state achieved at approximately 15 to 22 days following dosing at 960 mg twice daily. At steady state, the mean vemurafenib exposure in plasma is stable (concentrations before and 2-4 hours after the morning dose) as indicated by the mean ratio of 1.13.  The potential effect of food on vemurafenib absorption has not been studied. In clinical trials, vemurafenib was administered without regard to food.",
                      "Markup": [
                        {
                          "Start": 23,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 93,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 621,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 796,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 861,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Reference": [
                  "US Natl Inst Health; DailyMed. Current Medication Information for ZELBORAF (vemurafenib) tablet, film coated (April 2012). Available from, as of July 17, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=38eea320-7e0c-485a-bc30-98c3c45e2763"
                ],
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Following oral administration of (14)C-vemurafenib 960 mg in the tablet formulation, approximately 94% of the radioactive dose was recovered in feces and approximately 1% was recovered in the urine. The population apparent clearance of vemurafenib in patients with metastatic melanoma is estimated to be 31 L/day (with 32% inter-patient variability).",
                      "Markup": [
                        {
                          "Start": 39,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 236,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "For more Absorption, Distribution and Excretion (Complete) data for Vemurafenib (6 total), please visit the HSDB record page.",
                      "Markup": [
                        {
                          "Start": 108,
                          "Length": 16,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/source/hsdb/8143#section=Absorption-Distribution-and-Excretion-(Complete)"
                        },
                        {
                          "Start": 68,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "Metabolism/Metabolites",
            "Description": "Metabolism/Metabolites information related to the record",
            "Information": [
              {
                "ReferenceNumber": 8,
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Vemurafenib is metabolized by CYP3A4 and the metabolites make up 5% of the components in plasma. The parent compound makes up for the remaining 95%.",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Reference": [
                  "European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report (EPAR): Vemurafenib p.20 (2012). Available from, as of July 17, 2013: https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002409/WC500124400.pdf"
                ],
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "The results from in vitro studies indicate that CYP3A4 was the major enzyme responsible in the metabolism of vemurafenib. The formation of mono-hydroxyl metabolites were inhibited for approximately 82% using the CYP inhibitor ketoconazole. No significant inhibition in the metabolism was observed in human liver microsomes in the presence of quinidine (CYP2D6 inhibitor), sulfaphenazole (CYP2C9 inhibitor), tranylcypromine (CYP2A6 inhibitor) and (-)-N-3-benzyl-phenobarbital (CYP2C19 inhibitor). In addition, CYP3A4 was responsible for the formation of the mono-hydroxylation metabolites.",
                      "Markup": [
                        {
                          "Start": 109,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 226,
                          "Length": 12,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/ketoconazole",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-3823"
                        },
                        {
                          "Start": 342,
                          "Length": 9,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/quinidine",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-441074"
                        },
                        {
                          "Start": 372,
                          "Length": 14,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/sulfaphenazole",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-5335"
                        },
                        {
                          "Start": 407,
                          "Length": 15,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/tranylcypromine",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-5530"
                        },
                        {
                          "Start": 461,
                          "Length": 13,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/phenobarbital",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-4763"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Reference": [
                  "European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report (EPAR): Vemurafenib p.19 (2012). Available from, as of July 17, 2013: https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002409/WC500124400.pdf"
                ],
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "In vitro metabolism was analyzed for rat, mouse, dog, cynomolgus and human. The metabolism of vemurafenib was investigated both in vitro using microsomes and hepatocytes of various species and in vivo in rat, dog and human. In vitro analysis of vemurafenib metabolism in liver hepatocytes at the concentration of 10 uM, humans, dogs, and cynomolgus monkeys did not metabolize vemurafenib extensively (unchanged vemurafenib > or = 89%).",
                      "Markup": [
                        {
                          "Start": 94,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 245,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 376,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 411,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Reference": [
                  "European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report (EPAR): Vemurafenib p.33 (2012). Available from, as of July 17, 2013: https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002409/WC500124400.pdf"
                ],
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "In study /of patients/, identification of vemurafenib and metabolites in plasma, feces and urine was made for the first 96 hr, with a total collection period of 432 hrs (18 days). Mean data from the 7 patients indicated that over the period investigated (0 to 96 hours), potential metabolites each accounted for < 0.5% of the total administered dose in urine and .6% of the total administered dose in feces. In pooled fecal samples up to 48 hours post post-dose, parent compound accounted for at least 94% of total radioactivity (37% of the dose). In fecal samples taken 48-96 hr post-dose, the amount of metabolites increased, with M6, M3, and M8 representing approximately 19%, 14% and 12%, of the total chromatographic peak area, respectively (mean values) or 3%, 5% and 4% of the dose, respectively. Over the 0-96 hr collection period, potential metabolites M3 (mono-hydroxy) and M6 (glucosylation) each accounted for <0.5% of the total administered dose in urine. Vemurafenib accounted for approximately 1% of the total dose in urine.",
                      "Markup": [
                        {
                          "Start": 42,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "Biological Half-Life",
            "Description": "Biological Half-Life information related to the record",
            "Information": [
              {
                "ReferenceNumber": 8,
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "The elimination half-life of Vemurafenib is estimated to be 57 hours (range of 30-120 hours).",
                      "Markup": [
                        {
                          "Start": 29,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Reference": [
                  "European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report (EPAR): Vemurafenib p.19 (2012). Available from, as of July 17, 2013: https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002409/WC500124400.pdf"
                ],
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Single dose studies to determine pharmacokinetics were conducted in mouse, rat, rabbit, dog and monkey. In all pre-clinical species, half-lifes were between 2 and 5 hours ... . Only after intraperitoneal (IP) administration in mice, the half-life was much longer (20.6 h). Compared with other species, rabbits showed higher plasma exposure levels with a longer mean terminal half-life between 12 and 18 hours."
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Reference": [
                  "US Natl Inst Health; DailyMed. Current Medication Information for ZELBORAF (vemurafenib) tablet, film coated (April 2012). Available from, as of July 17, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=38eea320-7e0c-485a-bc30-98c3c45e2763"
                ],
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "The median of the individual elimination half-life estimates for vemurafenib is 57 hours (the 5th and 95th percentile range is 30 to 120 hours).",
                      "Markup": [
                        {
                          "Start": 65,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "Mechanism of Action",
            "Description": "Mechanism of Action  information related to the record",
            "Information": [
              {
                "ReferenceNumber": 8,
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase. Vemurafenif is a small molecule that interacts as a competitive inhibitor of the mutated species of BRAF. It is especially potent against the BRAF V600E mutation. Vemurafenib blocks downstream processes to inhibit tumour growth and eventually trigger apoptosis. Vemurafenib does not have antitumour effects against melanoma cell lines with the wild-type BRAF mutation.",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 61,
                          "Length": 6,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/serine",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-5951"
                        },
                        {
                          "Start": 68,
                          "Length": 9,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/threonine",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-6288"
                        },
                        {
                          "Start": 249,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 348,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Reference": [
                  "European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report (EPAR): Vemurafenib p.17 (2012). Available from, as of July 17, 2013: https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002409/WC500124400.pdf"
                ],
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Cutaneous squamous cell carcinoma (cuSCC) has been reported in patients with metastatic melanoma and CRC treated with vemurafenib. Clinical findings indicate that cuSCC may be related to treatment with vemurafenib. In order to understand the potential mechanism by which vemurafenib treatment contributes to development of cuSCC, vemurafenib was tested in vivo in the A431 cuSCC xenograft model. There was dose-dependent tumour growth stimulation of the xenograft tumours at doses higher than 25 mg/kg bid. The optimal dose of 75 mg/kg bid of vemurafenib caused a 103% induction of growth compared to the control (p=0.002). Immunohistochemistry showed staining of pERK only in the tumour samples treated with vemurafenib (75 mg/kg) as compared to the vehicle treated control group. Combination studies of vemurafenib and a MEK inhibitor, RO5068760, were performed to confirm inhibition of pERK.",
                      "Markup": [
                        {
                          "Start": 118,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 202,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 271,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 330,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 543,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 709,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 805,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 823,
                          "Length": 3,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/MEK",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-6569"
                        },
                        {
                          "Start": 838,
                          "Length": 9,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/RO5068760",
                          "Type": "PubChem Internal Link",
                          "Extra": "multiple-CIDs"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Reference": [
                  "European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report (EPAR): Vemurafenib p.14 (2012). Available from, as of July 17, 2013: https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002409/WC500124400.pdf"
                ],
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "The effect of vemurafenib on RAF-MEK-ERK pathway inhibition was investigated in a panel of cancer cell lines, including melanoma cell lines expressing BRAFV600E, BRAFV600D, BRAFV600R, or BRAFWT. MEK and ERK phosphorylation (pMEK and pERK respectively) immunoassays were conducted to measure the levels of pMEK and pERK in various cancer cells treated with vemurafenib compared to vehicle control In cells expressing mutated BRAF (Colo829,WM2664 and WM1341D), vemurafenib inhibited both pERK and pMEK in a dose dependent manner. However, cells expressing BRAF WT vemurafenib induced rather than inhibited ERK or MEK phosphorylation in the cells expressing BRAFWT, such as HCT116, CHL-1 and SK-MEL-2 cells.",
                      "Markup": [
                        {
                          "Start": 14,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 33,
                          "Length": 3,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/MEK",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-6569"
                        },
                        {
                          "Start": 195,
                          "Length": 3,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/MEK",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-6569"
                        },
                        {
                          "Start": 356,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 459,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 562,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 611,
                          "Length": 3,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/MEK",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-6569"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Reference": [
                  "US Natl Inst Health; DailyMed. Current Medication Information for ZELBORAF (vemurafenib) tablet, film coated (April 2012). Available from, as of July 17, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=38eea320-7e0c-485a-bc30-98c3c45e2763"
                ],
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Vemurafenib is a low molecular weight, orally available, inhibitor of some mutated forms of BRAF serine-threonine kinase, including BRAFV600E. Vemurafenib also inhibits other kinases in vitro such as CRAF, ARAF, wild-type BRAF, SRMS, ACK1, MAP4K5 and FGR at similar concentrations. Some mutations in the BRAF gene including V600E result in constitutively activated BRAF proteins, which can cause cell proliferation in the absence of growth factors that would normally be required for proliferation. Vemurafenib has anti-tumor effects in cellular and animal models of melanomas with mutated BRAFV600E.",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 97,
                          "Length": 6,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/serine",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-5951"
                        },
                        {
                          "Start": 104,
                          "Length": 9,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/threonine",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-6288"
                        },
                        {
                          "Start": 143,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 499,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              }
            ]
          }
        ]
      },
      {
        "TOCHeading": "Use and Manufacturing",
        "Description": "The use and manufacture of the chemical and related information",
        "Section": [
          {
            "TOCHeading": "Uses",
            "Description": "This section presents the major uses of the chemical in the United States today. In addition, past uses of the chemical are summarized.",
            "Information": [
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Reference": [
                  "US Natl Inst Health; DailyMed. Current Medical Information. Available from, as of Jun 27, 2013: https://dailymed.nlm.nih.gov/dailymed/about.cfm"
                ],
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Antineoplastic"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "MEDICATION"
                    }
                  ]
                }
              }
            ],
            "Section": [
              {
                "TOCHeading": "Use Classification",
                "Description": "This section contains use classification/category information from various sources",
                "Information": [
                  {
                    "ReferenceNumber": 18,
                    "Name": "Use Classification",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Human drugs -> Zelboraf -> EMA Drug Category",
                          "Markup": [
                            {
                              "Start": 15,
                              "Length": 8,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Zelboraf",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 18,
                    "Name": "Use Classification",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Antineoplastic agents -> Human pharmacotherapeutic group"
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 19,
                    "Name": "Use Classification",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Human drugs -> Rare disease (orphan)"
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 20,
                    "Name": "Use Classification",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Human drugs -> Rare disease (orphan)"
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 21,
                    "Name": "Use Classification",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Human Drugs -> EU pediatric investigation plans"
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 29,
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients"
                        }
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "TOCHeading": "Formulations/Preparations",
            "Description": "Formulations/Preparations from HSDB and other sources",
            "Information": [
              {
                "ReferenceNumber": 33,
                "Description": "PEER REVIEWED",
                "Reference": [
                  "American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1235"
                ],
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Oral: Tablets, film-coated: 240 mg, Zelboraf (Genentech).",
                      "Markup": [
                        {
                          "Start": 36,
                          "Length": 8,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Zelboraf",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              }
            ]
          }
        ]
      },
      {
        "TOCHeading": "Safety and Hazards",
        "Description": "Safety and hazards information, properties, management techniques, reactivities and incompatibilities, first aid treatments, and more. For toxicity and related information, please visit Toxicity section.",
        "Section": [
          {
            "TOCHeading": "Hazards Identification",
            "Description": "Hazards Identification includes all hazards regarding the chemical; required label elements",
            "Section": [
              {
                "TOCHeading": "GHS Classification",
                "Description": "GHS (Globally Harmonized System of Classification and Labelling of Chemicals) is a United Nations system to identify hazardous chemicals and to inform users about these hazards. GHS has been adopted by many countries around the world and is now also used as the basis for international and national transport regulations for dangerous goods. The GHS hazard statements, class categories, pictograms, signal words, and the precautionary statements can be found on the PubChem GHS page.",
                "URL": "https://pubchem.ncbi.nlm.nih.gov/ghs/",
                "DisplayControls": {
                  "CreateTable": {
                    "FromInformationIn": "ThisSection",
                    "NumberOfColumns": 2,
                    "ColumnContents": [
                      "Name",
                      "Value"
                    ]
                  },
                  "ShowAtMost": 1
                },
                "Information": [
                  {
                    "ReferenceNumber": 14,
                    "Name": "Pictogram(s)",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "          ",
                          "Markup": [
                            {
                              "Start": 0,
                              "Length": 1,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/images/ghs/GHS07.svg",
                              "Type": "Icon",
                              "Extra": "Irritant"
                            },
                            {
                              "Start": 1,
                              "Length": 1,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/images/ghs/GHS08.svg",
                              "Type": "Icon",
                              "Extra": "Health Hazard"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 14,
                    "Name": "Signal",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Danger",
                          "Markup": [
                            {
                              "Start": 0,
                              "Length": 6,
                              "Type": "Color",
                              "Extra": "GHSDanger"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 14,
                    "Name": "GHS Hazard Statements",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]",
                          "Markup": [
                            {
                              "Start": 35,
                              "Length": 7,
                              "Type": "Color",
                              "Extra": "GHSWarning"
                            }
                          ]
                        },
                        {
                          "String": "H350 (100%): May cause cancer [Danger Carcinogenicity]",
                          "Markup": [
                            {
                              "Start": 31,
                              "Length": 6,
                              "Type": "Color",
                              "Extra": "GHSDanger"
                            }
                          ]
                        },
                        {
                          "String": "H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]",
                          "Markup": [
                            {
                              "Start": 66,
                              "Length": 7,
                              "Type": "Color",
                              "Extra": "GHSWarning"
                            }
                          ]
                        },
                        {
                          "String": "H373 (100%): Causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]",
                          "Markup": [
                            {
                              "Start": 77,
                              "Length": 7,
                              "Type": "Color",
                              "Extra": "GHSWarning"
                            }
                          ]
                        },
                        {
                          "String": "H413 (100%): May cause long lasting harmful effects to aquatic life [Hazardous to the aquatic environment, long-term hazard]"
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 14,
                    "Name": "Precautionary Statement Codes",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "P203, P260, P264, P270, P273, P280, P301+P317, P318, P319, P330, P405, and P501"
                        },
                        {
                          "String": "(The corresponding statement to each P-code can be found at the GHS Classification page.)",
                          "Markup": [
                            {
                              "Start": 64,
                              "Length": 18,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/ghs/#_prec"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 14,
                    "Name": "ECHA C&L Notifications Summary",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.",
                          "Markup": [
                            {
                              "Start": 0,
                              "Length": 92,
                              "Type": "Italics"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 15,
                    "Name": "Pictogram(s)",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "          ",
                          "Markup": [
                            {
                              "Start": 0,
                              "Length": 1,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/images/ghs/GHS09.svg",
                              "Type": "Icon",
                              "Extra": "Environmental Hazard"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 15,
                    "Name": "Signal",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Warning",
                          "Markup": [
                            {
                              "Start": 0,
                              "Length": 7,
                              "Type": "Color",
                              "Extra": "GHSWarning"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 15,
                    "Name": "GHS Hazard Statements",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "H410 (100%): Very toxic to aquatic life with long lasting effects [Warning Hazardous to the aquatic environment, long-term hazard]",
                          "Markup": [
                            {
                              "Start": 67,
                              "Length": 7,
                              "Type": "Color",
                              "Extra": "GHSWarning"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 15,
                    "Name": "Precautionary Statement Codes",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "P273, P391, and P501"
                        },
                        {
                          "String": "(The corresponding statement to each P-code can be found at the GHS Classification page.)",
                          "Markup": [
                            {
                              "Start": 64,
                              "Length": 18,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/ghs/#_prec"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 15,
                    "Name": "ECHA C&L Notifications Summary",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.",
                          "Markup": [
                            {
                              "Start": 0,
                              "Length": 92,
                              "Type": "Italics"
                            }
                          ]
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Hazard Classes and Categories",
                "Description": "The Hazard Classes and Categories are aligned with GHS (Globally Harmonized System of Classification and Labelling of Chemicals) hazard statement codes. More info can be found at the PubChem GHS summary page. The percentage data in the parenthesis from ECHA indicates that the hazard classes and categories information are consolidated from multiple companies, see the detailed explanation from the above GHS classification section.",
                "URL": "https://pubchem.ncbi.nlm.nih.gov/ghs/",
                "DisplayControls": {
                  "ShowAtMost": 2
                },
                "Information": [
                  {
                    "ReferenceNumber": 14,
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Acute Tox. 4 (100%)"
                        },
                        {
                          "String": "Carc. 1A (100%)"
                        },
                        {
                          "String": "Repr. 2 (100%)"
                        },
                        {
                          "String": "STOT RE 2 (100%)"
                        },
                        {
                          "String": "Aquatic Chronic 4 (100%)"
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 15,
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Aquatic Chronic 1 (100%)"
                        }
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "TOCHeading": "Fire Fighting",
            "Description": "Fire Fighting information",
            "Section": [
              {
                "TOCHeading": "Fire Fighting Procedures",
                "Description": "Fire fighting measures list suitable extinguishing techniques, equipment; chemical hazards from fire.",
                "Information": [
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "Selleck Chemicals; Material Safety Data Sheet: Vemurafenib, Cat. Number S1267, RN 918504-65-1 (Revision Date: 10/1/2012). Available from, as of July 19, 2013: https://www.selleckchem.com/msds/PLX-4032-MSDS.html"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Suitable extinguishing agents: water spray, carbon dioxide, dry chemical powder or foam. Protective equipment: wear self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes.",
                          "Markup": [
                            {
                              "Start": 31,
                              "Length": 5,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/water",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-962"
                            },
                            {
                              "Start": 44,
                              "Length": 14,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/carbon%20dioxide",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-280"
                            }
                          ]
                        }
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "TOCHeading": "Accidental Release Measures",
            "Description": "Accidental release measures lists emergency procedures; protective equipment; proper methods of containment and cleanup.",
            "Section": [
              {
                "TOCHeading": "Cleanup Methods",
                "Description": "Procedures for cleanup",
                "Information": [
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "Selleck Chemicals; Material Safety Data Sheet: Vemurafenib, Cat. Number S1267, RN 918504-65-1 (Revision Date: 10/1/2012). Available from, as of July 19, 2013: https://www.selleckchem.com/msds/PLX-4032-MSDS.html"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Accidental release measures: After Inhalation: cordon off area of spill; wear self-contained breathing apparatus, protective clothing and heavy rubber gloves. Measures for cleaning/collecting: absorb solutions with finely- powdered liquid-binding material (diatomite, universal binders); decontaminate surfaces and equipment by scrubbing with alcohol; dispose of contaminated material /in accordance with prevailing country, federal, state and local regulations/."
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Disposal Methods",
                "Description": "Disposal Methods for this chemical",
                "Information": [
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational harm/injury/toxicity or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal and plant life; and conformance with environmental and public health regulations.",
                          "Markup": [
                            {
                              "Start": 411,
                              "Length": 5,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/water",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-962"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator."
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Preventive Measures",
                "Description": "Information on Preventive Measures",
                "Information": [
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "Selleck Chemicals; Material Safety Data Sheet: Vemurafenib, Cat. Number S1267, RN 918504-65-1 (Revision Date: 10/1/2012). Available from, as of July 19, 2013: https://www.selleckchem.com/msds/PLX-4032-MSDS.html"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Information for safe handling: avoid inhalation and contact with skin, eyes and clothing; material may be an irritant."
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "Selleck Chemicals; Material Safety Data Sheet: Vemurafenib, Cat. Number S1267, RN 918504-65-1 (Revision Date: 10/1/2012). Available from, as of July 19, 2013: https://www.selleckchem.com/msds/PLX-4032-MSDS.html"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Handling should only be performed by personnel trained and familiar with handling of potent active pharmaceutical ingredients."
                        }
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "TOCHeading": "Handling and Storage",
            "Description": "Handling and storage lists precautions for safe handling and storage, including incompatibilities.",
            "Section": [
              {
                "TOCHeading": "Storage Conditions",
                "Description": "Information for Storage Conditions",
                "Information": [
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "US Natl Inst Health; DailyMed. Current Medication Information for ZELBORAF (vemurafenib) tablet, film coated (April 2012). Available from, as of July 17, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=38eea320-7e0c-485a-bc30-98c3c45e2763"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Store at room temperature 20 C - 25 degC (68 F - 77 F); excursions permitted between 15 C and 30 C (59 F and 86 F), See USP Controlled Room Temperature. Store in the original container with the lid tightly closed."
                        }
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "TOCHeading": "Exposure Control and Personal Protection",
            "Description": "This section contains chemical safety data related to Exposure controls and personal protection list OSHA's, Permissible Exposure Limits (PELs), Threshold Limit Values (TLVs), appropriate engineering controls, personal protective equipment (PPE), Biological Exposure Indices (BEI), Concentration producing a 50% decrease in respiratory rate in experimental animals following a 10-minute exposure (RD50), Maximum Allowable Concentration from German Research Foundation (MAK), and more.",
            "Section": [
              {
                "TOCHeading": "Personal Protective Equipment (PPE)",
                "Description": "Personal Protection and related information",
                "Information": [
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "Selleck Chemicals; Material Safety Data Sheet: Vemurafenib, Cat. Number S1267, RN 918504-65-1 (Revision Date: 10/1/2012). Available from, as of July 19, 2013: https://www.selleckchem.com/msds/PLX-4032-MSDS.html"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Personal protective equipment as follows: Breathing equipment: NIOSH/MSHA-approved respirator.   Protection of hands: chemical-resistant rubber gloves. Eye protection: chemical safety goggles."
                        }
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "TOCHeading": "Regulatory Information",
            "Description": "Related Regulatory Information",
            "Section": [
              {
                "TOCHeading": "FDA Requirements",
                "Description": "FDA Requirements for the chemical's safety and hard information",
                "Information": [
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "DHHS/FDA; Electronic Orange Book-Approved Drug Products with Therapeutic Equivalence Evaluations. Available from, as of July 29, 2013: https://www.fda.gov/cder/ob/"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including vemurafenib, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.",
                          "Markup": [
                            {
                              "Start": 136,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "TOCHeading": "Other Safety Information",
            "Description": "Other Safety Information includes the date of preparation or last revision",
            "Section": [
              {
                "TOCHeading": "Toxic Combustion Products",
                "Description": "Toxic Combustion Products and related information",
                "Information": [
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "Selleck Chemicals; Material Safety Data Sheet: Vemurafenib, Cat. Number S1267, RN 918504-65-1 (Revision Date: 10/1/2012). Available from, as of July 19, 2013: https://www.selleckchem.com/msds/PLX-4032-MSDS.html"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Emits toxic fumes such as carbon monoxide, etc.",
                          "Markup": [
                            {
                              "Start": 26,
                              "Length": 15,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/carbon%20monoxide",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-281"
                            }
                          ]
                        }
                      ]
                    }
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "TOCHeading": "Toxicity",
        "Description": "Toxicity information related to this record, includes routes of exposure; related symptoms, acute and chronic effects; numerical measures of toxicity.",
        "Section": [
          {
            "TOCHeading": "Toxicological Information",
            "Description": "Toxicological Information",
            "Section": [
              {
                "TOCHeading": "Toxicity Summary",
                "Description": "Toxicity Summary",
                "Information": [
                  {
                    "ReferenceNumber": 8,
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "In the few toxicity reports, it has been shown an increased in the development of cutaneous squamous cell carcinomas or acceleration in pre-existant tumor growth."
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Hepatotoxicity",
                "Description": "This section provides a short description about the hepatotoxicity that associated with the agent, the rate of serum enzyme elevations during use, and the frequency and character of the clinically apparent liver injury associated with the medication.",
                "URL": "https://www.ncbi.nlm.nih.gov/books/NBK547852/",
                "Information": [
                  {
                    "ReferenceNumber": 34,
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "In large clinical trials of vemurafenib, abnormalities in routine liver tests were common and serum aminotransferase elevations occurred in up to one third of patients. ALT and AST values greater than 5 times the upper limit of normal (ULN) occurred in 3% of patients, and rare instances of clinically apparent liver injury were reported, but the clinical features of the injury have not been described. The onset of liver test abnormalities was typically within 3 to 6 weeks of starting vemurafenib, and the abnormalities resolved rapidly either spontaneously or with temporary drug discontinuation. Vermurafenib has also been linked to instances of drug related rash with eosinophilia and systemic manifestations (DRESS) as well as Stevens Johnson syndrome, both of which can be accompanied by liver dysfunction and in some cases jaundice with clinically apparent liver injury.",
                          "Markup": [
                            {
                              "Start": 28,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 488,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        },
                        {
                          "String": "Likelihood score: E* (unproven but suspected cause of clinically apparent liver injury."
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Interactions",
                "Description": "Interactions",
                "Information": [
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1235"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Concomitant use of vemurafenib with drugs known to prolong the QT interval, including class Ia (e.g., quinidine, procainamide) and class III (e.g., amiodarone, sotalol) antiarrhythmic agents, some antipsychotic agents (e.g., chlorpromazine, thioridazine, haloperidol, asenapine, olanzapine, paliperidone, pimozide, quetiapine, ziprasidone), some antibiotics (e.g., gatifloxacin, moxifloxacin), and tetrabenazine is not recommended by the manufacturer.",
                          "Markup": [
                            {
                              "Start": 19,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 102,
                              "Length": 9,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/quinidine",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-441074"
                            },
                            {
                              "Start": 113,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/procainamide",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-4913"
                            },
                            {
                              "Start": 148,
                              "Length": 10,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/amiodarone",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-2157"
                            },
                            {
                              "Start": 160,
                              "Length": 7,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/sotalol",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-5253"
                            },
                            {
                              "Start": 225,
                              "Length": 14,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/chlorpromazine",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-2726"
                            },
                            {
                              "Start": 241,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/thioridazine",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-5452"
                            },
                            {
                              "Start": 255,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/haloperidol",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-3559"
                            },
                            {
                              "Start": 268,
                              "Length": 9,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/asenapine",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-9903970"
                            },
                            {
                              "Start": 279,
                              "Length": 10,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/olanzapine",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-135398745"
                            },
                            {
                              "Start": 291,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/paliperidone",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-115237"
                            },
                            {
                              "Start": 305,
                              "Length": 8,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/pimozide",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-16362"
                            },
                            {
                              "Start": 315,
                              "Length": 10,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/quetiapine",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-5002"
                            },
                            {
                              "Start": 327,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/ziprasidone",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-60854"
                            },
                            {
                              "Start": 365,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/gatifloxacin",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-5379"
                            },
                            {
                              "Start": 379,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/moxifloxacin",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-152946"
                            },
                            {
                              "Start": 398,
                              "Length": 13,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/tetrabenazine",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-6018"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1235"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Concomitant use of vemurafenib with CYP2C9 substrates may result in increased plasma concentrations of the CYP2C9 substrate and possible toxicity. When the CYP2C9 substrate warfarin was administered concomitantly with vemurafenib, the systemic exposure of S-warfarin increased by 18%. Vemurafenib and warfarin should be used concomitantly with caution and additional monitoring of the international normalized ratio (INR) should be considered.",
                          "Markup": [
                            {
                              "Start": 19,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 173,
                              "Length": 8,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/warfarin",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-54678486"
                            },
                            {
                              "Start": 218,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 256,
                              "Length": 10,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/S-warfarin",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-54688261"
                            },
                            {
                              "Start": 285,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 301,
                              "Length": 8,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/warfarin",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-54678486"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1235"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Concomitant use of vemurafenib with CYP3A4 substrates may result in decreased plasma concentrations of the CYP3A4 substrate and possible decreased efficacy. When the CYP3A4 substrate midazolam was administered concomitantly with vemurafenib, the systemic exposure of midazolam decreased by 39%. Concomitant use of vemurafenib with CYP3A4 substrates that have a narrow therapeutic index should be avoided.",
                          "Markup": [
                            {
                              "Start": 19,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 183,
                              "Length": 9,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/midazolam",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-4192"
                            },
                            {
                              "Start": 229,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 267,
                              "Length": 9,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/midazolam",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-4192"
                            },
                            {
                              "Start": 314,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1235"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Concomitant use of vemurafenib with CYP2D6 substrates may result in increased plasma concentrations of the CYP2D6 substrate and possible toxicity. When the CYP2D6 substrate dextromethorphan was administered concomitantly with vemurafenib, the systemic exposure of dextromethorphan increased by 47%. Concomitant use of vemurafenib with CYP2D6 substrates that have a narrow therapeutic index should be avoided. If concomitant use cannot be avoided, dosage reduction of the CYP2D6 substrate should be considered, and the drugs should be used concomitantly with caution.",
                          "Markup": [
                            {
                              "Start": 19,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 173,
                              "Length": 16,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/dextromethorphan",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-5360696"
                            },
                            {
                              "Start": 226,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 264,
                              "Length": 16,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/dextromethorphan",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-5360696"
                            },
                            {
                              "Start": 318,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "For more Interactions (Complete) data for Vemurafenib (9 total), please visit the HSDB record page.",
                          "Markup": [
                            {
                              "Start": 82,
                              "Length": 16,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/source/hsdb/8143#section=Interactions-(Complete)"
                            },
                            {
                              "Start": 42,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Antidote and Emergency Treatment",
                "Description": "Antidote and Emergency Treatment",
                "Information": [
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "Currance, P.L. Clements, B., Bronstein, A.C. (Eds).; Emergency Care For Hazardous Materials Exposure. 3Rd edition, Elsevier Mosby, St. Louis, MO 2005, p. 160"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/",
                          "Markup": [
                            {
                              "Start": 324,
                              "Length": 5,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/water",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-962"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "Currance, P.L. Clements, B., Bronstein, A.C. (Eds).; Emergency Care For Hazardous Materials Exposure. 3Rd edition, Elsevier Mosby, St. Louis, MO 2005, p. 160"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/",
                          "Markup": [
                            {
                              "Start": 216,
                              "Length": 6,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/element/Oxygen",
                              "Type": "PubChem Internal Link",
                              "Extra": "Element-Oxygen"
                            },
                            {
                              "Start": 468,
                              "Length": 5,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/water",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-962"
                            },
                            {
                              "Start": 637,
                              "Length": 5,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/water",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-962"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "Currance, P.L. Clements, B., Bronstein, A.C. (Eds).; Emergency Care For Hazardous Materials Exposure. 3Rd edition, Elsevier Mosby, St. Louis, MO 2005, p. 160-1"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: \"To keep open\", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... .  /Poisons A and B/",
                          "Markup": [
                            {
                              "Start": 378,
                              "Length": 9,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/albuterol",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-2083"
                            },
                            {
                              "Start": 766,
                              "Length": 8,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/diazepam",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-3016"
                            },
                            {
                              "Start": 778,
                              "Length": 9,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/lorazepam",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-3958"
                            },
                            {
                              "Start": 798,
                              "Length": 26,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/proparacaine%20hydrochloride",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-517321"
                            }
                          ]
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Human Toxicity Excerpts",
                "Description": "Human Toxicity Excerpts",
                "Information": [
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "PMID:22828249",
                      "Minor DR et al; Melanoma Res 22 (5): 410-1 (2012)"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "/CASE REPORTS/ The BRAF inhibitor vemurafenib can cause severe cutaneous reactions, including Stevens-Johnson syndrome, particularly when administered after ipilimumab, which usually prevents further drug administration. /The investigators/ report the case of a patient with Stevens-Johnson syndrome due to vemurafenib, who was retreated with vemurafenib with a program of slow desensitization with dexamethasone and diphenhydramine. Vemurafenib was tolerated at a 50% dose after a 3-week desensitization. Desensitization may be possible in patients who develop Stevens-Johnson syndrome after vemurafenib treatment.",
                          "Markup": [
                            {
                              "Start": 34,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 307,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 343,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 399,
                              "Length": 13,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/dexamethasone",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-5743"
                            },
                            {
                              "Start": 417,
                              "Length": 15,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/diphenhydramine",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-3100"
                            },
                            {
                              "Start": 434,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 593,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "PMID:22828248",
                      "Monfort JB et al; Melanoma Res 22 (5): 399-401 (2012)"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "/CASE REPORTS/ Vemurafenib is a targeted therapy, used in patients with metastatic cutaneous melanoma who carry the BRAF V600E mutation, with a relative reduction of 63% in the risk of death. Several adverse events have been described previously, such as photosensitivity or squamous-cell carcinomas. Two cases of panniculitis have been reported recently with two different selective BRAF inhibitors. /The reseaerchers/ report two cases of neutrophilic panniculitis in patients treated by vemurafenib for a metastatic melanoma. Clinical and biological examinations showed no indications for an immune nor an infectious cause of neutrophilic panniculitis. Thus, /the researchers/ believe that vemurafenib caused this panniculitis. Treatment with vemurafenib was maintained in both patients because of the clinical and radiological tumoral responses. One patient showed spontaneous recovery, whereas the other patient presented several recurrences of panniculitis. We believe that physicians should be aware of this cutaneous side effect of vemurafenib, but it should not lead to discontinuation of this treatment.",
                          "Markup": [
                            {
                              "Start": 15,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 489,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 692,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 745,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 1039,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "PMID:23626542",
                      "Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3617885",
                      "Schmitt L et al; Case Rep Dermatol 5 (1): 69-72 (2013)"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "/CASE REPORTS/ The BRAF inhibitor vemurafenib is state of the art in therapy of patients with malignant melanoma in non-resectable stage III or stage IV and evidence of oncogenetic BRAF mutation. Multiple cutaneous side effects like rash and keratoacanthoma-like lesions have been described so far./The researchers/ report a patient who presented multiple wart-like lesions under therapy with vemurafenib. Histologically we have seen multiple melanocytic nevi with a wart-like appearance. One melanoma in situ developed on the left forearm. Eruptive nevi and induction of melanoma may be a further side effect in patients undergoing a therapy with BRAF inhibitors",
                          "Markup": [
                            {
                              "Start": 34,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 393,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "Gupta M et al; Arch Dermatol 148 (8): 966-8 (2012) 22911209"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "/CASE REPORTS/ Treatment with vemurafenib, a small-molecule BRAF inhibitor, has led to dramatic regression of metastatic melanomas harboring a V600E BRAF mutation. As with other kinase inhibitors, the use of vemurafenib has been accompanied by several dermatologic adverse effects. We describe a patient who experienced exacerbation of preexisting acantholytic dyskeratosis in a dose-dependent manner shortly after starting vemurafenib treatment. This was subsequently complicated by Kaposi varicelliform eruption and cessation of the drug treatment owing to progression of the disease.",
                          "Markup": [
                            {
                              "Start": 30,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 208,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 424,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "For more Human Toxicity Excerpts (Complete) data for Vemurafenib (9 total), please visit the HSDB record page.",
                          "Markup": [
                            {
                              "Start": 93,
                              "Length": 16,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/source/hsdb/8143#section=Human-Toxicity-Excerpts-(Complete)"
                            },
                            {
                              "Start": 53,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Non-Human Toxicity Excerpts",
                "Description": "Non-Human Toxicity Excerpts",
                "Information": [
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report (EPAR): Vemurafenib p.18 (2012). Available from, as of July 17, 2013: https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002409/WC500124400.pdf"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "/LABORATORY ANIMALS: Acute Exposure/ ...  Vemurafenib was administered as a single oral dose to male Sprague Dawley rats at doses of 0, 30, 100, or 1000 mg/kg (corn oil formulation). Animals were observed twice daily for mortality and moribundity. The positive control, chlorpromazine, produced the expected cascade of CNS depression. The NOAEL of vemurafenib was 1000 mg/kg with an estimated Cmax of 160 uM.",
                          "Markup": [
                            {
                              "Start": 42,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 270,
                              "Length": 14,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/chlorpromazine",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-2726"
                            },
                            {
                              "Start": 348,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "US Natl Inst Health; DailyMed. Current Medication Information for ZELBORAF (vemurafenib) tablet, film coated (April 2012). Available from, as of July 17, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=38eea320-7e0c-485a-bc30-98c3c45e2763"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Consistent with the increased incidence of cutaneous squamous cell carcinomas in patients treated with vemurafenib, the treatment of mice implanted with human cuSCC cells with vemurafenib caused a dose dependent acceleration of the growth of the implanted tumors.",
                          "Markup": [
                            {
                              "Start": 161,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 234,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "US Natl Inst Health; DailyMed. Current Medication Information for ZELBORAF (vemurafenib) tablet, film coated (April 2012). Available from, as of July 17, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=38eea320-7e0c-485a-bc30-98c3c45e2763"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Vemurafenib revealed no evidence of teratogenicity in rat embryo/fetuses at doses up to 250 mg/kg/day (approximately 1.3 times the human clinical exposure based on AUC) or rabbit embryo/fetuses at doses up to 450 mg/kg/day (approximately 0.6 times the human clinical exposure based on AUC). Fetal drug levels were 3-5% of maternal levels, indicating that vemurafenib has the potential to be transmitted from the mother to the developing fetus.",
                          "Markup": [
                            {
                              "Start": 61,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 416,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "US Natl Inst Health; DailyMed. Current Medication Information for ZELBORAF (vemurafenib) tablet, film coated (April 2012). Available from, as of July 17, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=38eea320-7e0c-485a-bc30-98c3c45e2763"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "/GENOTOXICITY/ Vemurafenib did not cause genetic damage when tested in in vitro assay (bacterial mutation (AMES Assay)), or in the in vivo rat bone marrow micronucleus test.",
                          "Markup": [
                            {
                              "Start": 15,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report (EPAR): Vemurafenib p.23-4 (2012). Available from, as of July 17, 2013: https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002409/WC500124400.pdf"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "/GENOTOXICITY/"
                        },
                        {
                          "String": "Table: Genotoxicity Studies [Table#8116]",
                          "Markup": [
                            {
                              "Start": 28,
                              "Length": 12,
                              "Type": "Inline Table",
                              "Extra": "[Table#8116]"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 33,
                    "Name": "[Table#8116]",
                    "Value": {
                      "Binary": [
                        "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"
                      ],
                      "MimeType": "text/csv"
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Populations at Special Risk",
                "Description": "Populations at Special Risk",
                "Information": [
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1234"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "The manufacturer does not recommend initiation of vemurafenib in patients with electrolyte abnormalities unresponsive to corrective measures or congenital long QT syndrome.",
                          "Markup": [
                            {
                              "Start": 50,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1234"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "In a population pharmacokinetic analysis, the clearance of vemurafenib was not affected in patients with mild or moderate renal impairment. Pharmacokinetic data in patients with severe renal impairment are limited; therefore, the drug should be used with caution in these patients.",
                          "Markup": [
                            {
                              "Start": 59,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1234"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "In a population pharmacokinetic analysis, the clearance of vemurafenib was not affected in patients with mild or moderate hepatic impairment. Pharmacokinetic data in patients with severe hepatic impairment are limited; therefore, the drug should be used with caution in these patients.",
                          "Markup": [
                            {
                              "Start": 59,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Protein Binding",
                "Description": "Protein Binding",
                "Information": [
                  {
                    "ReferenceNumber": 8,
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Vemurafenib highly binds to plasma proteins where >99% of the administered dose will be found protein bound to serum albumin and alpha-1 acid glycoprotein.",
                          "Markup": [
                            {
                              "Start": 0,
                              "Length": 11,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "TOCHeading": "Ecological Information",
            "Description": "This section provides eco-related toxicity information.",
            "Section": [
              {
                "TOCHeading": "Environmental Fate/Exposure Summary",
                "Description": "Environmental Fate/Exposure Summary",
                "Information": [
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Vernurafenib's production and administration as a medication may result in its release to the environment through various waste streams. If released to air, an estimated vapor pressure of 8.2X10-15 mm Hg at 25 C indicates vernurafenib will exist solely in the particulate phase in the atmosphere. Particulate-phase vernurafenib will be removed from the atmosphere by wet and dry deposition. Vernurafenib does not contain chromophores that absorb at wavelengths >290 nm and, therefore, is not expected to be susceptible to direct photolysis by sunlight. If released to soil, the neutral species of vernurafenib is expected to have no mobility based upon an estimated Koc of 6.8X10+5. The estimated pKa of vernurafenib is 7.1, indicating that this compound will exist partially in the anion form in the environment and anions generally do not adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts. Volatilization from moist soil surfaces is not expected to be an important fate process based upon an estimated Henry's Law constant of 1.2X10-17 atm-cu m/mole. Vernurafenib is not expected to volatilize from dry soil surfaces based upon its vapor pressure. Biodegradation data in soil or water were not available. If released into water, vernurafenib is expected to adsorb to suspended solids and sediment based upon the estimated Koc. Volatilization from water surfaces is not expected to be an important fate process based upon this compound's estimated Henry's Law constant. An estimated BCF of 310 suggests the potential for bioconcentration in aquatic organisms is high. Hydrolysis is not expected to be an important environmental fate process since this compound lacks functional groups that hydrolyze under environmental conditions (pH 5 to 9). Occupational exposure to vernurafenib may occur through inhalation and dermal contact with this compound at workplaces where vernurafenib is produced or used. Exposure to vernurafenib among the general population may be limited to those administered the drug, an antineoplastic. (SRC)",
                          "Markup": [
                            {
                              "Start": 0,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 223,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 316,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 392,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 598,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 705,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 891,
                              "Length": 6,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/element/Carbon",
                              "Type": "PubChem Internal Link",
                              "Extra": "Element-Carbon"
                            },
                            {
                              "Start": 1101,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 1229,
                              "Length": 5,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/water",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-962"
                            },
                            {
                              "Start": 1272,
                              "Length": 5,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/water",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-962"
                            },
                            {
                              "Start": 1279,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 1397,
                              "Length": 5,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/water",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-962"
                            },
                            {
                              "Start": 1818,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 1918,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 1964,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Artificial Pollution Sources",
                "Description": "Artificial Sources",
                "Information": [
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "(1) US Natl Inst Health; DailyMed. Current Medical Information. Available from, as of Jun 27, 2013: https://dailymed.nlm.nih.gov/dailymed/about.cfm"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Vernurafenib's production and administration as a medication(1) may result in its release to the environment through various waste streams(SRC).",
                          "Markup": [
                            {
                              "Start": 0,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Environmental Fate",
                "Description": "Environmental Fate",
                "Information": [
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "(1) Swann RL et al; Res Rev 85: 17-28 (1983) (2) US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.1. Nov, 2012. Available from, as of Aug 6, 2013: https://www.epa.gov/oppt/exposure/pubs/episuitedl.htm (3) ACE Organic; Public access ACE pages. ACE acidity and basicity calculator., Grossman RB, Finkel R., Univ KY, Dept Chem. 2006. Available from, as of Aug 6, 2013: https://aceorganic.pearsoncmg.com/epoch-plugin/public/pKa.jsp (4) Doucette WJ; pp. 141-188 in Handbook of Property Estimation Methods for Chemicals. Boethling RS, Mackay D, eds. Boca Raton, FL: Lewis Publ (2000) (5) Meylan WM, Howard PH; Environ Toxicol Chem 10: 1283-93 (1991)"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 6.8X10+5(SRC), determined from a structure estimation method(2), indicates that the neutral species of vernurafenib is expected to be immobile in soil(SRC). The estimated pKa of vernurafenib is 7.1(3), indicating that this compound will exist partially in the anion form in the environment and anions generally do not adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4). Volatilization of vernurafenib from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 1.2X10-17 atm-cu m/mole(SRC), using a fragment constant estimation method(5). Vernurafenib is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 8.2X10-15 mm Hg at 25 C(SRC), determined from a fragment constant method(2). Biodegradation data in soil were not available(SRC, 2013).",
                          "Markup": [
                            {
                              "Start": 184,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 259,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 448,
                              "Length": 6,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/element/Carbon",
                              "Type": "PubChem Internal Link",
                              "Extra": "Element-Carbon"
                            },
                            {
                              "Start": 518,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 730,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "(1) Swann RL et al; Res Rev 85: 17-28 (1983) (2) US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.1. Nov, 2012. Available from, as of Aug 6, 2013: https://www.epa.gov/oppt/exposure/pubs/episuitedl.htm (3) Lyman WJ et al; Handbook of Chemical Property Estimation Methods. Washington, DC: Amer Chem Soc pp. 15-1 to 15-29 (1990) (4) Meylan WM, Howard PH; Environ Toxicol Chem 10: 1283-93 (1991) (5) Franke C et al; Chemosphere 29: 1501-14 (1994)"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 6.8X10+5(SRC), determined from a structure estimation method(2), indicates that vernurafenib is expected to adsorb to suspended solids and sediment(SRC). Volatilization from water surfaces is not expected(3) based upon an estimated Henry's Law constant of 1.2X10-17 atm-cu m/mole(SRC), developed using a fragment constant estimation method(4). According to a classification scheme(5), an estimated BCF of 310(SRC), from an estimated log Kow of 5.17(2) and a regression-derived equation(2), suggests the potential for bioconcentration in aquatic organisms is high(SRC). Biodegradation data in water were not available(SRC, 2013).",
                          "Markup": [
                            {
                              "Start": 157,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 251,
                              "Length": 5,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/water",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-962"
                            },
                            {
                              "Start": 669,
                              "Length": 5,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/water",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-962"
                            }
                          ]
                        }
                      ]
                    }
                  },
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "(1) Bidleman TF; Environ Sci Technol 22: 361-367 (1988) (2) US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.1. Nov, 2012. Available from, as of Aug 6, 2013: https://www.epa.gov/oppt/exposure/pubs/episuitedl.htm (3) Lyman WJ et al; Handbook of Chemical Property Estimation Methods. Washington, DC: Amer Chem Soc pp. 8-12 (1990)"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), vernurafenib, which has an estimated vapor pressure of 8.2X10-15 mm Hg at 25 C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase vernurafenib may be removed from the air by wet and dry deposition(SRC). Vernurafenib does not contains chromophores that absorb at wavelengths >290 nm(3) and, therefore, is not expected to be susceptible to direct photolysis by sunlight(SRC).",
                          "Markup": [
                            {
                              "Start": 124,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 355,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 428,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Environmental Abiotic Degradation",
                "Description": "Environmental Abiotic Degradation",
                "Information": [
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "(1) Lyman WJ et al; Handbook of Chemical Property Estimation Methods. Washington, DC: Amer Chem Soc pp. 7-4, 7-5, 8-12 (1990)"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Vernurafenib is not expected to undergo hydrolysis in the environment due to the lack of functional groups that hydrolyze under environmental conditions(1). Vernurafenib does not contain chromophores that absorb at wavelengths >290 nm(1) and, therefore, is not expected to be susceptible to direct photolysis by sunlight(SRC).",
                          "Markup": [
                            {
                              "Start": 0,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 157,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Environmental Bioconcentration",
                "Description": "Environmental Bioconcentration",
                "Information": [
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "(1) US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.1. Nov, 2012. Available from, as of Aug 6, 2013: https://www.epa.gov/oppt/exposure/pubs/episuitedl.htm (2) Franke C et al; Chemosphere 29: 1501-14 (1994)"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "An estimated BCF of 310 was calculated in fish for vernurafenib(SRC), using an estimated log Kow of 5.17(1) and a regression-derived equation(1). According to a classification scheme(2), this BCF suggests the potential for bioconcentration in aquatic organisms is high(SRC).",
                          "Markup": [
                            {
                              "Start": 51,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Soil Adsorption/Mobility",
                "Description": "Soil Adsorption/Mobility",
                "Information": [
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "(1) US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.1. Nov, 2012. Available from, as of Aug 6, 2013: m https://www.epa.gov/oppt/exposure/pubs/episuitedl.ht (2) Swann RL et al; Res Rev 85: 17-28 (1983) (3) ACE Organic; Public access ACE pages. ACE acidity and basicity calculator., Grossman RB, Finkel R., Univ KY, Dept Chem. 2006. Available from, as of Aug 6, 2013: https://aceorganic.pearsoncmg.com/epoch-plugin/public/pKa.jsp (4) Doucette WJ; pp. 141-188 in Handbook of Property Estimation Methods for Chemicals. Boethling RS, Mackay D, eds. Boca Raton, FL: Lewis Publ (2000)"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Using a structure estimation method based on molecular connectivity indices(1), the Koc of vernurafenib can be estimated to be 6.8X10+5(SRC). According to a classification scheme(2), this estimated Koc value suggests that the neutral species of vernurafenib is expected to be immobile in soil. The estimated pKa of vernurafenib is 7.1(3), indicating that this compound will exist partially in the anion form in the environment and anions generally do not adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4).",
                          "Markup": [
                            {
                              "Start": 91,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 245,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 315,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 504,
                              "Length": 6,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/element/Carbon",
                              "Type": "PubChem Internal Link",
                              "Extra": "Element-Carbon"
                            }
                          ]
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Volatilization from Water/Soil",
                "Description": "Volatilization from Water/Soil",
                "Information": [
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Reference": [
                      "(1) Meylan WM, Howard PH; Environ Toxicol Chem 10: 1283-93 (1991) (2) Lyman WJ et al; Handbook of Chemical Property Estimation Methods. Washington, DC: Amer Chem Soc pp. 15-1 to 15-29 (1990) (3) US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.1. Nov, 2012. Available from, as of Aug 5, 2013: https://www.epa.gov/oppt/exposure/pubs/episuitedl.htm"
                    ],
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "The Henry's Law constant for vernurafenib is estimated as 1.2X10-17 atm-cu m/mole(SRC) using a fragment constant estimation method(1). This Henry's Law constant indicates that vernurafenib is expected to be essentially nonvolatile from water and moist soil surfaces(2). Vernurafenib is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 8.2X10-15 mm Hg(SRC), determined from a fragment constant method(3).",
                          "Markup": [
                            {
                              "Start": 29,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 176,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 236,
                              "Length": 5,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/water",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-962"
                            },
                            {
                              "Start": 270,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "Probable Routes of Human Exposure",
                "Description": "Probable Routes of Human Exposure",
                "Information": [
                  {
                    "ReferenceNumber": 33,
                    "Description": "PEER REVIEWED",
                    "Value": {
                      "StringWithMarkup": [
                        {
                          "String": "Occupational exposure to vernurafenib may occur through inhalation and dermal contact with this compound at workplaces where vernurafenib is produced or used. Exposure to vernurafenib among the general population may be limited to those administered the drug, an antineoplastic. (SRC)",
                          "Markup": [
                            {
                              "Start": 25,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 125,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            },
                            {
                              "Start": 171,
                              "Length": 12,
                              "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                              "Type": "PubChem Internal Link",
                              "Extra": "CID-42611257"
                            }
                          ]
                        }
                      ]
                    }
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "TOCHeading": "Associated Disorders and Diseases",
        "Description": "Disease information available for this compound",
        "DisplayControls": {
          "CreateTable": {
            "FromInformationIn": "Subsections",
            "NumberOfColumns": 2,
            "ColumnHeadings": [
              "Disease",
              "References"
            ],
            "ColumnContents": [
              "Name",
              "Value"
            ]
          }
        },
        "Information": [
          {
            "ReferenceNumber": 5,
            "Value": {
              "ExternalTableName": "ctd_chemical_disease"
            }
          }
        ]
      },
      {
        "TOCHeading": "Literature",
        "Description": "Literature citation references mainly refers to regular publications such as journal articles, etc.",
        "URL": "https://pubchemdocs.ncbi.nlm.nih.gov/literature",
        "Section": [
          {
            "TOCHeading": "Coronavirus Studies",
            "Description": "Literature references aggregated from multiple sources including PubMed and ClinicalTrials.gov. For additional clinical studies, see clinical trials section.",
            "URL": "https://pubchemdocs.ncbi.nlm.nih.gov/covid-19",
            "Information": [
              {
                "ReferenceNumber": 44,
                "Value": {
                  "ExternalTableName": "literature_coronavirus",
                  "ExternalTableNumRows": 5
                }
              }
            ]
          },
          {
            "TOCHeading": "NLM Curated PubMed Citations",
            "Description": "The \"NLM Curated PubMed Citations\" section links to all PubMed records that are tagged with the same MeSH term that has been associated with a particular compound.",
            "Information": [
              {
                "ReferenceNumber": 52,
                "URL": "https://www.ncbi.nlm.nih.gov/sites/entrez?LinkName=pccompound_pubmed_mesh&db=pccompound&cmd=Link&from_uid=42611257",
                "Value": {
                  "Boolean": [
                    true
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "Springer Nature References",
            "Description": "Literature references related to scientific contents from Springer Nature journals and books. These references have been ranked automatically by an algorithm which calculates the relevance for each substance in a Springer Nature document. It is based on: 1. the TF-IDF, adapted to chemical structures, 2. location information in the text (e.g. title, abstract, keywords), and 3. the document size.  Springer Nature aims to provide only high qualitative and relevant content but references of lower relevance aren't withheld as they might contain also very useful information",
            "URL": "https://group.springernature.com/gp/group/aboutus",
            "Information": [
              {
                "ReferenceNumber": 46,
                "Name": "Springer Nature References",
                "Value": {
                  "ExternalTableName": "springernature"
                }
              }
            ]
          },
          {
            "TOCHeading": "Thieme References",
            "Description": "Literature references related to scientific contents from Thieme Chemistry journals and books. The Thieme Chemistry content within this section is provided under a CC-BY-NC-ND 4.0 license (https://creativecommons.org/licenses/by-nc-nd/4.0/), unless otherwise stated.",
            "URL": "https://www.thieme.de/en/thieme-chemistry/home-51399.htm",
            "Information": [
              {
                "ReferenceNumber": 47,
                "Name": "Thieme References",
                "Value": {
                  "ExternalTableName": "ThiemeChemistry"
                }
              }
            ]
          },
          {
            "TOCHeading": "Depositor Provided PubMed Citations",
            "Description": "This section displays a concatenated list of all PubMed records that have been cited by the depositors of all PubChem Substance records that contain the same chemical structure as the compound.",
            "Information": [
              {
                "ReferenceNumber": 52,
                "Name": "Depositor Provided PubMed Citations",
                "URL": "https://www.ncbi.nlm.nih.gov/sites/entrez?LinkName=pccompound_pubmed&db=pccompound&cmd=Link&from_uid=42611257",
                "Value": {
                  "ExternalTableName": "collection=pubmed&pmidsrcs=xref",
                  "ExternalTableNumRows": 41
                }
              }
            ]
          },
          {
            "TOCHeading": "General References",
            "Description": "General References",
            "DisplayControls": {
              "ListType": "Numbered"
            },
            "Information": [
              {
                "ReferenceNumber": 8,
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Jordan EJ, Kelly CM: Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother. 2012 Dec;13(17):2533-43. doi: 10.1517/14656566.2012.737780. Epub 2012 Oct 24. [PMID:23094782]",
                      "Markup": [
                        {
                          "Start": 169,
                          "Length": 13,
                          "URL": "https://www.ncbi.nlm.nih.gov/pubmed/23094782"
                        },
                        {
                          "Start": 21,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    },
                    {
                      "String": "Kim G, McKee AE, Ning YM, Hazarika M, Theoret M, Johnson JR, Xu QC, Tang S, Sridhara R, Jiang X, He K, Roscoe D, McGuinn WD, Helms WS, Russell AM, Miksinski SP, Zirkelbach JF, Earp J, Liu Q, Ibrahim A, Justice R, Pazdur R: FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. Clin Cancer Res. 2014 Oct 1;20(19):4994-5000. doi: 10.1158/1078-0432.CCR-14-0776. Epub 2014 Aug 5. [PMID:25096067]",
                      "Markup": [
                        {
                          "Start": 439,
                          "Length": 13,
                          "URL": "https://www.ncbi.nlm.nih.gov/pubmed/25096067"
                        },
                        {
                          "Start": 245,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    },
                    {
                      "String": "Luke JJ, Hodi FS: Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma. Clin Cancer Res. 2012 Jan 1;18(1):9-14. doi: 10.1158/1078-0432.CCR-11-2197. Epub  2011 Nov 14. [PMID:22083257]",
                      "Markup": [
                        {
                          "Start": 197,
                          "Length": 13,
                          "URL": "https://www.ncbi.nlm.nih.gov/pubmed/22083257"
                        },
                        {
                          "Start": 18,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    },
                    {
                      "String": "Schirosi L, Strippoli S, Gaudio F, Graziano G, Popescu O, Guida M, Simone G, Mangia A: Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients? BMC Cancer. 2016 Nov 18;16(1):905. [PMID:27863476]",
                      "Markup": [
                        {
                          "Start": 241,
                          "Length": 13,
                          "URL": "https://www.ncbi.nlm.nih.gov/pubmed/27863476"
                        }
                      ]
                    },
                    {
                      "String": "Stempel JM, Bustamante Alvarez JG, Carpio AM, Mittal V, Dourado C: Erdheim-Chester disease, moving away from the orphan diseases: A case report. Respir Med Case Rep. 2016 Dec 3;20:55-58. eCollection 2017. [PMID:27995058]",
                      "Markup": [
                        {
                          "Start": 206,
                          "Length": 13,
                          "URL": "https://www.ncbi.nlm.nih.gov/pubmed/27995058"
                        }
                      ]
                    },
                    {
                      "String": "Zhang W, Heinzmann D, Grippo JF: Clinical Pharmacokinetics of Vemurafenib. Clin Pharmacokinet. 2017 Mar 2. doi: 10.1007/s40262-017-0523-7. [PMID:28255850]",
                      "Markup": [
                        {
                          "Start": 140,
                          "Length": 13,
                          "URL": "https://www.ncbi.nlm.nih.gov/pubmed/28255850"
                        },
                        {
                          "Start": 62,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    },
                    {
                      "String": "Goldinger SM, Rinderknecht J, Dummer R, Kuhn FP, Yang KH, Lee L, Ayala RC, Racha J, Geng W, Moore D, Liu M, Joe AK, Bazan SP, Grippo JF: A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma. Pharmacol Res Perspect. 2015 Mar;3(2):e00113. doi: 10.1002/prp2.113. [PMID:25729580]",
                      "Markup": [
                        {
                          "Start": 318,
                          "Length": 13,
                          "URL": "https://www.ncbi.nlm.nih.gov/pubmed/25729580"
                        },
                        {
                          "Start": 198,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    },
                    {
                      "String": "Roche news",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 10,
                          "URL": "https://www.roche.com/media/store/releases/med-cor-2011-08-17.htm"
                        }
                      ]
                    },
                    {
                      "String": "FDA News and Events",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 19,
                          "URL": "https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm583931.htm"
                        }
                      ]
                    },
                    {
                      "String": "FDA Vemurafenib application",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 27,
                          "URL": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202429Orig1s000ClinPharmR.pdf"
                        },
                        {
                          "Start": 4,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "Chemical Co-Occurrences in Literature",
            "Description": "Chemical co-occurrences in literature highlight chemicals mentioned together in scientific articles. This may suggest an important relationship exists between the two. Please note that this content is not human curated. It is generated by text-mining algorithms that can be fooled such that a co-occurrence may be happenstance or a casual mention. The lists are ordered by relevancy as indicated by count of publications and other statistics, with the most relevant mentions appearing at the top.",
            "URL": "https://pubchemdocs.ncbi.nlm.nih.gov/knowledge-panels",
            "Information": [
              {
                "ReferenceNumber": 52,
                "Name": "Co-Occurrence Panel",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "ChemicalNeighbor"
                    },
                    {
                      "String": "Chemical"
                    },
                    {
                      "String": "ChemicalName_1"
                    },
                    {
                      "String": "ChemicalName_2"
                    },
                    {
                      "String": "SUMMARY_URL.cid"
                    },
                    {
                      "String": "CID"
                    },
                    {
                      "String": "CID"
                    }
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "Chemical-Gene Co-Occurrences in Literature",
            "Description": "Chemical-gene co-occurrences in the literature highlight chemical-'gene' pairs mentioned together in scientific articles. Note that a co-occurring 'gene' entity is organism non-specific and could refer to a gene, protein, or enzyme. This may suggest an important relationship exists between the two. Please note that this content is not human curated. It is generated by text-mining algorithms that can be fooled such that a co-occurrence may be happenstance or a casual mention. The lists are ordered by relevancy as indicated by count of publications and other statistics, with the most relevant mentions appearing at the top.",
            "URL": "https://pubchemdocs.ncbi.nlm.nih.gov/knowledge-panels",
            "Information": [
              {
                "ReferenceNumber": 52,
                "Name": "Co-Occurrence Panel",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "ChemicalGeneSymbolNeighbor"
                    },
                    {
                      "String": "Gene/Protein/Enzyme"
                    },
                    {
                      "String": "ChemicalName"
                    },
                    {
                      "String": "GeneSymbolName"
                    },
                    {
                      "String": "SUMMARY_URL.genesymbol"
                    },
                    {
                      "String": "CID"
                    },
                    {
                      "String": "GeneSymbol"
                    }
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "Chemical-Disease Co-Occurrences in Literature",
            "Description": "Chemical-disease co-occurrences in literature highlight chemical-disease pairs mentioned together in scientific articles. This may suggest an important relationship exists between the two. Please note that this content is not human curated. It is generated by text-mining algorithms that can be fooled such that a co-occurrence may be happenstance or a casual mention. The lists are ordered by relevancy as indicated by count of publications and other statistics, with the most relevant mentions appearing at the top.",
            "URL": "https://pubchemdocs.ncbi.nlm.nih.gov/knowledge-panels",
            "Information": [
              {
                "ReferenceNumber": 52,
                "Name": "Co-Occurrence Panel",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "ChemicalDiseaseNeighbor"
                    },
                    {
                      "String": "Disease"
                    },
                    {
                      "String": "ChemicalName"
                    },
                    {
                      "String": "DiseaseName"
                    },
                    {
                      "String": "https://meshb.nlm.nih.gov/record/ui?ui="
                    },
                    {
                      "String": "CID"
                    },
                    {
                      "String": "MeSH"
                    }
                  ]
                }
              }
            ]
          }
        ]
      },
      {
        "TOCHeading": "Patents",
        "Description": "A PubChem summary page displays Patent information when available for the given molecule.",
        "URL": "https://pubchemdocs.ncbi.nlm.nih.gov/patents",
        "DisplayControls": {
          "ListType": "Columns"
        },
        "Information": [
          {
            "ReferenceNumber": 8,
            "Value": {
              "StringWithMarkup": [
                {
                  "String": "US8470818",
                  "Markup": [
                    {
                      "Start": 0,
                      "Length": 9,
                      "URL": "https://pubchem.ncbi.nlm.nih.gov/patent/US8470818"
                    }
                  ]
                },
                {
                  "String": "US8143271",
                  "Markup": [
                    {
                      "Start": 0,
                      "Length": 9,
                      "URL": "https://pubchem.ncbi.nlm.nih.gov/patent/US8143271"
                    }
                  ]
                },
                {
                  "String": "US7863288",
                  "Markup": [
                    {
                      "Start": 0,
                      "Length": 9,
                      "URL": "https://pubchem.ncbi.nlm.nih.gov/patent/US7863288"
                    }
                  ]
                },
                {
                  "String": "US7504509",
                  "Markup": [
                    {
                      "Start": 0,
                      "Length": 9,
                      "URL": "https://pubchem.ncbi.nlm.nih.gov/patent/US7504509"
                    }
                  ]
                },
                {
                  "String": "US8741920",
                  "Markup": [
                    {
                      "Start": 0,
                      "Length": 9,
                      "URL": "https://pubchem.ncbi.nlm.nih.gov/patent/US8741920"
                    }
                  ]
                },
                {
                  "String": "US9447089",
                  "Markup": [
                    {
                      "Start": 0,
                      "Length": 9,
                      "URL": "https://pubchem.ncbi.nlm.nih.gov/patent/US9447089"
                    }
                  ]
                }
              ]
            }
          }
        ],
        "Section": [
          {
            "TOCHeading": "Depositor-Supplied Patent Identifiers",
            "Description": "Patent identifiers and more information provided by depositors in form of a widget.",
            "Information": [
              {
                "ReferenceNumber": 52,
                "Value": {
                  "ExternalTableName": "patent"
                }
              },
              {
                "ReferenceNumber": 52,
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Link to all deposited patent identifiers",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 40,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/42611257/xrefs/PatentID/TXT"
                        }
                      ]
                    }
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "WIPO PATENTSCOPE",
            "Description": "Use the provided link to show patents associated with this chemical structure in WIPO's PATENTSCOPE system.",
            "URL": "https://patentscope.wipo.int/",
            "Information": [
              {
                "ReferenceNumber": 76,
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Patents are available for this chemical structure:"
                    },
                    {
                      "String": "https://patentscope.wipo.int/search/en/result.jsf?inchikey=GPXBXXGIAQBQNI-UHFFFAOYSA-N",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 86,
                          "URL": "https://patentscope.wipo.int/search/en/result.jsf?inchikey=GPXBXXGIAQBQNI-UHFFFAOYSA-N"
                        }
                      ]
                    }
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "FDA Orange Book Patents",
            "Description": "This section includes the patent information from the FDA Orange Book.",
            "DisplayControls": {
              "CreateTable": {
                "FromInformationIn": "ThisSection",
                "NumberOfColumns": 2,
                "ColumnContents": [
                  "Name",
                  "Value"
                ]
              },
              "ShowAtMost": 3
            },
            "Information": [
              {
                "ReferenceNumber": 23,
                "Name": "Patent",
                "URL": "http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=7504509.PN.&OS=PN/7504509&RS=PN/7504509",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "7504509"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 23,
                "Name": "Expiration",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Oct 22, 2026"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 23,
                "Name": "Applicant",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "HOFFMANN LA ROCHE"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 23,
                "Name": "Drug Application",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "N202429 (Prescription Drug: ZELBORAF. Ingredients: VEMURAFENIB)",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 7,
                          "URL": "https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=N&Appl_No=202429"
                        },
                        {
                          "Start": 28,
                          "Length": 8,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/ZELBORAF",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 51,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/VEMURAFENIB",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 24,
                "Name": "Patent",
                "URL": "http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=7863288.PN.&OS=PN/7863288&RS=PN/7863288",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "7863288"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 24,
                "Name": "Expiration",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Jun 20, 2029"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 24,
                "Name": "Applicant",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "HOFFMANN LA ROCHE"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 24,
                "Name": "Drug Application",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "N202429 (Prescription Drug: ZELBORAF. Ingredients: VEMURAFENIB)",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 7,
                          "URL": "https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=N&Appl_No=202429"
                        },
                        {
                          "Start": 28,
                          "Length": 8,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/ZELBORAF",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 51,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/VEMURAFENIB",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 25,
                "Name": "Patent",
                "URL": "http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8143271.PN.&OS=PN/8143271&RS=PN/8143271",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "8143271"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 25,
                "Name": "Expiration",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Jun 21, 2026"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 25,
                "Name": "Applicant",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "HOFFMANN LA ROCHE"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 25,
                "Name": "Drug Application",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "N202429 (Prescription Drug: ZELBORAF. Ingredients: VEMURAFENIB)",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 7,
                          "URL": "https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=N&Appl_No=202429"
                        },
                        {
                          "Start": 28,
                          "Length": 8,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/ZELBORAF",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 51,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/VEMURAFENIB",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 26,
                "Name": "Patent",
                "URL": "http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8470818.PN.&OS=PN/8470818&RS=PN/8470818",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "8470818"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 26,
                "Name": "Expiration",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Aug 2, 2026"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 26,
                "Name": "Applicant",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "HOFFMANN LA ROCHE"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 26,
                "Name": "Drug Application",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "N202429 (Prescription Drug: ZELBORAF. Ingredients: VEMURAFENIB)",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 7,
                          "URL": "https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=N&Appl_No=202429"
                        },
                        {
                          "Start": 28,
                          "Length": 8,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/ZELBORAF",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 51,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/VEMURAFENIB",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 27,
                "Name": "Patent",
                "URL": "http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8741920.PN.&OS=PN/8741920&RS=PN/8741920",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "8741920"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 27,
                "Name": "Expiration",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Jul 27, 2030"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 27,
                "Name": "Applicant",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "HOFFMANN LA ROCHE"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 27,
                "Name": "Drug Application",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "N202429 (Prescription Drug: ZELBORAF. Ingredients: VEMURAFENIB)",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 7,
                          "URL": "https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=N&Appl_No=202429"
                        },
                        {
                          "Start": 28,
                          "Length": 8,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/ZELBORAF",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 51,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/VEMURAFENIB",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 28,
                "Name": "Patent",
                "URL": "http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=9447089.PN.&OS=PN/9447089&RS=PN/9447089",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "9447089"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 28,
                "Name": "Expiration",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Jun 6, 2032"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 28,
                "Name": "Applicant",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "HOFFMANN LA ROCHE"
                    }
                  ]
                }
              },
              {
                "ReferenceNumber": 28,
                "Name": "Drug Application",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "N202429 (Prescription Drug: ZELBORAF. Ingredients: VEMURAFENIB)",
                      "Markup": [
                        {
                          "Start": 0,
                          "Length": 7,
                          "URL": "https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=N&Appl_No=202429"
                        },
                        {
                          "Start": 28,
                          "Length": 8,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/ZELBORAF",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 51,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/VEMURAFENIB",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    }
                  ]
                }
              }
            ]
          }
        ]
      },
      {
        "TOCHeading": "Biomolecular Interactions and Pathways",
        "Description": "A PubChem summary page displays biomolecular interactions and pathways information when available for the given record.",
        "Section": [
          {
            "TOCHeading": "Protein Bound 3D Structures",
            "Description": "Experimentally resolved 3D structures that contain biomolecules bound to the small molecule. For structures containing glycans, GlyTouCan identifiers annotated by the TCarp project of GlycoNAVI.org are included.",
            "Information": [
              {
                "ReferenceNumber": 45,
                "Value": {
                  "ExternalTableName": "pdb"
                }
              },
              {
                "ReferenceNumber": 52,
                "URL": "https://www.ncbi.nlm.nih.gov/structure?cmd=Link&LinkName=pccompound_structure&from_uid=42611257",
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "View 3 proteins in NCBI Structure"
                    }
                  ]
                }
              }
            ],
            "Section": [
              {
                "TOCHeading": "Ligands from Protein Bound 3D Structures",
                "Description": "Ligands extracted from macromolecular structures.",
                "DisplayControls": {
                  "CreateTable": {
                    "FromInformationIn": "Subsections",
                    "NumberOfColumns": 2,
                    "ColumnContents": [
                      "Name",
                      "Value"
                    ]
                  },
                  "MoveToTop": true,
                  "ShowAtMost": 1
                },
                "Section": [
                  {
                    "TOCHeading": "PDBe Ligand Code",
                    "Description": "The ligand code for this structure from the Protein Data Bank in Europe (PDBe).",
                    "Information": [
                      {
                        "ReferenceNumber": 43,
                        "URL": "http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/032",
                        "Value": {
                          "StringWithMarkup": [
                            {
                              "String": "032"
                            }
                          ]
                        }
                      }
                    ]
                  },
                  {
                    "TOCHeading": "PDBe Structure Code",
                    "Description": "The PDBe code for the full structure from the Protein Data Bank in Europe (PDBe) from which this ligand's coordinates were taken.",
                    "Information": [
                      {
                        "ReferenceNumber": 43,
                        "URL": "http://www.ebi.ac.uk/pdbe/entry/pdb/3OG7",
                        "Value": {
                          "StringWithMarkup": [
                            {
                              "String": "3OG7"
                            }
                          ]
                        }
                      }
                    ]
                  },
                  {
                    "TOCHeading": "PDBe Conformer",
                    "Description": "The chemical structure and experimental 3D coordinates of this ligand from the Protein Data Bank in Europe (PDBe).",
                    "Information": [
                      {
                        "ReferenceNumber": 43,
                        "URL": "http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/032",
                        "Value": {
                          "ExternalDataURL": [
                            "https://pubchem.ncbi.nlm.nih.gov/rest/pug_view/data/key/8198708_1"
                          ],
                          "MimeType": "pubchem/compound-gzip-asnb"
                        }
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "TOCHeading": "Drug-Gene Interactions",
            "Description": "Drug-gene interactions provided by the Drug Gene Interaction Database (DGIdb)",
            "Information": [
              {
                "ReferenceNumber": 7,
                "Value": {
                  "ExternalTableName": "collection=dgidb&view=concise_cid"
                }
              }
            ]
          },
          {
            "TOCHeading": "Chemical-Gene Interactions",
            "Description": "Interactions between chemical and this gene",
            "Section": [
              {
                "TOCHeading": "CTD Chemical-Gene Interactions",
                "Description": "Chemical-gene interactions provided by the Comparative Toxicogenomics Database (CTD)",
                "Information": [
                  {
                    "ReferenceNumber": 5,
                    "Value": {
                      "ExternalTableName": "ctdchemicalgene"
                    }
                  }
                ]
              }
            ]
          },
          {
            "TOCHeading": "DrugBank Interactions",
            "Description": "Drug interactions with macromolecules such as targets, enzymes, transporters, and carriers",
            "Information": [
              {
                "ReferenceNumber": 8,
                "Value": {
                  "ExternalTableName": "collection=drugbank&view=concise_cid"
                }
              }
            ]
          },
          {
            "TOCHeading": "Drug-Drug Interactions",
            "Description": "A drug-drug interaction is a change in the action or side effects of a drug caused by concomitant administration with another drug.",
            "Information": [
              {
                "ReferenceNumber": 8,
                "Value": {
                  "ExternalTableName": "drugbankddi"
                }
              }
            ]
          },
          {
            "TOCHeading": "Drug-Food Interactions",
            "Description": "A drug-food interaction occurs when your food and medicine interfere with one another",
            "DisplayControls": {
              "ListType": "Bulleted"
            },
            "Information": [
              {
                "ReferenceNumber": 8,
                "Value": {
                  "StringWithMarkup": [
                    {
                      "String": "Do not take with or immediately after a high-fat meal. Taking vemurafenib with a high-fat meal may increase the AUC and Cmax by approximately 5 fold and 2.5 fold, respectively.",
                      "Markup": [
                        {
                          "Start": 62,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    },
                    {
                      "String": "Exercise caution with grapefruit products. Grapefruit inhibits the CYP3A4 metabolism of vemurafenib, which may increase its serum concentration.",
                      "Markup": [
                        {
                          "Start": 88,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    },
                    {
                      "String": "Exercise caution with St. John's Wort. This herb induces the CYP3A4 metabolism of vemurafenib and may reduce its serum concentration.",
                      "Markup": [
                        {
                          "Start": 82,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        }
                      ]
                    },
                    {
                      "String": "Limit caffeine intake. Vemurafenib inhibits CYP1A2, which may increase the serum levels and adverse effects of caffeine.",
                      "Markup": [
                        {
                          "Start": 6,
                          "Length": 8,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/caffeine",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-2519"
                        },
                        {
                          "Start": 23,
                          "Length": 11,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/Vemurafenib",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-42611257"
                        },
                        {
                          "Start": 111,
                          "Length": 8,
                          "URL": "https://pubchem.ncbi.nlm.nih.gov/compound/caffeine",
                          "Type": "PubChem Internal Link",
                          "Extra": "CID-2519"
                        }
                      ]
                    },
                    {
                      "String": "Take with or without food."
                    }
                  ]
                }
              }
            ]
          },
          {
            "TOCHeading": "Pathways",
            "Description": "Pathways that include the compound as a component.",
            "Information": [
              {
                "ReferenceNumber": 52,
                "Value": {
                  "ExternalTableName": "collection=pathway&core=1"
                }
              }
            ]
          }
        ]
      },
      {
        "TOCHeading": "Biological Test Results",
        "Description": "A PubChem substance or compound summary page displays biological test results from the PubChem BioAssay database, if/as available, for the chemical structure currently displayed. (Note that you can embed biological test results displays within your own web pages, for a PubChem Compound or Substance of interest, by using the BioActivity Widget.)",
        "URL": "https://pubchemdocs.ncbi.nlm.nih.gov/bioassays",
        "Section": [
          {
            "TOCHeading": "BioAssay Results",
            "Description": "BioActivity information showed in tabular widget.",
            "Information": [
              {
                "ReferenceNumber": 52,
                "Value": {
                  "ExternalTableName": "bioactivity"
                }
              }
            ]
          }
        ]
      },
      {
        "TOCHeading": "Taxonomy",
        "Description": "The organism(s) where the compound originated or is associated",
        "Information": [
          {
            "ReferenceNumber": 11,
            "Reference": [
              "Zebrafish Pathway Metabolite MetFrag Local CSV (Beta) | DOI:10.5281/zenodo.3457553"
            ],
            "Value": {
              "ExternalTableName": "collection=norman_zebrafish&view=concise_cid"
            }
          }
        ]
      },
      {
        "TOCHeading": "Classification",
        "Description": "Classification systems from MeSH, ChEBI, Kegg, etc.",
        "URL": "https://pubchem.ncbi.nlm.nih.gov/classification",
        "Section": [
          {
            "TOCHeading": "Ontologies",
            "Description": "Ontologies",
            "Section": [
              {
                "TOCHeading": "MeSH Tree",
                "Description": "MeSH tree",
                "Information": [
                  {
                    "ReferenceNumber": 53,
                    "Name": "HID",
                    "URL": "https://pubchem.ncbi.nlm.nih.gov/classification/#hid=1",
                    "Value": {
                      "Number": [
                        1
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "NCI Thesaurus Tree",
                "Description": "NCI Thesaurus (NCIt) hierarchy",
                "URL": "https://ncithesaurus.nci.nih.gov",
                "Information": [
                  {
                    "ReferenceNumber": 70,
                    "Name": "HID",
                    "URL": "https://pubchem.ncbi.nlm.nih.gov/classification/#hid=112",
                    "Value": {
                      "Number": [
                        112
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "ChEBI Ontology",
                "Description": "ChEBI Ontology tree",
                "Information": [
                  {
                    "ReferenceNumber": 54,
                    "Name": "HID",
                    "URL": "https://pubchem.ncbi.nlm.nih.gov/classification/#hid=2",
                    "Value": {
                      "Number": [
                        2
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "KEGG: Drug",
                "Description": "KEGG : Drug tree",
                "Information": [
                  {
                    "ReferenceNumber": 55,
                    "Name": "HID",
                    "URL": "https://pubchem.ncbi.nlm.nih.gov/classification/#hid=14",
                    "Value": {
                      "Number": [
                        14
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "KEGG: USP",
                "Description": "KEGG : USP tree",
                "Information": [
                  {
                    "ReferenceNumber": 56,
                    "Name": "HID",
                    "URL": "https://pubchem.ncbi.nlm.nih.gov/classification/#hid=15",
                    "Value": {
                      "Number": [
                        15
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "KEGG: ATC",
                "Description": "KEGG : ATC tree",
                "Information": [
                  {
                    "ReferenceNumber": 57,
                    "Name": "HID",
                    "URL": "https://pubchem.ncbi.nlm.nih.gov/classification/#hid=16",
                    "Value": {
                      "Number": [
                        16
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "KEGG: Target-based Classification of Drugs",
                "Description": "KEGG : Target-based Classification of Drugs tree",
                "Information": [
                  {
                    "ReferenceNumber": 58,
                    "Name": "HID",
                    "URL": "https://pubchem.ncbi.nlm.nih.gov/classification/#hid=22",
                    "Value": {
                      "Number": [
                        22
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "KEGG: Drug Groups",
                "Description": "KEGG : Drug Groups tree",
                "Information": [
                  {
                    "ReferenceNumber": 66,
                    "Name": "HID",
                    "URL": "https://pubchem.ncbi.nlm.nih.gov/classification/#hid=96",
                    "Value": {
                      "Number": [
                        96
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "KEGG: Drug Classes",
                "Description": "KEGG : Drug Classes tree",
                "Information": [
                  {
                    "ReferenceNumber": 72,
                    "Name": "HID",
                    "URL": "https://pubchem.ncbi.nlm.nih.gov/classification/#hid=118",
                    "Value": {
                      "Number": [
                        118
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "WHO ATC Classification System",
                "Description": "The Anatomical Therapeutic Chemical (ATC) Classification System is used for the classification of drugs. This pharmaceutical coding system divides drugs into different groups according to the organ or system on which they act and/or their therapeutic and chemical characteristics. Each bottom-level ATC code stands for a pharmaceutically used substance, or a combination of substances, in a single indication (or use). This means that one drug can have more than one code: acetylsalicylic acid (aspirin), for example, has A01AD05 as a drug for local oral treatment, B01AC06 as a platelet inhibitor, and N02BA01 as an analgesic and antipyretic. On the other hand, several different brands share the same code if they have the same active substance and indications.",
                "URL": "http://www.whocc.no/atc/",
                "Information": [
                  {
                    "ReferenceNumber": 61,
                    "Name": "HID",
                    "URL": "https://pubchem.ncbi.nlm.nih.gov/classification/#hid=79",
                    "Value": {
                      "Number": [
                        79
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "FDA Pharm Classes",
                "Description": "FDA Pharm Classes tree",
                "Information": [
                  {
                    "ReferenceNumber": 60,
                    "Name": "HID",
                    "URL": "https://pubchem.ncbi.nlm.nih.gov/classification/#hid=78",
                    "Value": {
                      "Number": [
                        78
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "ChemIDplus",
                "Description": "ChemIDplus tree",
                "Information": [
                  {
                    "ReferenceNumber": 63,
                    "Name": "HID",
                    "URL": "https://pubchem.ncbi.nlm.nih.gov/classification/#hid=84",
                    "Value": {
                      "Number": [
                        84
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "IUPHAR/BPS Guide to PHARMACOLOGY Target Classification",
                "Description": "Protein classification from IUPHAR/BPS Guide to PHARMACOLOGY",
                "URL": "http://guidetopharmacology.org/targets.jsp",
                "Information": [
                  {
                    "ReferenceNumber": 65,
                    "Name": "HID",
                    "URL": "https://pubchem.ncbi.nlm.nih.gov/classification/#hid=92",
                    "Value": {
                      "Number": [
                        92
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "ChEMBL Target Tree",
                "Description": "Protein target tree from ChEMBL",
                "URL": "https://www.ebi.ac.uk/chembl/target/browser",
                "Information": [
                  {
                    "ReferenceNumber": 64,
                    "Name": "HID",
                    "URL": "https://pubchem.ncbi.nlm.nih.gov/classification/#hid=87",
                    "Value": {
                      "Number": [
                        87
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "UN GHS Classification",
                "Description": "The United Nations' Globally Harmonized System of Classification and Labelling of Chemicals (GHS) provides a harmonized basis for globally uniform physical, environmental, and health and safety information on hazardous chemical substances and mixtures.",
                "Information": [
                  {
                    "ReferenceNumber": 62,
                    "Name": "HID",
                    "URL": "https://pubchem.ncbi.nlm.nih.gov/classification/#hid=83",
                    "Value": {
                      "Number": [
                        83
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "NORMAN Suspect List Exchange Classification",
                "Description": "NORMAN Suspect List Exchange Classification",
                "Information": [
                  {
                    "ReferenceNumber": 67,
                    "Name": "HID",
                    "URL": "https://pubchem.ncbi.nlm.nih.gov/classification/#hid=101",
                    "Value": {
                      "Number": [
                        101
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "EPA DSSTox Classification",
                "Description": "EPA DSSTox Classification",
                "Information": [
                  {
                    "ReferenceNumber": 68,
                    "Name": "HID",
                    "URL": "https://pubchem.ncbi.nlm.nih.gov/classification/#hid=105",
                    "Value": {
                      "Number": [
                        105
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "FDA Drug Type and Pharmacologic Classification",
                "Description": "The FDA Drug Type and Pharmacologic Classification is based on the FDA drug type and pharm classes data from the National Drug Code (NDC) Directory.",
                "Information": [
                  {
                    "ReferenceNumber": 71,
                    "Name": "HID",
                    "URL": "https://pubchem.ncbi.nlm.nih.gov/classification/#hid=116",
                    "Value": {
                      "Number": [
                        116
                      ]
                    }
                  }
                ]
              },
              {
                "TOCHeading": "PFAS and Fluorinated Organic Compounds in PubChem",
                "Description": "A classification tree to browse per- and polyfluoroalkyl substances (PFAS) and other fluorinated organic compounds in PubChem.",
                "Information": [
                  {
                    "ReferenceNumber": 73,
                    "Name": "HID",
                    "URL": "https://pubchem.ncbi.nlm.nih.gov/classification/#hid=120",
                    "Value": {
                      "Number": [
                        120
                      ]
                    }
                  }
                ]
              }
            ]
          }
        ]
      }
    ],
    "Reference": [
      {
        "ReferenceNumber": 1,
        "SourceName": "CAS Common Chemistry",
        "SourceID": "918504-65-1",
        "Name": "Vemurafenib",
        "Description": "CAS Common Chemistry is an open community resource for accessing chemical information. Nearly 500,000 chemical substances from CAS REGISTRY cover areas of community interest, including common and frequently regulated chemicals, and those relevant to high school and undergraduate chemistry classes. This chemical information, curated by our expert scientists, is provided in alignment with our mission as a division of the American Chemical Society.",
        "URL": "https://commonchemistry.cas.org/detail?cas_rn=918504-65-1",
        "LicenseNote": "The data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated.",
        "LicenseURL": "https://creativecommons.org/licenses/by-nc/4.0/",
        "ANID": 13078053
      },
      {
        "ReferenceNumber": 3,
        "SourceName": "ChemIDplus",
        "SourceID": "0918504651",
        "Name": "Vemurafenib [USAN:INN]",
        "Description": "ChemIDplus is a free, web search system that provides access to the structure and nomenclature authority files used for the identification of chemical substances cited in National Library of Medicine (NLM) databases, including the TOXNET system.",
        "URL": "https://chem.nlm.nih.gov/chemidplus/sid/0918504651",
        "LicenseURL": "https://www.nlm.nih.gov/copyright.html",
        "IsToxnet": true,
        "ANID": 1141370
      },
      {
        "ReferenceNumber": 8,
        "SourceName": "DrugBank",
        "SourceID": "DB08881",
        "Name": "Vemurafenib",
        "Description": "The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.",
        "URL": "https://www.drugbank.ca/drugs/DB08881",
        "LicenseNote": "Creative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)",
        "LicenseURL": "https://www.drugbank.ca/legal/terms_of_use",
        "ANID": 3624659
      },
      {
        "ReferenceNumber": 12,
        "SourceName": "EPA DSSTox",
        "SourceID": "DTXSID50238710",
        "Name": "Vemurafenib",
        "Description": "DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology.",
        "URL": "https://comptox.epa.gov/dashboard/DTXSID50238710",
        "LicenseURL": "https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources",
        "ANID": 1292529
      },
      {
        "ReferenceNumber": 16,
        "SourceName": "European Chemicals Agency (ECHA)",
        "SourceID": "850-250-7",
        "Name": "N-[3-[[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-1-propanesulfonamide",
        "Description": "The European Chemicals Agency (ECHA) is an agency of the European Union which is the driving force among regulatory authorities in implementing the EU's groundbreaking chemicals legislation for the benefit of human health and the environment as well as for innovation and competitiveness.",
        "URL": "https://echa.europa.eu/information-on-chemicals",
        "LicenseNote": "Use of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: \"Source: European Chemicals Agency, http://echa.europa.eu/\". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.",
        "LicenseURL": "https://echa.europa.eu/web/guest/legal-notice",
        "ANID": 15201409
      },
      {
        "ReferenceNumber": 17,
        "SourceName": "European Chemicals Agency (ECHA)",
        "SourceID": "800-227-2",
        "Name": "1029872-54-5",
        "Description": "The European Chemicals Agency (ECHA) is an agency of the European Union which is the driving force among regulatory authorities in implementing the EU's groundbreaking chemicals legislation for the benefit of human health and the environment as well as for innovation and competitiveness.",
        "URL": "https://echa.europa.eu/information-on-chemicals",
        "LicenseNote": "Use of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: \"Source: European Chemicals Agency, http://echa.europa.eu/\". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.",
        "LicenseURL": "https://echa.europa.eu/web/guest/legal-notice",
        "ANID": 15252713
      },
      {
        "ReferenceNumber": 33,
        "SourceName": "Hazardous Substances Data Bank (HSDB)",
        "SourceID": "8143",
        "Name": "Vemurafenib",
        "Description": "The Hazardous Substances Data Bank (HSDB) is a toxicology database that focuses on the toxicology of potentially hazardous chemicals. It provides information on human exposure, industrial hygiene, emergency handling procedures, environmental fate, regulatory requirements, nanomaterials, and related areas. The information in HSDB has been assessed by a Scientific Review Panel.",
        "URL": "https://pubchem.ncbi.nlm.nih.gov/source/hsdb/8143",
        "IsToxnet": true,
        "ANID": 5658
      },
      {
        "ReferenceNumber": 2,
        "SourceName": "ChEBI",
        "SourceID": "CHEBI:OBO:42611257",
        "Name": "Vemurafenib",
        "Description": "Chemical Entities of Biological Interest (ChEBI) is a database and ontology of molecular entities focused on 'small' chemical compounds, that is part of the Open Biomedical Ontologies effort. The term \"molecular entity\" refers to any constitutionally or isotopically distinct atom, molecule, ion, ion pair, radical, radical ion, complex, conformer, etc., identifiable as a separately distinguishable entity.",
        "URL": "http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:63637",
        "ANID": 2457442
      },
      {
        "ReferenceNumber": 30,
        "SourceName": "FDA Pharm Classes",
        "SourceID": "207SMY3FQT",
        "Name": "VEMURAFENIB",
        "Description": "FDA Pharmacologic class is a group of active moieties that share scientifically documented properties and is defined on the basis of any combination of attributes of the active moiety. Read more at https://www.fda.gov/industry/structured-product-labeling-resources/pharmacologic-class",
        "URL": "https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm",
        "LicenseNote": "Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.",
        "LicenseURL": "https://www.fda.gov/about-fda/about-website/website-policies#linking",
        "ANID": 6490569
      },
      {
        "ReferenceNumber": 31,
        "SourceName": "FDA Pharm Classes",
        "SourceID": "207SMY3FQT_1",
        "Name": "VEMURAFENIB",
        "Description": "FDA Pharmacologic class is a group of active moieties that share scientifically documented properties and is defined on the basis of any combination of attributes of the active moiety. Read more at https://www.fda.gov/industry/structured-product-labeling-resources/pharmacologic-class",
        "URL": "https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm",
        "LicenseNote": "Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.",
        "LicenseURL": "https://www.fda.gov/about-fda/about-website/website-policies#linking",
        "ANID": 13206789
      },
      {
        "ReferenceNumber": 34,
        "SourceName": "LiverTox",
        "SourceID": "Vemurafenib",
        "Name": "Vemurafenib",
        "Description": "LIVERTOX provides up-to-date, accurate, and easily accessed information on the diagnosis, cause, frequency, patterns, and management of liver injury attributable to prescription and nonprescription medications, herbals and dietary supplements.",
        "URL": "https://www.ncbi.nlm.nih.gov/books/n/livertox/Vemurafenib/",
        "LicenseURL": "https://www.nlm.nih.gov/copyright.html",
        "IsToxnet": true,
        "ANID": 2262518
      },
      {
        "ReferenceNumber": 39,
        "SourceName": "NCI Thesaurus (NCIt)",
        "SourceID": "C64768::Compound",
        "Description": "NCI Thesaurus (NCIt), from the U.S. National Cancer Institute, provides reference terminology for many NCI and other systems. It covers vocabulary for clinical care, translational and basic research, and public information and administrative activities.",
        "URL": "https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C64768",
        "LicenseNote": "Unless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.",
        "LicenseURL": "https://www.cancer.gov/policies/copyright-reuse",
        "ANID": 14394686
      },
      {
        "ReferenceNumber": 4,
        "SourceName": "ClinicalTrials.gov",
        "SourceID": "cid42611257",
        "Description": "ClinicalTrials.gov is an NIH registry and results database of publicly and privately supported clinical studies of human participants conducted around the world.",
        "URL": "https://clinicaltrials.gov/",
        "LicenseNote": "The ClinicalTrials.gov data carry an international copyright outside the United States and its Territories or Possessions. Some ClinicalTrials.gov data may be subject to the copyright of third parties; you should consult these entities for any additional terms of use.",
        "LicenseURL": "https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use",
        "ANID": 5187400
      },
      {
        "ReferenceNumber": 5,
        "SourceName": "Comparative Toxicogenomics Database (CTD)",
        "SourceID": "D000077484::Compound",
        "Description": "CTD is a robust, publicly available database that aims to advance understanding about how environmental exposures affect human health.",
        "URL": "https://ctdbase.org/detail.go?type=chem&acc=D000077484",
        "LicenseNote": "It is to be used only for research and educational purposes. Any reproduction or use for commercial purpose is prohibited without the prior express written permission of NC State University.",
        "LicenseURL": "http://ctdbase.org/about/legal.jsp",
        "ANID": 9023067
      },
      {
        "ReferenceNumber": 6,
        "SourceName": "DailyMed",
        "SourceID": "VEMURAFENIB",
        "Name": "VEMURAFENIB",
        "Description": "DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).",
        "URL": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=VEMURAFENIB",
        "LicenseURL": "https://www.nlm.nih.gov/copyright.html",
        "ANID": 2127912
      },
      {
        "ReferenceNumber": 7,
        "SourceName": "Drug Gene Interaction database (DGIdb)",
        "SourceID": "VEMURAFENIB",
        "Description": "The Drug Gene Interaction Database (DGIdb, www.dgidb.org) is a web resource that consolidates disparate data sources describing drug - gene interactions and gene druggability.",
        "URL": "https://www.dgidb.org/drugs/VEMURAFENIB",
        "LicenseNote": "The data used in DGIdb is all open access and where possible made available as raw data dumps in the downloads section.",
        "LicenseURL": "http://www.dgidb.org/downloads",
        "ANID": 8266577
      },
      {
        "ReferenceNumber": 18,
        "SourceName": "European Medicines Agency (EMA)",
        "SourceID": "EMEA/H/C/002409_1",
        "Name": "Zelboraf (EMEA/H/C/002409)",
        "Description": "The European Medicines Agency (EMA) presents information on regulatory topics of the medicinal product lifecycle in EU countries.",
        "URL": "https://www.ema.europa.eu/en/medicines/human/EPAR/zelboraf",
        "LicenseNote": "Information on the European Medicines Agency's (EMA)  website is subject to a disclaimer and copyright and limited reproduction notices.",
        "LicenseURL": "https://www.ema.europa.eu/en/about-us/legal-notice",
        "ANID": 8855363
      },
      {
        "ReferenceNumber": 21,
        "SourceName": "European Medicines Agency (EMA)",
        "SourceID": "P/0210/2016_1",
        "Name": "vemurafenib (P/0210/2016)",
        "Description": "The European Medicines Agency (EMA) presents information on regulatory topics of the medicinal product lifecycle in EU countries.",
        "URL": "https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000978-pip01-10-m01",
        "LicenseNote": "Information on the European Medicines Agency's (EMA)  website is subject to a disclaimer and copyright and limited reproduction notices.",
        "LicenseURL": "https://www.ema.europa.eu/en/about-us/legal-notice",
        "ANID": 8858569
      },
      {
        "ReferenceNumber": 38,
        "SourceName": "NCI Cancer Drugs",
        "SourceID": "cd_239",
        "Name": "vemurafenib",
        "Description": "The collection of NCI Cancer Drugs has over 200 cancer drug information summaries from NCI. The summaries provide consumer-friendly information about cancer drugs and drug combinations.",
        "URL": "https://www.cancer.gov/about-cancer/treatment/drugs/vemurafenib",
        "LicenseURL": "https://www.cancer.gov/policies/copyright-reuse",
        "ANID": 13502457
      },
      {
        "ReferenceNumber": 9,
        "SourceName": "Drugs and Lactation Database (LactMed)",
        "SourceID": "NBK500866",
        "Name": "Vemurafenib",
        "Description": "The LactMed database contains information on drugs and other chemicals to which breastfeeding mothers may be exposed. https://www.ncbi.nlm.nih.gov/books/NBK501922/",
        "URL": "https://www.ncbi.nlm.nih.gov/books/NBK500866/",
        "LicenseURL": "https://www.nlm.nih.gov/copyright.html",
        "ANID": 5123412
      },
      {
        "ReferenceNumber": 10,
        "SourceName": "DTP/NCI",
        "SourceID": "NSC 761431",
        "Name": "Vemurafenib",
        "Description": "The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.",
        "URL": "https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=761431",
        "LicenseNote": "Unless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.",
        "LicenseURL": "https://www.cancer.gov/policies/copyright-reuse",
        "ANID": 6610139
      },
      {
        "ReferenceNumber": 11,
        "SourceName": "ECI Group, LCSB, University of Luxembourg",
        "SourceID": "Compound::42611257",
        "Description": "The Environmental Cheminformatics group focuses on the comprehensive identification of known and unknown chemicals in our environment to investigate their effects on health and disease. They develop a combination of computational and experimental methods to improve structure elucidation, including cheminformatics approaches, primarily focused on interrogating non-target high resolution mass spectrometry data, following FAIR and Open Science principles.",
        "LicenseNote": "Data: CC-BY 4.0; Code: Artistic-2.0",
        "LicenseURL": "https://creativecommons.org/licenses/by/4.0/",
        "ANID": 15051344
      },
      {
        "ReferenceNumber": 13,
        "SourceName": "EU Clinical Trials Register",
        "SourceID": "cid42611257",
        "Description": "The EU Clinical Trials Register contains information on interventional clinical trials on medicines conducted in the European Union (EU), or the European Economic Area (EEA) which started after 1 May 2004.",
        "URL": "https://www.clinicaltrialsregister.eu/",
        "ANID": 6484055
      },
      {
        "ReferenceNumber": 14,
        "SourceName": "European Chemicals Agency (ECHA)",
        "SourceID": "232880",
        "Name": "1029872-54-5",
        "Description": "The information provided here is aggregated from the \"Notified classification and labelling\" from ECHA's C&L Inventory. Read more: https://echa.europa.eu/information-on-chemicals/cl-inventory-database",
        "URL": "https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/232880",
        "LicenseNote": "Use of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: \"Source: European Chemicals Agency, http://echa.europa.eu/\". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.",
        "LicenseURL": "https://echa.europa.eu/web/guest/legal-notice",
        "ANID": 1956699
      },
      {
        "ReferenceNumber": 15,
        "SourceName": "European Chemicals Agency (ECHA)",
        "SourceID": "296182",
        "Name": "N-[3-[[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-1-propanesulfonamide",
        "Description": "The information provided here is aggregated from the \"Notified classification and labelling\" from ECHA's C&L Inventory. Read more: https://echa.europa.eu/information-on-chemicals/cl-inventory-database",
        "URL": "https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/296182",
        "LicenseNote": "Use of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: \"Source: European Chemicals Agency, http://echa.europa.eu/\". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.",
        "LicenseURL": "https://echa.europa.eu/web/guest/legal-notice",
        "ANID": 8550488
      },
      {
        "ReferenceNumber": 19,
        "SourceName": "European Medicines Agency (EMA)",
        "SourceID": "EU/3/16/1669_1",
        "Name": "vemurafenib (EU/3/16/1669)",
        "Description": "The European Medicines Agency (EMA) presents information on regulatory topics of the medicinal product lifecycle in EU countries.",
        "URL": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3161669",
        "LicenseNote": "Information on the European Medicines Agency's (EMA)  website is subject to a disclaimer and copyright and limited reproduction notices.",
        "LicenseURL": "https://www.ema.europa.eu/en/about-us/legal-notice",
        "ANID": 8857132
      },
      {
        "ReferenceNumber": 20,
        "SourceName": "European Medicines Agency (EMA)",
        "SourceID": "EU/3/17/1846_1",
        "Name": "vemurafenib (EU/3/17/1846)",
        "Description": "The European Medicines Agency (EMA) presents information on regulatory topics of the medicinal product lifecycle in EU countries.",
        "URL": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3171846",
        "LicenseNote": "Information on the European Medicines Agency's (EMA)  website is subject to a disclaimer and copyright and limited reproduction notices.",
        "LicenseURL": "https://www.ema.europa.eu/en/about-us/legal-notice",
        "ANID": 8857293
      },
      {
        "ReferenceNumber": 29,
        "SourceName": "FDA Orange Book",
        "SourceID": "org_42611257",
        "Description": "The publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act).",
        "URL": "https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book",
        "LicenseNote": "Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.",
        "LicenseURL": "https://www.fda.gov/about-fda/about-website/website-policies#linking",
        "ANID": 3596403
      },
      {
        "ReferenceNumber": 42,
        "SourceName": "NORMAN Suspect List Exchange",
        "SourceID": "nrm_42611257",
        "Description": "The NORMAN network enhances the exchange of information on emerging environmental substances, and encourages the validation and harmonisation of common measurement methods and monitoring tools so that the requirements of risk assessors and risk managers can be better met. It specifically seeks both to promote and to benefit from the synergies between research teams from different countries in the field of emerging substances.",
        "LicenseNote": "Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0",
        "LicenseURL": "https://creativecommons.org/licenses/by/4.0/",
        "ANID": 13095983
      },
      {
        "ReferenceNumber": 48,
        "SourceName": "WHO Anatomical Therapeutic Chemical (ATC) Classification",
        "SourceID": "2084",
        "Description": "The WHO Anatomical Therapeutic Chemical (ATC) Classification System is a classification of active ingredients of drugs according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties.",
        "URL": "https://www.whocc.no/atc/",
        "LicenseNote": "Use of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed.",
        "LicenseURL": "https://www.whocc.no/copyright_disclaimer/",
        "ANID": 754345
      },
      {
        "ReferenceNumber": 22,
        "SourceName": "FDA Medication Guides",
        "SourceID": "Zelboraf",
        "Name": "Zelboraf",
        "Description": "FDA Medication Guides are paper handouts that come with many prescription medicines. The guides address issues that are specific to particular drugs and drug classes, and they contain FDA-approved information that can help patients avoid serious adverse events. https://www.fda.gov/Drugs/DrugSafety/ucm085729.htm",
        "URL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=medguide.page",
        "LicenseNote": "Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.",
        "LicenseURL": "https://www.fda.gov/about-fda/about-website/website-policies#linking",
        "ANID": 2141768
      },
      {
        "ReferenceNumber": 23,
        "SourceName": "FDA Orange Book",
        "SourceID": "orgp_7504509",
        "Name": "Patent:7504509",
        "Description": "The publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act).",
        "URL": "https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book",
        "LicenseNote": "Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.",
        "LicenseURL": "https://www.fda.gov/about-fda/about-website/website-policies#linking",
        "ANID": 404505
      },
      {
        "ReferenceNumber": 24,
        "SourceName": "FDA Orange Book",
        "SourceID": "orgp_7863288",
        "Name": "Patent:7863288",
        "Description": "The publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act).",
        "URL": "https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book",
        "LicenseNote": "Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.",
        "LicenseURL": "https://www.fda.gov/about-fda/about-website/website-policies#linking",
        "ANID": 404857
      },
      {
        "ReferenceNumber": 25,
        "SourceName": "FDA Orange Book",
        "SourceID": "orgp_8143271",
        "Name": "Patent:8143271",
        "Description": "The publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act).",
        "URL": "https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book",
        "LicenseNote": "Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.",
        "LicenseURL": "https://www.fda.gov/about-fda/about-website/website-policies#linking",
        "ANID": 405154
      },
      {
        "ReferenceNumber": 26,
        "SourceName": "FDA Orange Book",
        "SourceID": "orgp_8470818",
        "Name": "Patent:8470818",
        "Description": "The publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act).",
        "URL": "https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book",
        "LicenseNote": "Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.",
        "LicenseURL": "https://www.fda.gov/about-fda/about-website/website-policies#linking",
        "ANID": 405579
      },
      {
        "ReferenceNumber": 27,
        "SourceName": "FDA Orange Book",
        "SourceID": "orgp_8741920",
        "Name": "Patent:8741920",
        "Description": "The publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act).",
        "URL": "https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book",
        "LicenseNote": "Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.",
        "LicenseURL": "https://www.fda.gov/about-fda/about-website/website-policies#linking",
        "ANID": 405969
      },
      {
        "ReferenceNumber": 28,
        "SourceName": "FDA Orange Book",
        "SourceID": "orgp_9447089",
        "Name": "Patent:9447089",
        "Description": "The publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act).",
        "URL": "https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book",
        "LicenseNote": "Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.",
        "LicenseURL": "https://www.fda.gov/about-fda/about-website/website-policies#linking",
        "ANID": 406796
      },
      {
        "ReferenceNumber": 36,
        "SourceName": "National Drug Code (NDC) Directory",
        "SourceID": "n_VEMURAFENIB",
        "Name": "VEMURAFENIB",
        "Description": "The National Drug Code (NDC) is a unique, three-segment number that serves as FDA's identifier for drugs. The NDC Directory contains information on active and certified finished and unfinished drugs submitted to FDA.",
        "URL": "https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory",
        "LicenseNote": "Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.",
        "LicenseURL": "https://www.fda.gov/about-fda/about-website/website-policies#linking",
        "ANID": 15088840
      },
      {
        "ReferenceNumber": 32,
        "SourceName": "FDA/SPL Indexing Data",
        "SourceID": "207SMY3FQT",
        "Name": "207SMY3FQT",
        "Description": "The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).",
        "URL": "https://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSystem-UniqueIngredientIdentifierUNII/",
        "LicenseNote": "Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.",
        "LicenseURL": "https://www.fda.gov/about-fda/about-website/website-policies#linking",
        "ANID": 5809321
      },
      {
        "ReferenceNumber": 35,
        "SourceName": "MassBank of North America (MoNA)",
        "SourceID": "CCMSLIB00000078077",
        "Name": "Vemurafenib (PLX4032)",
        "Description": "MassBank of North America (MoNA) is a metadata-centric, auto-curating repository designed for efficient storage and querying of mass spectral records. There is only 1 MS data record for this compound, click the link above to see the spectral information at MoNA website.",
        "URL": "https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=compound.metaData%3Dq%3D%27name%3D%3D%22InChIKey%22%20and%20value%3D%3D%22GPXBXXGIAQBQNI-UHFFFAOYSA-N%22%27",
        "LicenseNote": "The content of the MoNA database is licensed under CC BY 4.0.",
        "LicenseURL": "https://mona.fiehnlab.ucdavis.edu/documentation/license",
        "ANID": 3429095
      },
      {
        "ReferenceNumber": 37,
        "SourceName": "National Drug Code (NDC) Directory",
        "SourceID": "s_VEMURAFENIB",
        "Name": "VEMURAFENIB",
        "Description": "The National Drug Code (NDC) is a unique, three-segment number that serves as FDA's identifier for drugs. The NDC Directory contains information on active and certified finished and unfinished drugs submitted to FDA.",
        "URL": "https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory",
        "LicenseNote": "Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.",
        "LicenseURL": "https://www.fda.gov/about-fda/about-website/website-policies#linking",
        "ANID": 15094715
      },
      {
        "ReferenceNumber": 40,
        "SourceName": "NIPH Clinical Trials Search of Japan",
        "SourceID": "cid42611257",
        "Description": "NIPH Clinical Trials Search of Japan allows one to search clinical research (trials) from the registries of three institutions; the University Hospital Medical Information Network Center (UMIN-CTR), the Japan Pharmaceutical Information Center (JAPIC), and the Japan Medical Association Center for Clinical Trials.",
        "URL": "https://rctportal.niph.go.jp/en/",
        "ANID": 6488792
      },
      {
        "ReferenceNumber": 41,
        "SourceName": "NLM RxNorm Terminology",
        "SourceID": "1147220",
        "Description": "RxNorm provides normalized names for clinical drugs and links its names to many of the drug vocabularies commonly used in pharmacy management and drug interaction software.",
        "URL": "https://rxnav.nlm.nih.gov/id/rxnorm/1147220",
        "LicenseNote": "The RxNorm Terminology is created by the National Library of Medicine (NLM) and is in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from NLM. Credit to the U.S. National Library of Medicine as the source is appreciated but not required. The full RxNorm dataset requires a free license.",
        "LicenseURL": "https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html",
        "ANID": 15097761
      },
      {
        "ReferenceNumber": 43,
        "SourceName": "Protein Data Bank in Europe (PDBe)",
        "SourceID": "032",
        "Description": "The Protein Data Bank in Europe (PDBe) manages the PDB with its wwPDB partners and provides a high-quality, up-to-date and integrated resource of macromolecular structures to support basic and applied research and education across the sciences.",
        "URL": "http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/032",
        "ANID": 8198708
      },
      {
        "ReferenceNumber": 44,
        "SourceName": "PubChem",
        "SourceID": "covid19_l_4917",
        "URL": "https://pubchem.ncbi.nlm.nih.gov",
        "ANID": 12464447
      },
      {
        "ReferenceNumber": 45,
        "SourceName": "RCSB Protein Data Bank (RCSB PDB)",
        "SourceID": "42611257",
        "Description": "The RCSB Protein Data Bank (PDB) contains crystallographic data defining 3D shapes of proteins, nucleic acids, and complex assemblies that helps students and researchers understand all aspects of biomedicine and agriculture, from protein synthesis to health and disease.",
        "URL": "https://www.rcsb.org/",
        "LicenseNote": "Data files contained in the PDB archive (ftp://ftp.wwpdb.org) are free of all copyright restrictions and made fully and freely available for both non-commercial and commercial use. Users of the data should attribute the original authors of that structural data.",
        "LicenseURL": "https://www.rcsb.org/pages/policies",
        "ANID": 13146755
      },
      {
        "ReferenceNumber": 46,
        "SourceName": "Springer Nature",
        "SourceID": "33053989-397259249",
        "Description": "Literature references related to scientific contents from Springer Nature journals and books. Read more: https://link.springer.com/",
        "ANID": 3848603
      },
      {
        "ReferenceNumber": 47,
        "SourceName": "Thieme Chemistry",
        "SourceID": "33053989-397259249",
        "Description": "Literature references related to scientific contents from Thieme journals and books. Read more: http://www.thieme-chemistry.com",
        "LicenseNote": "The Thieme Chemistry contribution within PubChem is provided under a CC-BY-NC-ND 4.0 license, unless otherwise stated.",
        "LicenseURL": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
        "ANID": 5702574
      },
      {
        "ReferenceNumber": 49,
        "SourceName": "Wikidata",
        "SourceID": "Q423111",
        "Name": "Vemurafenib",
        "Description": "Link to the compound information in Wikidata.",
        "URL": "https://www.wikidata.org/wiki/Q423111",
        "LicenseNote": "CCZero",
        "LicenseURL": "https://creativecommons.org/publicdomain/zero/1.0/",
        "ANID": 16295761
      },
      {
        "ReferenceNumber": 50,
        "SourceName": "Wikipedia",
        "SourceID": "wdQ423111",
        "Name": "Vemurafenib",
        "Description": "Link to the compound information in Wikipedia.",
        "URL": "https://en.wikipedia.org/wiki/Vemurafenib",
        "ANID": 17361220
      },
      {
        "ReferenceNumber": 51,
        "SourceName": "Medical Subject Headings (MeSH)",
        "SourceID": "2028046",
        "Name": "Vemurafenib",
        "Description": "MeSH (Medical Subject Headings) is the U.S. National Library of Medicine's controlled vocabulary thesaurus used for indexing articles for PubMed.",
        "URL": "https://www.ncbi.nlm.nih.gov/mesh/2028046",
        "LicenseNote": "Works produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.",
        "LicenseURL": "https://www.nlm.nih.gov/copyright.html"
      },
      {
        "ReferenceNumber": 52,
        "SourceName": "PubChem",
        "SourceID": "PubChem",
        "Description": "Data deposited in or computed by PubChem",
        "URL": "https://pubchem.ncbi.nlm.nih.gov"
      },
      {
        "ReferenceNumber": 53,
        "SourceName": "Medical Subject Headings (MeSH)",
        "SourceID": "DescTree",
        "Name": "MeSH Tree",
        "Description": "MeSH (Medical Subject Headings) is the NLM controlled vocabulary thesaurus used for indexing articles for PubMed.",
        "URL": "http://www.nlm.nih.gov/mesh/meshhome.html",
        "LicenseNote": "Works produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.",
        "LicenseURL": "https://www.nlm.nih.gov/copyright.html"
      },
      {
        "ReferenceNumber": 54,
        "SourceName": "ChEBI",
        "SourceID": "OBO",
        "Name": "ChEBI Ontology",
        "Description": "The ChEBI Ontology is a structured classification of the entities contained within ChEBI.",
        "URL": "http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology"
      },
      {
        "ReferenceNumber": 55,
        "SourceName": "KEGG",
        "SourceID": "br08301",
        "Name": "Therapeutic category of drugs in Japan",
        "Description": "KEGG is an encyclopedia of genes and genomes. Assigning functional meanings to genes and genomes both at the molecular and higher levels is the primary objective of the KEGG database project.",
        "URL": "http://www.genome.jp/kegg-bin/get_htext?br08301.keg",
        "LicenseNote": "Academic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial license",
        "LicenseURL": "https://www.kegg.jp/kegg/legal.html"
      },
      {
        "ReferenceNumber": 56,
        "SourceName": "KEGG",
        "SourceID": "br08302",
        "Name": "USP drug classification",
        "Description": "KEGG is an encyclopedia of genes and genomes. Assigning functional meanings to genes and genomes both at the molecular and higher levels is the primary objective of the KEGG database project.",
        "URL": "http://www.genome.jp/kegg-bin/get_htext?br08302.keg",
        "LicenseNote": "Academic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial license",
        "LicenseURL": "https://www.kegg.jp/kegg/legal.html"
      },
      {
        "ReferenceNumber": 57,
        "SourceName": "KEGG",
        "SourceID": "br08303",
        "Name": "Anatomical Therapeutic Chemical (ATC) classification",
        "Description": "KEGG is an encyclopedia of genes and genomes. Assigning functional meanings to genes and genomes both at the molecular and higher levels is the primary objective of the KEGG database project.",
        "URL": "http://www.genome.jp/kegg-bin/get_htext?br08303.keg",
        "LicenseNote": "Academic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial license",
        "LicenseURL": "https://www.kegg.jp/kegg/legal.html"
      },
      {
        "ReferenceNumber": 58,
        "SourceName": "KEGG",
        "SourceID": "br08310",
        "Name": "Target-based classification of drugs",
        "Description": "KEGG is an encyclopedia of genes and genomes. Assigning functional meanings to genes and genomes both at the molecular and higher levels is the primary objective of the KEGG database project.",
        "URL": "http://www.genome.jp/kegg-bin/get_htext?br08310.keg",
        "LicenseNote": "Academic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial license",
        "LicenseURL": "https://www.kegg.jp/kegg/legal.html"
      },
      {
        "ReferenceNumber": 60,
        "SourceName": "FDA Pharm Classes",
        "SourceID": "FDA_pharm_tree",
        "Name": "FDA Pharmacological Classification",
        "Description": "FDA published a final rule that amended the requirements for the content and format of approved labeling (prescribing information) for human prescription drug and biological products in January 2006.",
        "URL": "https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm",
        "LicenseNote": "Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.",
        "LicenseURL": "https://www.fda.gov/about-fda/about-website/website-policies#linking"
      },
      {
        "ReferenceNumber": 61,
        "SourceName": "WHO Anatomical Therapeutic Chemical (ATC) Classification",
        "SourceID": "ATCTree",
        "Name": "ATC Code",
        "Description": "In the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system, the active substances are divided into different groups according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties.",
        "URL": "https://www.whocc.no/atc_ddd_index/",
        "LicenseNote": "Use of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed.",
        "LicenseURL": "https://www.whocc.no/copyright_disclaimer/"
      },
      {
        "ReferenceNumber": 62,
        "SourceName": "UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)",
        "SourceID": "UN_GHS_tree",
        "Name": "GHS Classification Tree",
        "Description": "The United Nations' Globally Harmonized System of Classification and Labeling of Chemicals (GHS) provides a harmonized basis for globally uniform physical, environmental, and health and safety information on hazardous chemical substances and mixtures. It sets up criteria for the classification of chemicals for physical-chemical, health, and environmental hazards of chemical substances and mixtures and sets up standardized hazard information to facilitate global trade of chemicals.  Please note that obsolete codes are added in this classification for completeness purposes, as they are still in use. Any obsolete codes are annotated as such.",
        "URL": "http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html"
      },
      {
        "ReferenceNumber": 63,
        "SourceName": "ChemIDplus",
        "SourceID": "ChemIDplus_tree",
        "Name": "ChemIDplus Chemical Information Classification",
        "Description": "ChemIDplus is a TOXNET (TOXicology Data NETwork) databases that contain chemicals and drugs related information. It is managed by the Toxicology and Environmental Health Information Program (TEHIP) in the Division of Specialized Information Services (SIS) of the National Library of Medicine (NLM).",
        "URL": "https://chem.nlm.nih.gov/chemidplus/",
        "LicenseURL": "https://www.nlm.nih.gov/copyright.html",
        "IsToxnet": true
      },
      {
        "ReferenceNumber": 64,
        "SourceName": "ChEMBL",
        "SourceID": "Target Tree",
        "Name": "ChEMBL Protein Target Tree",
        "Description": "The ChEMBL Protein Target Tree is a structured classification of the protein target entities contained with the ChEMBL resource release version 30.",
        "URL": "https://www.ebi.ac.uk/chembl/g/#browse/targets",
        "LicenseNote": "Access to the web interface of ChEMBL is made under the EBI's Terms of Use (http://www.ebi.ac.uk/Information/termsofuse.html). The ChEMBL data is made available on a Creative Commons Attribution-Share Alike 3.0 Unported License (http://creativecommons.org/licenses/by-sa/3.0/).",
        "LicenseURL": "http://www.ebi.ac.uk/Information/termsofuse.html"
      },
      {
        "ReferenceNumber": 65,
        "SourceName": "IUPHAR/BPS Guide to PHARMACOLOGY",
        "SourceID": "Target Classification",
        "Name": "Guide to Pharmacology Target Classification",
        "Description": "An expert-driven guide to pharmacological targets and the substances that act on them",
        "URL": "https://www.guidetopharmacology.org/targets.jsp",
        "LicenseNote": "The Guide to PHARMACOLOGY database is licensed under the Open Data Commons Open Database License (ODbL) https://opendatacommons.org/licenses/odbl/. Its contents are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License (http://creativecommons.org/licenses/by-sa/4.0/)",
        "LicenseURL": "https://www.guidetopharmacology.org/about.jsp#license"
      },
      {
        "ReferenceNumber": 66,
        "SourceName": "KEGG",
        "SourceID": "br08330",
        "Name": "Drug Groups",
        "Description": "KEGG is an encyclopedia of genes and genomes. Assigning functional meanings to genes and genomes both at the molecular and higher levels is the primary objective of the KEGG database project.",
        "URL": "http://www.genome.jp/kegg-bin/get_htext?br08330.keg",
        "LicenseNote": "Academic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial license",
        "LicenseURL": "https://www.kegg.jp/kegg/legal.html"
      },
      {
        "ReferenceNumber": 67,
        "SourceName": "NORMAN Suspect List Exchange",
        "SourceID": "norman_sle_tree",
        "Name": "NORMAN Suspect List Exchange Classification",
        "Description": "The NORMAN Suspect List Exchange (NORMAN-SLE) is a central access point for NORMAN members (and others) to find suspect lists relevant for their environmental monitoring questions.<br>Update: 05/31/22 11:29:15",
        "URL": "https://www.norman-network.com/nds/SLE/",
        "LicenseNote": "Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0",
        "LicenseURL": "https://creativecommons.org/licenses/by/4.0/"
      },
      {
        "ReferenceNumber": 68,
        "SourceName": "EPA DSSTox",
        "SourceID": "dsstoxlist_tree",
        "Name": "CompTox Chemicals Dashboard Chemical Lists",
        "Description": "This classification lists the chemical categories from the EPA CompTox Chemicals Dashboard.<br>Update: 04/28/22 12:53:01",
        "URL": "https://comptox.epa.gov/dashboard/chemical-lists/",
        "LicenseURL": "https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources"
      },
      {
        "ReferenceNumber": 70,
        "SourceName": "NCI Thesaurus (NCIt)",
        "SourceID": "NCIt",
        "Name": "NCI Thesaurus Tree",
        "Description": "The NCI Thesaurus (NCIt) provides reference terminology for many NCI and other systems. It covers vocabulary for clinical care, translational and basic research, and public information and administrative activities.",
        "URL": "https://ncit.nci.nih.gov",
        "LicenseNote": "Unless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.",
        "LicenseURL": "https://www.cancer.gov/policies/copyright-reuse"
      },
      {
        "ReferenceNumber": 71,
        "SourceName": "National Drug Code (NDC) Directory",
        "SourceID": "fdandc_tree",
        "Name": "FDA Drug Type and Pharmacologic Classification",
        "Description": "The FDA Drug Type and Pharmacologic Classification is created based on the FDA drug types and pharm classes data from the National Drug Code (NDC) Directory.",
        "URL": "https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory",
        "LicenseNote": "Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.",
        "LicenseURL": "https://www.fda.gov/about-fda/about-website/website-policies#linking"
      },
      {
        "ReferenceNumber": 72,
        "SourceName": "KEGG",
        "SourceID": "br08332",
        "Name": "Drug Classes",
        "Description": "KEGG is an encyclopedia of genes and genomes. Assigning functional meanings to genes and genomes both at the molecular and higher levels is the primary objective of the KEGG database project.",
        "URL": "http://www.genome.jp/kegg-bin/get_htext?br08332.keg",
        "LicenseNote": "Academic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial license",
        "LicenseURL": "https://www.kegg.jp/kegg/legal.html"
      },
      {
        "ReferenceNumber": 73,
        "SourceName": "PubChem",
        "SourceID": "pfas5_pubchem_tree",
        "Name": "PFAS and Fluorinated Compounds in PubChem",
        "Description": "A classification tree to browse per- and polyfluoroalkyl substances (PFAS) and other fluorinated compounds in PubChem. The 'OECD PFAS definition' node contains PubChem content matching the OECD PFAS definition of saturated CF2 (Report ENV/CBC/MONO(2021)25 from 9 July 2021). The 'Organofluorine compounds' node contains organofluorine compounds in PubChem as defined in the same report. The 'Other diverse fluorinated compounds' node helps explore a wide variety of other fluorinated compounds. The 'PFAS and fluorinated compound collections' node gathers several collections of PFAS and/or fluorinated compounds from various resources. <br>Update: 06/16/22 11:56:01",
        "URL": "https://gitlab.lcsb.uni.lu/eci/pubchem-docs/-/raw/main/pfas-tree/PFAS_Tree.pdf?inline=false"
      },
      {
        "ReferenceNumber": 74,
        "SourceName": "Medical Subject Headings (MeSH)",
        "SourceID": "68000970",
        "Name": "Antineoplastic Agents",
        "Description": "MeSH (Medical Subject Headings) is the U.S. National Library of Medicine's controlled vocabulary thesaurus used for indexing articles for PubMed.",
        "URL": "https://www.ncbi.nlm.nih.gov/mesh/68000970",
        "LicenseNote": "Works produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.",
        "LicenseURL": "https://www.nlm.nih.gov/copyright.html"
      },
      {
        "ReferenceNumber": 75,
        "SourceName": "Medical Subject Headings (MeSH)",
        "SourceID": "68047428",
        "Name": "Protein Kinase Inhibitors",
        "Description": "MeSH (Medical Subject Headings) is the U.S. National Library of Medicine's controlled vocabulary thesaurus used for indexing articles for PubMed.",
        "URL": "https://www.ncbi.nlm.nih.gov/mesh/68047428",
        "LicenseNote": "Works produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.",
        "LicenseURL": "https://www.nlm.nih.gov/copyright.html"
      },
      {
        "ReferenceNumber": 76,
        "SourceName": "PATENTSCOPE (WIPO)",
        "Name": "SID 391271855",
        "Description": "The PATENTSCOPE database from WIPO includes patent and chemical structure search (with a free account) that gives access to millions of patent documents. The World Intellectual Property Organisation (WIPO) is a specialized United Nations (UN) agency headquartered in Geneva (Switzerland). Our mission is to lead the development of a balanced and effective international Intellectual Property (IP) system that enables innovation and creativity for the benefit of all. We help governments, businesses and society realize the benefits of Intellectual Property and are notably a world reference source for IP information.",
        "URL": "https://pubchem.ncbi.nlm.nih.gov/substance/391271855"
      },
      {
        "ReferenceNumber": 77,
        "SourceName": "NCBI",
        "SourceID": "LinkOut",
        "Description": "LinkOut is a service that allows one to link directly from NCBI databases to a wide range of information and services beyond NCBI systems.",
        "URL": "https://www.ncbi.nlm.nih.gov/projects/linkout"
      }
    ]
  }
}
